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Abstract 
The Government agenda is to move pharmacists away from dispensing medicines from a 
prescription to the provision of clinical services aimed at managing patients with long-term 
conditions. This thesis uses the approach defined by the MRC framework for developing 
complex interventions to ascertain whether there is a pharmacist role in this area.  
 
An initial study was conducted to determine the feasibility of a community pharmacist 
eczema management support service (PLEEZ). It demonstrated encouraging results, 
however failed to recruit the required number of participants. A pharmacist focus group 
indicated that the study had failed because of an insufficient population, overly complex 
study design and insufficient intervention preparation and training.  
 
Type 2 diabetes was subsequently chosen for the intervention as these patients have an 
anticipated greater pharmaceutical need and there is a larger available patient population. 
In line with the MRC framework, appropriate developmental work was then undertaken in 
the form of a literature review, an audit and a series of focus groups to determine the 
composition of a novel intervention focused on this condition. These results came together 
to form the diabetes community pharmacy drop-in clinic comprising the following 
elements: 
 
 Targeting poorly controlled patients 
 A system of referral from the medical practice  
 A suitable training programme  
 No appointment system 
 Additional pharmacist to support  
 A focus on adherence and dose optimisation as well as diet and lifestyle advice 
 
The clinics, in five pharmacies, recruited 33 participants providing positive results from the 
outcomes measured, excellent patient feedback and pharmacist comments that can be 
used to inform future studies. 
 
The thesis demonstrates that there is a potential role for the community pharmacist in the 
care of patients with type 2 diabetes, however further, large scale research is needed to 
confirm whether this is the case.  
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1  Introduction 
1.1 The history of community pharmacy 
Community pharmacy has been constantly evolving and reacting to the healthcare 
environment since its inception in the mid-1850s. The profession of pharmacy was 
created out of the Pharmacy Act 1852 which had been lobbied for by the recently founded 
Pharmaceutical Society of Great Britain. At this time, the pharmacist was engaged in a 
wide variety of roles from dispensing medicines from a physician-written prescription to 
minor surgery and dentistry (Anderson, 2005). It was only with subsequent legislation, 
surrounding other professions e.g. the Dentists Act 1921, that these latter roles were 
removed from pharmacists.  
 
One of the most important functions of a pharmacist at this time, and until the founding of 
the National Health Service (NHS), was to advise and treat patients who could not afford 
to see a general practitioner (GP). If someone wanted to see a GP, they had to pay for the 
consultation and then pay for the medicine that either the GP or the pharmacist would 
dispense. Patients who saw a pharmacist only had to pay for any medicines which they 
recommended. In a time when universal healthcare had not yet been established and 
wages were low, this was the only option available to many people.  
 
The transformation in the role of the pharmacist to the one we see today, began with the 
1911 National Insurance Act, the forerunner to the NHS. This changed the healthcare 
landscape so that certain people could see a doctor and then have prescriptions 
dispensed by a pharmacist for no charge. Within one year of operation, the number of 
prescriptions dispensed by pharmacists trebled and as a result, pharmacists started to 
move away from advising patients and towards medicines supply as their main role.  
 
When the NHS was established in 1948, this role transformation was complete. With the 
advent of free GP consultations for all, most patients chose to access a medical 
practitioner rather than consult a pharmacist. Consequently, the pharmacist engaged less 
with patients and more with dispensing medicines from NHS prescriptions which had also 
significantly increased in number due to the more popular use of medical practitioners. As 
the NHS evolved, the reliance on community pharmacies for dispensing medicines 
continued to rise; however, this became more efficient due to the introduction of patient-
packs and a reduced need for compounding medicines. In the early 2000s, the 
Government decided to expand the role of the pharmacist to encompass a more patient-
focused approach to their work. This role expansion originates from the notion, outlined by 
the Nuffield report in 1986, that community pharmacists are well-trained healthcare 
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professionals with regular interactions with patients but have little impact on their care 
(The Nuffield Foundation, 1986). 
 
1.2 Government vision for community pharmacy 
Today, an average adult visits a community pharmacy 16 times per year with 86% of the 
population visiting at least once per year, 78% of those for health related reasons 
(Department of Health, 2008). This figure equates to over 47 million people visiting a 
community pharmacy at one point during the year and demonstrates the readiness with 
which the public use community pharmacy. Over the previous decade the UK Government 
has published three health White Papers outlining its vision for community pharmacy with 
these figures in mind.  
 
A Vision for Pharmacy in the new NHS, in 2003, outlined the Government’s overarching 
view that community pharmacy should be given a clearer NHS identity, as many members 
of the public view pharmacy as distinct from the NHS rather than an integral part of it 
(Department of Health, 2003). It set out to develop a new pharmacy contract that placed 
more emphasis on providing patient services and valued the role of dispensing 
technicians more in the day-to-day dispensing activities. Choosing health through 
pharmacy – a programme for pharmaceutical public health 2005 - 2015 moved this vision 
forward by establishing the new contract and placing pharmacy, especially community 
pharmacy, at the heart of the Government’s public health strategy. This stated that 
pharmacists should be involved in improving the public health with a specific focus on 
long-term conditions in the form of support for self-care together with involvement in 
disease management as part of the wider primary care team (Department of Health, 
2005a).  
 
Long-term conditions affect a significant proportion of the population and can often be life-
long and have a detrimental effect on a person’s quality of life. In 2007/8 the NHS was 
treating approximately 1.9 million people for coronary heart disease, 6.9 million for 
hypertension, 2.1 million for diabetes mellitus and 3.1 million for asthma (The Health and 
Social Care Information Centre, 2008). The majority of these patients will be treated with 
medication dispensed by a community pharmacy in primary care which in 2009 cost the 
NHS £8.5 billion, with each person in the population receiving an average of 17.1 items 
annually (The Health and Social Care Information Centre, 2010).  
 
The 2005 White Paper also referred to the need for robust research to underpin these 
new roles, encouraging pharmacists to work with academic institutions to achieve this 
goal (Department of Health, 2005a). This was further re-enforced in Pharmacy in England: 
building on strengths - delivering the future, published in 2008, which provided greater 
4 
 
detail on implementation, strategy and funding arrangements. This paper also referenced 
the changes needed to pharmacist education and training, the need to use the pharmacy 
workforce to better effect and the necessity of improving communication between 
pharmacists, the public and other healthcare professionals to ensure this role is properly 
understood. As a result of these White Papers, the community pharmacy contract was re-
negotiated in 2005 and detailed a new operational platform and payment structure for the 
Government vision to account for these new roles (PSNC, 2005). 
 
1.3 The community pharmacy contract 
In 2005 a new community pharmacy contract was implemented in the United Kingdom 
(Department of Health, 2005b). Although dispensing formed the core service together with 
supply of appliances and waste disposal, additional clinical services were, for the first 
time, recognised in the payment system to community pharmacies. The new pharmacy 
contract divides services into three categories: essential, advanced and enhanced 
services. The organisation, provision and payment arrangements for pharmaceutical 
services differ between the constituent countries of the UK. This following explanation 
refers to pharmaceutical services in England only.  
 
1.3.1 Essential Services 
Community pharmacies are required to demonstrate that they are providing the eight 
essential services (detailed in box 1) in order to keep their contract with the primary care 
trust. 
 
Box 1 Essential pharmacy services 
Dispensing Public health 
Repeat dispensing Signposting 
Supply of appliances Support for self-care 
Disposal of unwanted medicines Clinical governance 
 
These form the core elements of community pharmacy practice and represent the more 
traditional services that most people associate with community pharmacists and are 
designed to formalise the pharmacist’s role in providing public health advice, health 
promotion and support for self-care.  
 
Repeat dispensing was introduced as an adjunct to the pharmacist’s normal dispensing 
activities and is a system where up to six-months’ worth of prescriptions are kept at the 
pharmacy, so that when a patient needs their monthly prescription they only have to go to 
the pharmacy rather than placing a request at their local surgery. The process was 
designed to make it easier for patients to obtain their repeat prescriptions but it also 
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provided a valuable opportunity for the pharmacist to engage with, and improve their 
relationship with, the patient (National Prescribing Centre, 2010). As part of the service 
the pharmacist should ensure that the patient requires all of the medicines on the 
prescription before dispensing, thereby, changing the responsibility of community 
pharmacists to one of monitoring as well as dispensing.  
 
1.3.2 Advanced services 
Advanced services are those that are agreed nationally between the Department of Health 
and the Pharmaceutical Services Negotiating Committee (PSNC) and which pharmacy 
premises and pharmacists have to be accredited to provide. There are currently four 
nationally agreed advanced services: medicine use reviews (MURs) and prescription 
intervention (PIs), new medicine service (NMS), appliance use reviews (AURs) and stoma 
appliance customisation.  
 
MURs are the most prevalent of these services and involve the pharmacist entering into a 
consultation with a patient about their medicines. This consultation is centred on a 
patient’s adherence to their medicines and any problems they may have in taking them. 
This could raise problems that can be dealt with by the pharmacy team e.g. patient unable 
to read the medicine labels and therefore large print labels can be used from then 
onwards, or by the GP e.g. the patient is experiencing side effects from one of their 
prescribed medicines. The consultation is designed to last 10-15 minutes and whilst it is 
not a full clinical review of the medicines, some of the recommendations made to the GP 
maybe clinical in nature. 
 
In order to be able to provide the MUR service, pharmacists are required to undergo a 
short training course which details the service specification and provides an overview on 
consultation techniques that may be useful for conducting this type of conversation with 
the patient. There are a number of different training courses available ranging from those 
that can be completed in approximately three hours to those that are more intensive and 
require the submission of case studies. There is no stipulation as to how long the course 
must be and how much training a pharmacist must have had before they start to provide 
the service. All training packages are designed for self-completion and there is no face-to-
face element. 
 
The NMS was introduced in October 2011 with the aim of improving adherence to newly-
prescribed medicines for certain long-term conditions e.g. hypertension or asthma and is 
based on proof of concept research by The School of Pharmacy, London and the 
University of Nottingham (Barber et al., 2004, Clifford et al., 2006, Elliott et al., 2008). The 
service involves an initial interaction between the patient and pharmacist where consent to 
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participate in the service is obtained and basic counselling regarding the new medicine is 
given to the patient. The intervention phase of the service occurs 7-14 days after this 
initial conversation and is designed to offer patients any advice they may want about their 
medicine and to discuss any problems or concerns they may have had with taking the 
medicine so far. Follow-up occurs 14-21 days after the intervention phase and is aimed at 
making sure the patient is still taking their medicine and that any problems highlighted at 
the second stage of the service have been resolved to the patient’s satisfaction. Both the 
intervention and follow-up stages can be conducted in person or over the telephone and 
there is a facility to refer any problems directly back to the patient’s GP if necessary. The 
training requirement for NMS is a self-assessment of the pharmacist’s competence to 
conduct the service which is based on their ability to remember the service specification 
and a brief appraisal of their own communication skills (PSNC, 2011).  
 
At the end of the year April 2010 – March 2011, 2.1 million MURs had been conducted, 
400,000 more than were conducted the year before (The NHS Information Centre, 2011a) 
with 87.9% of pharmacies providing an average of 219 each, which is just over half of the 
total allowable number of MURs per pharmacy (400) in any particular year. With the NMS, 
approximately 6,000 pharmacies are claiming payment for a total of 418,744 interventions 
provided between October 2011 and July 2012 (PSNC, 2012c), representing just over half 
of pharmacies conducting this service each month.  
 
1.3.3 Enhanced services 
These are services commissioned by primary care trusts (PCTs) according to the needs 
of the local population. The Department of Health has so far specified 19 enhanced 
services (detailed in box 2) that can be commissioned by PCTs (Department of Health 
and Welsh Assembly Government, 2012).   
 
Box 2 List of enhanced services 
Schools service Medication review service 
Gluten free food supply Medicines assessment and compliance support 
Home delivery service On demand specialist drugs 
Anticoagulation monitoring Minor ailment scheme 
Disease specific management Independent prescribing service 
Supplementary prescribing Care home service 
Screening service Patient group direction service 
Language access service Stop smoking 
Prescriber support service Needle and syringe exchange 
Supervised administration service  
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The training requirement for enhanced services is often more detailed than that for the 
advanced services and usually comprises a self-directed element e.g. completion of the 
relevant Centre for Pharmacy Postgraduate Education (CPPE) learning package, along 
with a face-to-face event provided by the commissioning organisation. These training 
events are then run at regular intervals to capture any new pharmacists who wish to 
provide the service but also to act as a refresher for pharmacists currently providing the 
service.  
 
In total, 30,962 locally enhanced services were provided by community pharmacies in the 
year 2010-11, an increase of 4.9% on the previous year (The NHS Information Centre, 
2011a). This figure is the number of services in operation, not the actual number of 
patients who used the service. Data relating to the uptake of these services is currently 
unavailable. The five services that were commissioned the most (number (%) of 
pharmacies providing the service given in brackets) were stop smoking (6,104 (55.7%)), 
supervised administration (5,385 (49.2%)), minor ailment service (3,686 (33.7%)), 
medicines provided through patient group direction (3,552 (32.4%)), and medication 
review (2,383 (21.8%)). These five services have remained the most popular since 
enhanced services were introduced in 2005.  
 
For the first time, these enhanced services provide the pharmacist with the opportunity to 
prescribe medicines both as an independent and supplementary prescriber. In 2010, an 
evaluation of pharmacist independent prescribing found that between 2-3% of 
pharmacists were qualified as prescribers and approximately 71% of those were currently 
using their skills (Latter et al., 2010). However, this report also identifies that although 
patients and professionals like the idea of non-medical prescribing, only about half of 
PCTs have a strategy in place to increase their role in the NHS. As of 2012, there are only 
two documented community pharmacy services that involve the pharmacist 
(supplementary) prescribing, one in Lincolnshire relating to the supply of oral 
contraception and one in Tyneside relating to substance misuse (Pharmaceutical Services 
Negotiating Committee, 2013). 
 
Research suggests that the types of service a pharmacy provides depends on what kind 
of business they are, with some pharmacies not providing certain services due to the 
opinions of other customers that use the business e.g. supervised consumption in a 
supermarket (Bush et al., 2007). 
 
1.4 Provision of community pharmacy contract services 
Despite these innovations in service provision and changes to the pharmacy contract, the 
pharmacist’s core role remains the supply of medicines by prescription and is viewed as 
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such by many pharmacists (Bryant et al., 2009). Despite the increasing number of 
services being provided there remains concern from pharmacists, other healthcare 
professionals and commissioning organisations about the quality, ability to provide and 
need for some of these new services. The training requirement for these enhanced roles 
varies significantly and may be one reason why quality and effectiveness is being 
questioned. However, other factors such as workload, supervision and skill mix, 
commercial pressures, interprofessional working and evidence base can all be seen to 
influence the extent to which pharmacists engage with their new roles as providers of 
patient-focused services. Research that has attempted to explore these factors has 
largely centred on MURs and how pharmacists have implemented them since their 
introduction.  
 
1.4.1 Community pharmacy workload 
Since the new pharmacy contract, community pharmacists have had to start providing 
additional patient-focused services against a background of increasing prescription 
volumes. In 1948, when the NHS was first established, 13,000 pharmacies were 
dispensing approximately 250 million prescriptions (Anderson, 2007). This has risen to 
reach 850.7 million prescription items from 10,951 pharmacies in 2010/11 (The NHS 
Information Centre, 2011a)  which was an increase of 4.6% on the previous year, one that 
is forecast to rise further due to the increasing age of the population (The Office for 
National Statistics, 2010), increases in the prevalence of certain long term conditions e.g. 
diabetes (The Health and Social Care Information Centre & The Yorkshire and Humber 
Public Health Observatory, 2009) and advances in medical technology.  
 
167 out of 280 (59.6%) pharmacists who were surveyed whilst working for one particular 
multiple pharmacy chain in the UK highlighted at the inception of the pharmacy contract 
that time constraints would be a major factor in their ability to conduct MURs (Latif and 
Boardman, 2008). A similar postal questionnaire was posted to a comparable group of 
pharmacists working in another multiple pharmacy chain in 2009 and a similar response 
rate returned similar thoughts about time constraints. However, fewer respondents 
highlighted this as a barrier to performing MURs than in the original survey (Latif et al., 
2010) indicating that pharmacists may have become better at integrating service provision 
into their core dispensing activities.  
 
Latif’s other work centred on case studies of two pharmacies providing the MUR service 
and discovered that in these two pharmacies the workload experienced by the 
pharmacists may have impacted on their ability to conduct the service (Latif et al., 2011). 
This aspect of attempting to fit MURs into other tasks associated with community 
pharmacy e.g. dispensing, is something that has been documented more widely in the 
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literature (Harding and Wilcock, 2010) and that it is often a struggle to conduct MURs 
whilst maintaining dispensing volumes (McDonald et al., 2010). This conflict in the 
requirements of the pharmacist and the reason why workload is an important factor to 
understand in relation to service provision is largely related to the framework in which 
community pharmacy operates, with legislation being one of the barriers to the 
implementation of pharmacy services. 
 
1.4.2 Supervision and skill mix 
The Medicines Act 1968 and various Health Acts stipulate that a pharmacist must be in a 
position to ‘supervise’ the dispensing of medicines and sales of certain over-the-counter 
(OTC) medicines personally. This means that the pharmacist must always clinically check 
a prescription and be in a position to advise and intervene in the sale or supply of 
medicines should it be necessary (Royal Pharmaceutical Society, 2011). Guidance states 
that providing pharmacy staff are appropriately qualified, pharmacists do not need to be 
physically present for certain aspects of the dispensing process (Royal Pharmaceutical 
Society, 2011). A debate on the supervision rules is underway by the profession to 
establish to what extent these rules should be amended to allow the pharmacist more 
freedom to conduct other aspects of their work e.g. provision of pharmacy services 
(Branford and Phillips, 2010). 
 
These rules have restricted the activities of the pharmacist to only those which take place 
in the pharmacy and do not take him/her away from the dispensary for long periods of 
time. Consequently, this has limited the extent to which pharmacists can enter into private 
consultations with patients away from the dispensary or pharmacy counter and means 
that, even after seven years of the new contract, they are largely confined to the 
dispensary, clinically checking prescriptions for most of his/her time. In the cases studies 
described by Latif et al. previously it is interesting to note that counter staff and dispensers 
had to make judgement calls about whether they could interrupt a pharmacist’s 
consultation in order for them to check a prescription for a waiting patient (Latif et al., 
2011), thereby attempting to balance the medicine-focused and patient-focused role of the 
community pharmacy.  
 
Better use of the pharmacy team may prove effective at freeing up pharmacist time to 
concentrate on services. The most recent pharmacy White Paper outlined plans to use the 
pharmacy workforce to better effect  with a suggestion that pharmacy technicians may, in 
the future, have a role in the sale or supply of medicines (Department of Health, 2008).  
 
Currently, pharmacists have identified that where they have appropriately trained 
members of staff that can perform activities such as checking prescriptions, it releases 
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them to engage more with enhanced and advanced services (McDonald et al., 2010). It 
should also be noted that it is not simply the training of the support staff but the number of 
them present, as a checking technician requires a number of other support staff (at least 
two) in order that they can check prescriptions legally and safely (Harding and Wilcock, 
2010). 
 
One other aspect that has helped to increase the number of services that are provided is 
related to the way in which the community pharmacy plans their workload. Most 
community pharmacies now operate a delivery service and a prescription collection 
service which means that workload can be planned and the pharmacist is not in a position 
of having to immediately respond to a patient’s prescription request as often (McDonald et 
al., 2010). This move to a more planned working day has largely been led by multiple 
pharmacy companies in order to release the pharmacist to provide MURs to increase their 
income as well as encouraging patients to use the same pharmacy for all of their 
prescriptions. The incentive to increase the number of services provided was a reduction 
in the fee paid per item dispensed to pay for the additional service provision. Therefore, 
pharmacies have to either dispense more medicines or maintain dispensing volume whilst 
providing services simply to maintain their current income.  
 
1.4.3 Commercial pressures 
Bradley et al. discovered that the number of MURs conducted in large multiples differs 
from that in small independent pharmacies (Bradley et al., 2008). In multiples there is an 
emphasis on achieving targets for MURs, the 400 limit applied by the Department of 
Health is seen as an immutable goal with pharmacists being reprimanded if they fall short 
of this figure (McDonald et al., 2010). Particularly within the large company environment, it 
is seen as a quantity driven exercise to generate greater profit for the company 
(McDonald et al., 2010) and pressures are applied to pharmacists to encourage them to 
achieve this figure (Murphy, 2007).  
 
Bush et al. refer to this as the ‘corporatization’ of community pharmacy meaning that 
community pharmacy companies have adopted policies that make sense for the business 
but not necessarily for the patient or the NHS and that sometimes these professional and 
commercial responsibilities can conflict with each other (Bush et al., 2009). This pressure 
from companies to conduct a certain number of MURs may be having an effect on the 
quality of them with some pharmacists saying they have conducted them when there is 
not necessarily a need (Wilcock and Harding, 2008). Representatives of organisations 
responsible for monitoring the number of MURs have also reported that they suspect 
those pharmacists performing high numbers of MURs may not be conducting good quality 
reviews something that is also being acknowledged by the medical practices when they 
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receive the associated paperwork (Bradley et al., 2008). As a result this may be one of the 
causes for the poor nature of inter-professional working between community pharmacists 
and GPs.   
 
1.4.4 Inter-professional working 
Community pharmacists work in a unique environment in the healthcare sector, namely in 
isolation. It has been suggested that this isolation can lead to a diminishing of ethical 
values in a pharmacist’s professional practice as they do not interact regularly with other 
healthcare professionals (Cooper et al., 2009). It has also been suggested that community 
pharmacists feel subordinate to general practitioners, possibly because many doctors 
view them as ‘shopkeepers’ with little to add to the clinical management of the patient 
(Hughes and McCann, 2003). 
 
This was also enforced in the development of the 2003 general medical services (GMS) 
contract and the 2005 pharmacy contract. Both contracts were designed with other 
professions in mind; however, they operate entirely in isolation from each other without 
taking in to account continuity of care, quality and patient safety (Richardson and Pollock, 
2010). There may also be a lack of communication between community pharmacists and 
GPs with pharmacists suggesting that since the introduction of MURs, interaction with the 
GP has not altered (Blenkinsopp et al., 2007a). In a survey of community pharmacists and 
GPs about clinical service provision, both identified that the current funding system does 
not facilitate inter-professional working and that these services if not linked well together 
could lead to conflicting information for the patient (Bryant et al., 2009).  
 
In terms of MURs, pharmacists hold the view that GPs place no value on the paperwork 
that they receive from the consultation and it is thought that GPs are resistant to them 
because they are merely formalising the role that pharmacists should already be doing but 
are now getting paid separately for (McDonald et al., 2010). Even when pharmacists 
submit a copy of the MUR form to the GP, it is often the case that they receive little 
feedback on the service they have just provided (Wilcock and Harding, 2008).  
 
From the GPs’ perspective they found it difficult when the MUR paperwork they were 
receiving was often not the best quality in terms of the recommendations made (Celino et 
al., 2007). In a survey conducted in 2007, GPs gave a mixed response to questions 
relating to MURs calling them useless, noting them as frustrating when pharmacists 
requested that they measure a patient’s blood pressure when it had already been done 
and conducting MURs on patients whose treatment had not changed in several years and 
they knew were compliant (Wilcock and Harding, 2007). Community pharmacists do not 
have access to patient’s medical notes and therefore if the patient does not remember 
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when they last had a blood pressure measurement, it may seem logical for a pharmacist 
to suggest one on the MUR form, however, this has the possibility of leading to duplication 
with information that is already present in the medical notes. Therefore, the pharmacist 
thinks he/she is being helpful where the GP views it as unnecessary interference as the 
measurement has already been performed. This has also been confirmed in survey 
research with GPs that demonstrated that over two-thirds of the sample (n=83) thought 
that pharmacy clinical services would lead to a duplication of work (Bryant et al., 2009). 
 
One factor that may be affecting the level of inter-professional working between the two 
professions is the evidence base and there is a call for higher quality evidence to support 
the continued introduction and provision of pharmacy services (Richardson and Pollock, 
2010). 
 
1.4.5 Evidence base for current pharmacy services 
The most prevalent advanced service currently being performed in community pharmacy 
is medicine use reviews (MURs). However, the evidence for their benefit for both the 
patient and the NHS is lacking. There are examples of MUR services that have worked 
well particularly in the field of asthma, depression and Parkinson’s disease.  
 
In an evaluation of an asthma targeted MUR service in Hampshire and the Isle of Wight, 
Portlock et al. describe how pharmacists identified patients who were non-adherent to 
their therapy and then helped them to understand their medicines better. From 965 
patients who received an MUR and subsequently completed a satisfaction questionnaire, 
41% of those patients who were classed as primarily adherent had problems with inhaler 
technique (secondary non-adherence) and 36% had issues with the beliefs they held 
about their medicines (Portlock et al., 2009). In the satisfaction questionnaire of attitudes 
towards the MUR service, 33% of patients said it gave them more confidence, 90% 
understood more about their treatment and 83% knew more about their condition. This is 
the purpose of the MUR and the pharmacist is equipped to deal with all the patient issues 
identified.  
 
This study, whilst extremely encouraging for asthma targeted MURs, demonstrates the 
importance of appropriate outcome measures. This study did not set out to demonstrate 
any benefit on asthma symptoms or the cost-effectiveness of the service. Without these 
two measures it becomes harder to demonstrate the effectiveness of the intervention 
and/or benefit to the NHS. It also utilised a weak study design, by simply providing the 
patients with a feedback questionnaire and making no follow-up provision to determine the 
effect on their asthma symptoms. However, it did provide evidence that targeting patients 
who potentially require help with their treatments or those who are resistant to treatment 
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by identifying them from the pharmacy or medical records may be a better group of 
patients for pharmacists to target. This has been demonstrated to be successful in other 
pharmacy settings (Lowey et al., 2007). The Isle of Wight project led to the introduction of 
targeted MURs nationally in 2011 aimed at patients on respiratory medicines 
(Pharmaceutical Services Negotiating Committee, 2011). 
 
This study was followed in the same region of the UK by the Evaluation of Inhaler 
Technique Improvement Project which aimed to focus on the same group of patients and 
provided them with two MURs, the second as a follow-up to the first (The Cambridge 
Consortium, 2012). In this before and after study, 600 patients with asthma and 828 with 
COPD received MURs which focused on their inhaler technique. As with the previous 
study and due to poor reporting of the method and results it is difficult to ascertain the 
benefit on patients despite using sophisticated IT software to collate data and link it to the 
medical practices.  
 
Both of these studies did focus on providing extra training to the participating pharmacists 
in order that they could provide the service. For the second project, despite a lack of 
information explaining what the training consisted of, the authors stated that the training 
was well received and that pharmacists felt able to deal effectively with patients’ concerns 
(The Cambridge Consortium, 2012).  
 
Other MUR projects have included targeted MURs for depressed patients (Cree, 2010).  
This project showed positive benefits when conducted by specially trained pharmacists 
working closely with the GP surgery and highlighted patients who were non-adherent and 
were experiencing side effects. The MUR covered topics such as what antidepressant the 
patient has been prescribed, if it was the first treatment course, what information they 
have already received, side effects and information provision regarding warnings about 
alcohol and driving. 145 MURs were conducted in nine pharmacies over a period of ten 
weeks, 54 of which were for patients new to the class of medicine. The study only 
determined the self-reported content of the MURs from the pharmacists and found that a 
large majority of patients had not received any additional printed information on their 
medicines prescribed for depression. As part of the service they referred 37 (25.5%) 
patients back to the GP for problems such as drug interactions and side effects. No follow-
up was provided and no patient satisfaction data was collected.  
 
Parkinson’s disease has also been the focus of a study in Greater Manchester where 
MURs were conducted on those patients prescribed medicines for the condition. The 
MURs included a series of traffic light questions that alerted the pharmacist to the level of 
control of the disease. This service resulted in 18 (34%) patients out of a total of 53 being 
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referred back to the specialist hospital unit with a third of patients reviewed found to have 
poor control of their Parkinson’s disease. Feedback from patients was positive and many 
did not know that a pharmacist could provide such a service (Colquhoun, 2010a).  
 
In a third study, a team from South Staffordshire demonstrated that targeted domiciliary 
MURs for patients discharged from a community hospital had a benefit. The project 
demonstrated that the service, which was performed on 69 patients within seven days of 
discharge, resulted in fewer admissions to both accident and emergency and the original 
community hospital as well as an improvement in functional independence, 28 days after 
discharge (Colquhoun, 2010b). The article does not mention how these figures were 
ascertained. Finally, from patients who have received an MUR it has been noted that 
there is only a small, non-significant increase in their satisfaction with information about 
the medicines as a result of the intervention by the pharmacist (Desborough et al., 2008).  
 
There is, therefore, some evidence to support the continued provision of MURs in 
community pharmacy. However, this evidence tends to focus on certain disease states 
and on providing an enhanced-MUR, with the pharmacist equipped with extra tools or 
training to be able to implement them effectively. All of these studies made increased 
communication between the pharmacist and GP essential if they were going to be 
effective. Communication may need to be improved more generally between the two 
professions in order that the quality of MURs can be improved (Blenkinsopp et al., 2007b, 
Bradley et al., 2008, Bush et al., 2009) and that targeted MURs that involve the GPs may 
provide the answer (Livingstone, 2010). However, the majority of studies described 
demonstrate a weak study design, rarely conducting a follow-up appointment or 
appropriate clinical measurements to monitor particular conditions. These studies rely 
either on the self-reporting of outcomes by the pharmacist or satisfaction surveys given to 
patients after they have experienced the MUR.  
 
In terms of the New Medicine Service, proof of concept research was published before the 
service was commissioned by the NHS, however, the service that was implemented does 
not align with the research in a number of ways. In the original article describing the 
service, patients were recruited by the dispensing pharmacist and then the intervention 
was performed by telephone by a colleague at the company’s head office (Clifford et al., 
2006). The head-office pharmacist had received half a day’s training on the theory 
surrounding non-adherence, communication skills and medicine-related problems. As part 
of the outcome assessment a researcher measured patients’ self-reporting of the following 
question: 
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People often miss taking doses of their medicines, for a wide variety of reasons. 
Have you missed any doses of your new medicine, or changed when you take it? 
 
This was used for the primary outcome measure of adherence and over a period of four 
weeks’ follow-up the intervention group reported better adherence than the control group. 
This may be due to the increased number of telephone calls being received from the 
company head office and therefore demonstrating the effect of a social desirability bias.  
 
When the service was implemented nationally, pharmacists were required to undertake no 
additional training in order to increase their knowledge of the service and communication 
skills. They had to answer questions on a form to acknowledge themselves as competent 
to provide the service. All pharmacists then had to conduct all aspects of the service 
without any additional support, meaning three additional patient interactions per service 
provided whilst still providing their core dispensing function and other pharmacy services.  
 
This service is undergoing a final evaluation (University of Nottingham, 2012) and the 
Department of Health has stipulated that the service will be discontinued if there is no 
proven benefit to the NHS.  
 
This lack of robust evidence together with constraints on time, training, skill mix and inter-
professional working have indicated that community pharmacy services may have not 
been as well received as many may have hoped. In the UK there has been other large-
scale research examining whether community pharmacy services provide a benefit to 
patients. Unfortunately, the evidence for other community pharmacy led services in the 
UK is largely neutral or incomplete. 
 
1.5 Research into potential pharmacy services 
1.5.1 UK pharmacy practice research 
The most robust pharmacy studies: RESPECT, HOMER, HEARTMED, MEDMAN and 
HEART-MOT have not focused on MURs but instead on a targeted intervention on either 
a particular patient group or disease state. There is a lack of literature examining the role 
of the community pharmacist in providing pharmacy services, however there is a 
significant body of work examining the role of the pharmacist in the wider primary care 
team. These studies have utilised different outcome measures, of different levels of 
appropriateness, and most have utilised a comparison group and been randomised 
therefore making the evidence they produce more robust.  
 
The RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the 
Community over Time) study investigated whether shared prescribing between GPs and 
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community pharmacists improved medication appropriateness in elderly patients 
(Richmond, 2010). Patients (over 75 years old and on more than five medicines) in five 
primary care trusts were recruited into a stepped wedge trial design with all patients 
recruited at the same time and acting as their own controls. The pharmacists had no 
knowledge of which patients had been recruited until just prior to the start of the 
intervention as they were recruited by virtue of their medical records at the GP surgery. 
After a control period, post recruitment, participants were given the intervention by the 
community pharmacist either in the pharmacy or the patient’s home.  
 
The intervention was the implementation of a pharmaceutical care plan (PCP) by the 
community pharmacist in collaboration with the patient and/or carers and the GP. The 
pharmacists followed a process to develop the PCP with the patient to determine what (if 
any) problems there may be with their therapy. Most of the intervention was based on 
clinical indications for use, presence of adverse drug reactions and the potential for drug 
interactions. Patients were also given access to medicines adherence aids if this was 
deemed necessary as well as education regarding their therapy. The intervention lasted 
12 months, the study recruited 760 participants of which 551 were included in the final 
analysis. These participants were recruited from 24 medical practices and 62 community 
pharmacies provided the service. 
 
In order to conduct this intervention the pharmacist received two days’ training provided 
by two universities. GPs were asked to attend the second training day so that both groups 
could learn about collaborative working relationships. The pharmacists received training 
on pharmaceutical care in the elderly as well as learning how to involve patients in the 
development of pharmaceutical care plans. The training took place just before the start of 
the intervention group, so that the pharmacists did not forget their newly acquired 
knowledge. 
 
The primary outcome measure of the study was the medication appropriateness index 
(MAI) in which an independent pharmacist assigned scores to each patient at various time 
points during the study. Secondary outcomes included patients’ knowledge and 
compliance, incidence of adverse events and health-related quality of life via the SF-36 
questionnaire. The results from the study demonstrate that the pharmacist intervention did 
not produce a significant result in terms of improvements in medication appropriateness 
nor did it have any significant effect on the health-related quality of life of the participants. 
The mean number of reviews conducted by the pharmacist on each patient over the 12 
month period of the study ranged from 4.1 to 11.1 between the five different primary care 
trusts (PCTs).  
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A cost-effectiveness analysis of their result found that the intervention cost £192 more 
than standard care per patient or £10,000 per Quality Adjusted Life Year (QALY) (Bojke, 
2010). The study highlighted that this estimate means that it is between 79-81% likely to 
be cost-effective to provide this intervention to patients given the current NICE thresholds 
of £20,000 - £30,000 per QALY. However, this study was only conducted over a period of 
twelve months and costs incurred after this time were not factored in and the authors state 
that this may be likely to underestimate the actual figure for cost-effectiveness. There was 
also a large degree of uncertainty in the results due to the heterogeneity of the sample 
which identified that it was possibly more cost effective to treat younger patients on fewer 
medicines.  
 
The rationale for conducting a cost-effectiveness analysis appears to be lacking as this 
study produced no significant difference between groups and cost more than standard 
care to provide. Other disease orientated primary outcomes may have been more 
appropriate in this study to demonstrate an effect in this group of patients. This may have 
given a better indication of any patient benefit arising from the study. 
 
The HOMER trial examined the role of pharmacists in medication review post discharge in 
a patient’s home (Holland et al., 2005), was conducted in Norfolk and Suffolk in the UK 
and used mainly community pharmacists. Twenty-Two Pharmacists were recruited to the 
study because they held a postgraduate qualification in pharmacy practice or had 
completed recent continuing professional development (CPD) in therapeutics. They 
received a two day training course that comprised lectures on adverse drug reactions, 
prescribing in the elderly and communication skills before they saw any patients.  
 
This study was a randomised controlled trial where the pharmacist visited the patient post-
discharge with the aim of performing a medication review. The pharmacist educated the 
patient and carers about their drugs and liaised with their GPs regarding any changes 
they felt should be made to their regimen. Any compliance issues were referred to their 
local community pharmacist. The pharmacist visited again six to eight weeks later to re-
enforce any advice given at the beginning and further advise participants. The control 
group received usual care.  
 
The study identified potential participants in hospital after they had been admitted as an 
emergency. Patients were eligible to take part if they were about to be discharged to the 
community, were over 80 years old and were prescribed two or more medicines. The 
team approached 1399 patients of which 872 patients were recruited and the final 
analysis was performed on 829. The main outcome measure was hospital re-admissions 
and the secondary outcome measures were quality of life, deaths and number of GP 
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home visits. The intervention by pharmacists increased hospital re-admissions by 
approximately 30% and GP visits by 43% when compared to the control group which 
could also have increased the number of medicines prescribed. There was no 
improvement in quality of life as measured by the EQ-5D instrument.  
 
A cost-effectiveness analysis was also performed in this study and stated that the cost per 
randomised patient of providing the intervention was £124, leading to a total intervention 
cost of £51,622. Due to the small, non-significant improvement in the EQ-5D the cost per 
quality adjusted life year (QALY) is £54,454 and considering this and the lack of a 
reduction in hospital admissions the authors state that further consideration should be 
given to whether medicines management should be implemented in community pharmacy 
(Pacini et al., 2007).  
 
This study set out to prove the value pharmacists could have post-discharge from hospital 
in the elderly, something that it did not achieve. There may be several reasons for this. 
The biggest criticism of the study and one reason why it failed to show a benefit may be 
due to the consultation skills of the pharmacist. It has been shown that the pharmacists 
took a didactic approach to the consultation in the patient’s home, giving the patient 
information and advice that they did not solicit (Salter et al., 2007). The recruitment and 
training of the pharmacists may have also played a role. There may have not been 
enough training for the pharmacists for such wide-ranging intervention (this was not a 
disease-specific intervention) on clinical skills or consultation skills. The authors also note 
that this intervention may have increased adherence to potentially inappropriate therapy 
which resulted in an increase in hospital admissions; a full clinical review of the medicines 
was not part of the study (Holland et al., 2005).  
 
The HOMER study was followed by the HEARTMED study conducted by the same 
research team which was a disease specific intervention (heart failure) and used the same 
methodology as HOMER (Holland et al., 2007). The pharmacists received one training 
course on the organisational and clinical aspects of the study. Half of the pharmacists also 
attended two evening events aimed at improving their consultation skills. Once recruited 
to the study, participants were visited at home by the pharmacist in order to review their 
medicines, educate patients about heart failure as well as providing them with lifestyle 
advice. Any recommendations for alterations to prescribed therapy were communicated to 
the GP and compliance problems were fed back to the community pharmacist. The follow-
up visit was scheduled in for 6-8 weeks after the initial visit. The control group received 
usual care.  
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The recruitment criteria were identical to HOMER with the exception of the age range; 
HEARTMED recruited patients over the age of 18. 555 patients were approached to 
participate, 339 randomised and the final analysis performed on 291 participants. The 
primary outcome measure was hospital emergency admissions with deaths, EQ-5D and a 
disease specific instrument forming the secondary outcome measures. As with HOMER 
the primary outcome measure increased (non-significantly) in the intervention group and 
there were no significant differences between groups for any of the secondary outcome 
measures.  
 
The results from this study demonstrate that even away from the busy environment of the 
community pharmacy, pharmacists are not able to have a significant impact on hospital 
admissions. Patients were recruited from the hospital to which they were admitted with 
heart failure, which may have helped to recruit a large number of people to the study. 
However, for this type of study it may not have been appropriate to recruit post-discharge 
as patients will have already had a medication review whilst as an inpatient. It may 
therefore be more appropriate and demonstrate a better effect by recruiting directly from 
the community. There is also another aspect of specialist training required to provide this 
type of intervention. Many patients will visit a specialist heart failure nurse before leaving 
hospital and receive information and advice about their condition. When compared to a 
generalist pharmacist who has received some additional training and who does not 
implement this training on a regular basis, it may not be a surprise that this study failed to 
produce significant positive results.   
 
The MEDMAN study, an RCT examining whether a community pharmacist-led medicines 
management service for patients with coronary heart disease (CHD), was conducted 
between 2002 and 2004 and recruited 1493 participants in 70 pharmacies across nine 
primary care organisations (Jaffray et al., 2007a). Pharmacists were provided with a 
training package developed by CPPE which consisted of a launch event, CHD training 
and a full day communication event and also included case studies. Participants were 
randomised to receive the service which consisted of an initial consultation with the 
pharmacist, who had been given data from their medical record, focussing on therapy, 
compliance, lifestyle and social support. Those randomised to the control group received 
usual care from the GP and community pharmacist, although the pharmacist was aware 
that they were participating in the study.  
 
The primary outcome measures for this study were the percentage of patients receiving 
appropriate treatment for CHD according to the National Service Framework (NSF), health 
status and a health economic analysis. The study produced no significant difference 
between control and intervention in the primary outcome measures of appropriate 
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treatment or health status. This may be due to the percentage of patients that were 
already on appropriate treatment at baseline and therefore there may have been little 
room for improvement. The cost-minimisation analysis demonstrated a significant 
difference between the control and intervention groups largely due to the training provided 
to the pharmacists. There were no other improvements in any of the secondary outcome 
measures apart from the participants satisfaction score in the intervention group. 
 
The failure of this study to produce a significant result may be due to a number of factors. 
Pharmacists were aware of those participants that were acting as controls and may have 
approached and treated them differently because of their involvement in the study. A 
method to avoid this may be to randomise by pharmacy. At the time of the study the 
Quality and Outcomes Framework (QOF) was being introduced in medical practices which 
incentivises appropriate prescribing and therefore GPs may have already reviewed all of 
their patients with CHD. As such, and due to the high number of participants who were 
already prescribed appropriate therapy at baseline, it may have been more appropriate to 
selectively target patients who were not conforming to treatment recommendations and 
focus the intervention on them.  
 
On further analysis of the paperwork that was submitted to the research team by the 
pharmacists and GPs there appeared to be a lack of consistency in the way pharmacists 
were completing their paperwork and recommendations (Krska et al., 2008). They 
discovered that pharmacists were only documenting around a third of potential 
recommendations to the prescriber including lifestyle issues, potentially ineffective therapy 
and the need for additional therapy. This may have led to a reduction in the potential 
effect size that resulted from the study.  
 
Participating pharmacists were also asked about their training for the study as part of the 
evaluation. The training programme for pharmacists was varied and provided an overview 
of all aspects needed to conduct the service. 50% of pharmacists at baseline identified 
that they needed more CHD training in order to feel comfortable providing the service and 
after this had been completed most felt confident providing the service (Jaffray et al., 
2007b). However, over 50% still required more training after these initial sessions to make 
them fully confident. This resulted in 68% of pharmacists undertaking an additional 10 
hours’ worth of training outside of the study in order to feel confident to provide the 
service. At the start, few pharmacists wanted extra training with regards to consultation 
and communication skills. It is not clear from the data whether it was compulsory for 
pharmacists to attend the training sessions but considering when this study was 
conducted, pharmacists were not used to conducting consultations with patients, 
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documenting advice and making clear recommendations to prescribers and this may have 
affected the success of the study.  
 
A review of the effect of pharmacist-led medication review on hospital admissions was 
conducted by Holland et al. in 2008. They found that, in line with the findings from their 
studies, pharmacist-led medication reviews do not have any effect on reducing hospital 
admissions or mortality (Holland et al., 2008). This review included 32 studies, eleven of 
which were conducted by a community pharmacist. Of these eleven, three were 
conducted by a sole pharmacist, the so called ‘super pharmacist’. The only potential 
benefit that this review identified was that of improved patient knowledge and adherence 
to medication.  
 
The HEART-MOT service was designed to opportunistically target people who were at 
risk of cardio-vascular disease (CVD) and provide them with a free risk assessment rather 
than provide a management service for an existing condition. This study was conducted in 
community pharmacies in Birmingham and was heavily marketed in pharmacies and 
surrounding areas (Horgan et al., 2010). No detail was provided on the pharmacists’ 
training for the service, however, they did have to have experience of providing cardio 
vascular risk assessments before they were allowed to participate. Once enrolled, 
participants had a full CV risk assessment conducted (blood pressure measurement, non-
fasting cholesterol, smoking and diabetes status) in order to calculate their 10 year risk of 
developing CVD. Patients identified as high risk were referred to their GP for further 
investigation. There was no follow-up provided to the participants.  
 
From the 1130 participants for whom there were data available, referrals to their GP were 
made in 70% of cases. Apart from data on the reason for referral, no other outcome 
measures were used. People were referred for the following reasons: elevated blood 
pressure, elevated cholesterol levels and when they were found to have an elevated CVD 
risk (n=201). Patients were required to take a referral sheet to the GP surgery themselves. 
The results from the study demonstrated that the service targeted hard to reach 
populations such as men and those patients from deprived areas and ethnic minorities 
and brought them into the care of the NHS. No outcomes data were collected and 
therefore the cost-effectiveness of the service could not be determined. 
 
Whilst these studies represent the more robust community pharmacy based research in 
the UK (with the exception of HEART-MOT) there were wide variations in the selection of 
outcome measures, delivery of training for the pharmacist for the service and consultation 
skills, types of intervention and lack of a quality health economics analysis. Only two of 
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the studies above performed a cost-effectiveness analysis, something that is essential to 
provide evidence of benefit to the NHS.  
 
The use of appropriate outcome measures is one that dominates the field of health 
research, not just pharmacy practice. There has been a rise in the use of patient reported 
outcome measures (PROMs) for studies involving patients as a method of measuring their 
disease state as it affects them (Dawson et al., 2010). Although beneficial to researchers, 
PROMs are not the only measures of patient outcomes. The classical clinical indicators 
e.g. HbA1C for diabetes or blood pressure for hypertension still need to be reported 
alongside PROMs in order that clinicians have all the information about the effect of a 
particular intervention, something that pharmacy practice research is not alone in omitting 
(Rahimi et al., 2010). Research methods in pharmacy practice and especially the 
appropriate selection of outcome measures needs to be improved which is something the 
Government (Department of Health, 2008) as well as leaders in the field acknowledge 
(Ambler et al., 2009, Bond, 2008, Simoens, 2008, Walker, 2010).  
 
The other aspect to community pharmacy research that can limit its ability to demonstrate 
effectiveness is that of intervention design. Most community pharmacy studies conducted 
in the UK are one-off interventions where the pharmacist is expected to have an effect on 
patient outcomes after a relatively small amount of time. This may be due to researchers 
being cognisant of the time pressures faced by community pharmacists and therefore 
attempting to make the intervention as quick as possible. However, if researchers want to 
prove the effectiveness of an intervention or service then it needs to be on the same terms 
as other healthcare professionals. It has already been demonstrated that building the 
relationship with the patient has benefits to health (Miller and Rollnick, 2002) and 
pharmacists cannot be expected to build this relationship in such a short period of time. 
However, in order for this to occur, significant changes to the contractual and operational 
frameworks in which community pharmacy is conducted be will needed.   
 
1.5.2 International community pharmacy research 
It is not just in the United Kingdom that research activity and the profession of pharmacy 
practice has expanded over the past few years. Community pharmacy has also 
undergone rapid and marked change in other countries around the world in the recent 
years (de Castro and Correr, 2007, Eickhoff and Schulz, 2006, Guignard and Bugnon, 
2006, van Mil, 2005, Westerlund and Bjork, 2006), but most notably in Canada, Australia, 
New Zealand and the United States. This section will explore community pharmacy and 
the research conducted in some of these countries. 
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1.5.2.1 Australia / New Zealand 
In both Australia and New Zealand, pharmacy is moving towards a much more service 
orientated profession in conjunction to its dispensing of medicines function. As in the UK, 
services to address the way in which patients take their medicines are now becoming 
more common. In fact, in both countries the medicine use review (MUR) now forms an 
integral part of the community pharmacist’s activities.  
 
In New Zealand, the Pharmaceutical Society of New Zealand in 2004 published its vision 
for pharmacy over the next ten years which outlined the need to change to a service 
driven, patient-focused profession (Pharmaceutical Society of New Zealand, 2004). 
Pharmacists have reacted positively to this shift, however, they highlight the need to 
maintain their original technical and clinical role within the health service (Scahill et al., 
2010). In both countries, pharmacists also highlight the lack of research support they 
receive to highlight the value of pharmacy and problems with remuneration for the new 
services that they are expected to perform (Scahill et al., 2009, Roberts et al., 2005).  
 
In a study by Saini et al. Australian pharmacists detail that they would be willing to 
participate in a research project if they had an interest in the research area, a belief that it 
will benefit the customer and felt that research in the field of pharmacy is actually 
important. Once again they also highlight that the availability of time is a key consideration 
as to whether they participate or not (Saini et al., 2006). Nonetheless, the research output 
from Australia has been promising over the past few years. 
 
Pharmacy practice research in Australia has made significant advances in the fields of 
diabetes and asthma (Saini et al., 2011). Ines Krass and her colleagues at Sydney 
University recently conducted The Pharmacy Diabetes Care Program in community 
pharmacies in four areas of Australia (Krass et al., 2007). This RCT was different to most 
pharmacy studies conducted in the UK by the virtue of the extended nature of the 
intervention. Participants met with the pharmacist five times over a period of six months. 
The intervention included a defined protocol and engaged the patients on a variety of 
topics including self-monitoring of blood glucose, education on all aspects of their disease 
and medication, adherence support and medication review. Control participants attended 
the pharmacies for baseline and final data collection which included patient 
questionnaires. 
 
In order for the pharmacists to deliver the intervention effectively they underwent a two 
day training course after completing a manual of self-directed learning. This training 
course comprised all aspects of diabetes care including role-playing exercises and 
training on the use of blood glucose testing meters.  
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The study recruited 56 pharmacies in total; 28 intervention and 28 control, with each 
pharmacy asked to recruit ten patients. This study targeted poorly controlled patients with 
type 2 diabetes on at least one anti-hyperglycaemic medicine or patients who had multiple 
co-morbidities such as hypertension or hyperlipidaemia and were prescribed medicines to 
treat these conditions. HbA1C and blood pressure data was confirmed by contacting the 
GP.  
 
The main outcome measures were mean HbA1C systolic and diastolic blood pressure, lipid 
profile and BMI, with the secondary outcome measures being scores on the EQ-5D quality 
of life scores. For the main outcome measure of diabetes control, the intervention group 
had a significantly greater reduction over a period of six months when compared to the 
control group. There were also reductions in blood pressure, total cholesterol and 
triglycerides but no significant difference between groups. Health-related quality of life, as 
measured by the EQ-5D improved significantly in the intervention group when compared 
to the control group.  
 
This study demonstrated that a prolonged intervention conducted by community 
pharmacists can be effective in improving a particular disease state. This study was 
helped by a number of factors: the fact that pharmacies were either providing the 
intervention or recruiting control patients potentially made it easier for the pharmacists to 
participate and also helped to reduce the risk of cross-contamination between the groups. 
Each pharmacy only had to recruit ten patients, which was an achievable target for each 
pharmacy and because of the high number of pharmacies participating, the overall 
number of patients remained high as well. This method also helped to demonstrate the 
potential benefits of many pharmacists and not just a singular pharmacist.  
 
This group of researchers has helped to demonstrate the effectiveness of this type of 
service on more than one occasion (Krass et al., 2005). They have also used a variety of 
other methods to measure the effectiveness of the services that they have trialled 
including cost-effectiveness studies (Taylor et al., 2005) and patient satisfaction with the 
service (Krass et al., 2009), all of which are discussed in more detail in chapter three.   
 
1.5.2.2 Canada 
Until 2003, community pharmacy research in Canada largely focused on the completion of 
questionnaires by patients and pharmacists (Sokar-Todd and Einarson, 2003). Again, as 
in the UK at the same time, Sokar-Todd and Einarson’s paper identifies the need to 
strengthen the design and quality of research studies in the field of community pharmacy. 
There are, however, examples of good research from Canada, most notably from the 
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SCRIP (Study of cardiovascular risk intervention by pharmacists) team based at the 
University of Alberta. This team has performed two RCTs in patients that have high 
cholesterol (SCRIP) (Tsuyuki et al., 2002) and hypertension with diabetes (SCRIP-HTN) 
(McLean et al., 2008). Both studies were conducted in community pharmacies in Alberta, 
Canada by pharmacist and nurse teams.  
 
The SCRIP-HTN study involved the participant attending a clinic at the community 
pharmacy conducted by the community pharmacist and nurse teams where they would 
undergo cardiovascular risk reduction counselling. At all points during the article, there is 
no distinction between the aspects of the service conducted by the pharmacist and those 
conducted by the nurse. The counselling included measurement and discussion of blood 
pressure and risks associated with it being high, how their diabetes affects blood pressure 
and how they could change their lifestyle to improve the control of their disease. They 
were also given a blood pressure record card where their BP readings were recorded after 
every consultation. Participants attended a consultation with the pharmacist or nurse 
every six weeks for a period of 24 weeks.  
 
The pharmacists who participated in the study underwent a training program that included 
online learning and a case based learning session both based on national guidelines. 
Recruitment criteria included all patients with diabetes with a blood pressure greater than 
130/80mmHg on two visits, two weeks apart. Diabetes was confirmed from the pharmacy 
records, if a patient had had oral hypoglycaemics medicines for the past six months or 
more.  
 
The main outcome measure for this study was blood pressure at 24 weeks with secondary 
outcome measures including the achievement of BP targets, number of medicines 
prescribed for hypertension and number of patients prescribed an angiotensin converting 
enzyme inhibitor (ACEI) or similar alternative. At 24 weeks, there was a significantly 
greater fall in systolic blood pressure in the intervention group (-10.1 mmHg) when 
compared to the control group (-5.0 mmHg). This effect was much greater if the 
participant had particularly poorly controlled blood pressure at baseline. The number of 
patients achieving targets for blood pressure (with co-morbid diabetes) experienced a 
significantly greater increase in the intervention group.  
 
Both of these studies appear to provide robust evidence for this kind of intervention. 
However, the lack of definition surrounding the role of the pharmacist and nurse leaves 
the reader confused as to which aspects the pharmacist is responsible for and therefore 
the degree to which the results can be attributed to them.  
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1.5.2.3 United States of America 
In the US, Lee and colleagues performed a randomised controlled trial in 200 patients 
who were on four or more chronic medicines at the Walter Reed Army Medical Center in 
Washington DC to determine if a pharmacy intervention over a period of six months 
improved their control of blood pressure and cholesterol levels (Lee et al., 2006).  
 
The study consisted of a run-in phase in which no participants received any educational 
intervention, instead a baseline adherence measure was performed. Phase one 
(observation) of the study followed this run-in and all patients participated in this aspect of 
the study, where they received the educational intervention which included medication 
education, the provision of adherence aids and regular follow-up every two months. All 
participants had their medication dispensed in a multidose adherence package that was 
returned to the pharmacy before the next one was issued. Phase one lasted 
approximately six months. The initial visit with the pharmacist lasted approximately one 
hour with subsequent visits lasting up to 30 minutes. After this the participants were 
randomised to either continue with the pharmaceutical care program or return to usual 
care which meant the participants returned to having their medicines dispensed as they 
would have done normally. This phase lasted a further six months for both groups. 
 
Patients were recruited from an outpatients service and a retirement home and were likely 
to be non-adherent to their medicines due to their age and the number of medicines they 
were prescribed. No information was given about the training of the pharmacists for the 
study.  
 
The primary outcome measure was the change in medication adherence as measured by 
a pill count from the returned multidose package and secondary outcome measures were 
changes in blood pressure and LDL-cholesterol. At the end of the study, the intervention 
group had a significantly higher adherence to medication than the control group as well as 
significantly lower systolic blood pressure. There were no significant changes between 
groups in diastolic blood pressure and LDL-cholesterol levels.  
 
All of these studies produced a positive result for the role expansion of community 
pharmacy. However, they demonstrated their effectiveness by allowing the pharmacist 
and patient time to develop a relationship and therefore have an effect on the condition 
they were treating. These studies had good clinical and humanistic outcomes and the 
design was practical enough to allow the pharmacist to conduct them at the same time as 
performing their normal role.  
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1.6 UK community pharmacy research practice 
We have seen that it is possible to conduct good quality research in community pharmacy 
from international studies, however, as demonstrated, research from UK has largely failed 
to produce a convincing argument for service expansion. This may be due to issues 
surrounding perception of research and its impact on practice, education and training and 
development and testing of research processes in this setting.  
 
1.6.1 Perception of research in community pharmacy 
Conducting research in the NHS is difficult in all settings but community pharmacy does 
not lend itself easily to performing research. As previously discussed, community 
pharmacy is an environment in which pharmacists have to provide clinically focused 
services alongside maintaining their dispensing function and this can affect their ability to 
engage from the outset. It may seem logical that research would be low on the list of 
priorities. Coupled with this the short duration of a visit by a patient to the pharmacy, 
sometimes only for a matter of minutes when they come to collect their prescription, a 
researcher can find it difficult to design and recruit patients to a study (Desborough et al., 
2008). One other aspect that makes it potentially more difficult for community pharmacists 
to recruit patients is the process of obtaining consent. In most settings in the NHS, the 
researcher/clinician has a potential participant in their clinic or practice and can devote a 
proportion of their time, which is largely protected from interruptions by the patient or staff, 
to recruit that patient. Community pharmacy is a unique healthcare environment in which it 
is difficult to obtain consent due to the nature of the work of the community pharmacist 
and their interactions with patients.  
 
Petty et al. examined this point in more detail when they asked why elderly patients 
declined to participate in a research project. They found that patients had the following 
reasons for not participating in the research project that they had been invited to join 
(Petty et al., 2001): 
 
 Nature of the invitation letter 
 Not contactable 
 Confusion or lack of understanding 
 Unwell 
 Unavailability 
 Impact of relationship with the doctor 
 Desire not to have medication altered 
 Perceived simplicity of medication regimen 
 Negative attitude to healthcare 
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 Mistrust of the stated study objectives 
 
With reference to the pharmacist’s views on conducting research, some work has already 
been conducted in this field. The issue of lack of availability of pharmacists’ time to 
provide these extra services repeatedly resurfaces in the literature as, discussed 
previously, pharmacists are still responsible for checking every prescription that is 
presented in the pharmacy, which, for a busy pharmacy, can take almost all of their 
working time. However, as Cvijovic et al. note, in Canadian pharmacy practice research 
this may be being given by pharmacists as something of an excuse to cover over issues 
relating to their own reservations about how taking part in research may impact on their 
‘established work routines’ and whether the pharmacist perceives the research to be 
valuable to them (Cvijovic et al., 2010). In a study that aimed to find out about barriers and 
perceptions of a particular research project conducted in community pharmacy, they found 
that “time” and “being too busy” were offered as acceptable excuses to researchers. 
However, this perhaps masked other issues relating to pharmacists’ understanding of a 
study they might be involved in, the questions they might be asked and also the value 
they themselves placed on the research. Similar reservations about taking part in 
research have also been noted for GPs and nurses (Roxburgh, 2006, Salmon et al., 
2007). 
 
1.6.2 Pharmacist education and training 
In the studies analysed in section 1.5.1 there are three main themes relating to the failure 
to prove an effect of community pharmacy interventions in the UK all of which are as a 
result of education and training. These themes centre on whether the pharmacist has the 
appropriate clinical, consultation and inter-professional skills. All of these are now taught 
as part of the pharmacy undergraduate degree programme, however, this has only 
become common in last ten years. 
 
The background to pharmacy education is one of science not practice. When the first 
pharmacy school was established in 1842 the basis of the course was chemistry 
(Unknown, 1843), and was an apprenticeship with a minor exam after a period of lectures 
and a major exam after working as a chemist’s assistant for a period of time.  There was 
no formal legislation covering the educational requirements of pharmacists and many 
chemists and druggists and members of parliament opposed such education in various 
attempts from 1852 to 1890 (Hansard, 1887). This position altered significantly in the early 
part of the 20th century with enactment of three key pieces of legislation: The Technical 
Instructions Act 1889, the Pharmacy Act 1908 and the National Insurance Act 1911 
(Anderson, 2005). The result was a requirement for people who wanted to train as a 
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pharmacist to attend a recognised school of pharmacy, undertake relevant work 
experience and pass examinations set by the Pharmaceutical Society.  
 
Until the 1980s the majority of the pharmacy course remained science-based as 
pharmacists, at the time, were still required to compound medicines in response to a 
prescription and therefore required this knowledge. As compounding became less 
common due to the introduction of original pack dispensing, many pharmacists found that 
their science based course was not preparing them for the realities of pharmacy in the 
mid-1980s (The Nuffield Foundation, 1986). The Nuffield Report of 1986 stated that the 
pharmacy degree should comprise more appropriate teaching to include clinical topics, 
core science as well as the social aspects of pharmacy e.g. patient behaviours and issues 
surrounding compliance as well as practical experience.  
 
However, this could only be achieved if the degree course was changed to include more 
clinical teaching so that they were able to advise patients and prescribers appropriately. 
This increased teaching that was now required of the pharmacy degree in terms of both 
clinical and practice subjects was difficult to fit into a three year degree and consequently 
in 1997, the requirements for registration as a pharmacist changed to a four-year master’s 
degree and a period of pre-registration training post-graduation (12-months).  
 
As a degree pharmacy is funded as a science based degree and not a health degree e.g. 
medicine. Consequently, the funding available for university education and therefore for 
clinical placements and significant clinical teaching is limited and the majority of pharmacy 
schools are still based within faculties of science and not faculties of health (Wright et al., 
2006.). The modernising pharmacy careers (MPC) programme board (a division of 
Medical Education England now Health Education England) is currently examining the 
possibility of changing the degree course to include, amongst other things, substantial 
placements and the integration of the pre-registration year into undergraduate training to 
fall in line with other healthcare professional training (Medical Education England, 2011). It 
has also recommended that the pharmacy degree course is funded by at least a 12-month 
clinical supplement in addition to its science funding. Working alongside this, MPC is also 
examining postgraduate education and training to ensure that pharmacists continue to 
learn and develop once they have left university (Howe and Wilson, 2012). 
 
These changes to the undergraduate and postgraduate education programmes may 
provide pharmacists with the improved clinical knowledge and skills to enable them to 
interact better with other healthcare professionals and patients. However, this only 
accounts for those pharmacists that are newly qualified. Researchers need to be aware of 
the need to increase the knowledge and skills of pharmacists that have been qualified for 
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many years and is especially true for consultation and communication skills. In the 
MEDMAN project examined earlier, pharmacists stated that they had no need for 
communication skills training, however, the HOMER study found that the pharmacists’ 
intervention may have increased hospital admissions and this is potentially due to their 
lack of ability to communicate effectively with patients. This may be something that has 
recently been highlighted as part of a series of focus groups with pharmacists. 
Pharmacists thought that their consultation skills, built up over a number of years’ 
experience, were adequate for their job and that they required little extra training to 
account for new techniques to  communicate with patients (Al-Nagar et al., 2012). It may 
also point to the need to train pharmacists more effectively in behaviour change 
techniques as these vary in their approaches and require specific skills and consultation 
styles.   
 
1.6.3 Development of complex interventions 
The other aspect to research that is conducted in the community pharmacy setting in the 
UK that may lead to a failure of the studies is the lack of preparatory work that is 
conducted before these projects are performed on a large scale. In 2000 the Medical 
Research Council published its guide to developing complex interventions in any setting 
(Medical Research Council, 2000). This was updated in 2008 and defined what 
constitutes a complex intervention (described in box 3) and what preparatory work should 
be conducted first. The guidance then states a four stage process for developing and 
evaluating a complex intervention and this is described in figure 1.1.  
 
Box 3 Aspects of complexity from the MRC framework (Medical Research Council, 
2008) 
 Number of and interactions between components within the experimental and control 
interventions 
 Number and difficulty of behaviours required by those delivering or receiving the 
intervention 
 Number of groups or organisational levels targeted by the intervention 
 Number and variability of outcomes 
 Degree of flexibility or tailoring of the intervention permitted 
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In the development phase it is important that a review of the literature is performed to 
identify current research to learn from previous work and to determine what works and 
what does not in any one particular setting. It is also necessary to conduct preliminary 
projects to inform the theory surrounding the research being performed. This may include 
qualitative methods or clinical audit to establish the basis for conducting any intervention. 
 
Feasibility testing and piloting are considered as ‘key elements’ that should be conducted 
when developing complex interventions (Medical Research Council, 2008). There is little 
consensus in relation to the definition of feasibility and piloting and therefore the terms are 
often used interchangeably. However, Arain et al. succinctly describe the differences 
between the two as follows (Arain et al., 2010): 
 
Feasibility: does not necessarily have to be randomised, can be used to detect response 
rates, number of eligible participants and the willingness of clinicians to recruit and 
randomise participants. This type of study may not have the same outcome measure as 
the main RCT. 
 
Pilot: small version of the main study to ensure all the components of the study work 
together as planned by the research team. The data from this study can be added to that 
of the main study (internal pilot) or removed and used separately (external pilot). 
 
With reference to the studies examined in section 1.5.1, a clinical audit would have 
identified issues surrounding participant identification for the MEDMAN study and 
Feasibility/piloting 
1 Testing procedures 
2 Estimating recruitment /retention 
3 Determining sample size 
 
Evaluation 
1 Assessing effectiveness 
2 Understanding change process 
3. Assessing cost-effectiveness 
 
Implementation 
1 Dissemination 
2 Surveillance and monitoring 
3 Long term follow-up 
 
Development 
1 Identifying the evidence base 
2 Identifying/developing theory 
3 Modelling process and outcomes 
 
Figure ‎1.1 The development and evaluation of complex interventions (adapted from MRC 2008) 
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feasibility testing some of the problems surrounding randomisation and potential 
contamination. This developmental work can also be used to determine not only the 
pharmacists’ satisfaction with the training provision but also the researcher’s viewpoint on 
whether it appeared adequate enough to enable the pharmacists to conduct the study. 
The evaluation of the feasibility study is also useful to identify if the appropriate outcome 
measures have been used and an estimation of the intervention effect size using these 
measures.  
 
In effect, this means that appropriate testing of small components of the research are 
essential before conducting a large scale study in an attempt to identify some of the 
problems that may occur with the project. This is particularly important for research 
conducted in the community pharmacy setting, as it is a unique healthcare environment 
that is largely isolated from the rest of the primary care team and as discussed there may 
be issues surrounding education and training as well as perception to overcome before 
conducting a full-scale RCT.  
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1.7 Conclusion 
Over the period from 1950 to 2000, community pharmacy has remained almost stationary 
in terms of healthcare provision, preferring to focus on dispensing as its main role. 
However, in recent years, with the UK government anxious to utilise the pharmacist’s 
skills to better effect within the NHS, their role has started to change into one that is more 
patient focused and less reliant on dispensing medicines.  
 
This vision for pharmacy in the 21st century is important as costs are set to rise in the NHS 
and pharmacists may provide a more cost-effective use of resources to combat the 
increasing number of people diagnosed with a long-term condition. Pharmacists are in the 
ideal location to realise this vision due to the significant and sustained number of 
interactions between patients and themselves. However, there may be several barriers to 
achieving this vision which include logistics, inter-professional working and evidence.  
 
Community pharmacists need to work more closely with other healthcare professionals 
and researchers to better define their role in the wider primary care team. This may come 
from changes to the undergraduate curriculum that encourages increased inter-
professional working from an early stage in a pharmacist’s career. It also extends to 
increasing the education and training provided to pharmacists that are currently qualified 
as unless they have the appropriate clinical and communication skills other members of 
the primary care team may not be ready to entrust their patients to the community 
pharmacist.  
 
Finally, there needs to be an increased effort on providing good quality evidence for 
community pharmacy services. There needs to be an approach to community pharmacy 
research that aligns with the MRC framework for developing these types of interventions. 
This needs to include appropriate preliminary work including literature reviews, clinical 
audit, qualitative approaches with interested stakeholders and appropriate feasibility and 
piloting before conducting large scale research in this setting.  
 
The Government has provided community pharmacy with the vision and this thesis will 
therefore focus on the design and implementation of a novel intervention focused on 
improving the care of patients with long-term conditions provided by the community 
pharmacist. The thesis will explore what this intervention should look like and what sort of 
problems the pharmacist should be discussing with the patient. It will use the MRC 
framework and attempt to factor in the elements described in this first chapter, including 
improved interprofessional working, outcome measures and logistics. These will be 
factored in after preliminary work has been conducted to determine what level of 
interprofessional working is necessary, which outcome measures are appropriate for the 
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type of study conducted and what level of support is required to assist the pharmacists in 
providing such an intervention in the community pharmacy environment.   
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 Chapter Two 
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2. A randomised controlled trial of a Pharmacist-LEd EcZema 
management support service (PLEEZ): a feasibility study 
 
2.1  Introduction 
The Government agenda for pharmacy is to expand the role of the community pharmacist 
in the management of long term conditions. One way of achieving this is via the 
implementation of enhanced pharmacy services as discussed in chapter one. Most 
enhanced services in community pharmacy focus on one specific area of concern with 
which pharmacists have the equipment and ability to assist patients e.g. smoking 
cessation, emergency hormonal contraception or NHS health checks. One clinical area 
that aligns with this is the condition of eczema. This condition has a low clinical risk of 
harm to the patient, does not necessarily require the patient’s medical notes and 
pharmacists would not require excessive clinical training to be able to conduct the service. 
The National Institute for Health and Clinical Excellence (NICE) guidance for atopic 
eczema in children also recommends research into educational programmes and 
adherence to therapy as there is little evidence currently available (National Collaborating 
Centre for Women's and Children's Health, 2007b). Pharmacists are already familiar with 
adherence interventions e.g. MUR and therefore eczema may provide the ideal target for 
an enhanced pharmacy intervention.  
 
2.1.1 Eczema 
Atopic eczema is a chronic, relapsing, inflammatory skin condition typically affecting the 
flexures where it presents as a papular rash; however, affected individuals will generally 
also have widespread dry skin. The aetiology of eczema is not fully understood but dry, 
inflamed skin is partially due to an inappropriate immune response resulting in the 
production of inflammatory mediators which cause damage to the stratum corneum 
(Kumar and Clark, 2002b). The highly itchy nature of the condition often results in the 
papular lesions becoming excoriated and thus colonised with Staph. aureus, hence 
impetigo-like lesions are common. In addition to contributing to secondary infections, it is 
likely that the itchy nature of eczema will result in insomnia (Plotkin, 2004). 
 
Eczema frequently presents in early childhood, improves with age and resolves by 
adulthood, although it can affect people of any age. UK reported lifetime eczema 
prevalence in children has ranged from 25% to 41% (Harris, 2007, Kurukulaaratchy et al., 
2003) and observation of epidemiological trends have demonstrated a gradual increase in 
eczema prevalence (Ninan and Russell, 1992). 
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Given the increasing prevalence of eczema, the costs incurred due to eczema are also set 
to rise. Estimations of annual eczema associated costs have included the cost of NHS 
care such as hospital and GP consultations and the cost of therapy. There is also a 
potential loss of parental income as a result of caring for an ill child. A positive correlation 
between annual cost and eczema severity has been reported with an analysis of severely 
affected children reporting a mean annual cost of £740 per child (Herd et al., 1996). 
Evidence has shown that approximately 80-85% of patients experience mild eczema 
symptoms, 15-20% experience moderate symptoms and 1-2% the severe form of the 
disease (Ben-Gashir et al., 2004, Emerson et al., 1998). 
 
The mainstay of treatment is regular emollient and soap substitute use of which numerous 
varieties are available, however, trials of acceptable rigour evaluating the impact of these 
emollients are limited. Due to the absence of any trial evidence to demonstrate superiority 
of one product over another, the recent NICE guideline for the management of eczema in 
children has recommended that: 
 
“Healthcare professionals should offer a range of different products to children 
with atopic eczema for topical application and for washing, and children should be 
encouraged to try out various combinations of topical products. The correct 
emollient is the one that the child will use.” (NICE, 2007) 
 
This advice is based on a recommendation by the Guideline Development Group (GDG) 
stating that “adherence to emollient therapy is likely to be key to successful therapy for 
eczema” (National Collaborating Centre for Women's and Children's Health, 2007a). For 
adherence to be successful healthcare professionals should take into account the 
following information when prescribing: any previous adverse reactions to emollients, 
application frequency and texture of the emollient. Tolerability can change over time and 
therefore the GDG recommends that patients are reviewed regularly by the care team to 
check for acceptability and parents monitor children for signs of reduced efficacy over a 
long period of treatment.  
 
In order for parents and children to achieve this acceptability of their prescribed 
emollients, any consultation with a healthcare professional must be focused on patient 
agreement. This is where the GP/nurse actively engage with the patient and/or parent to 
determine what their preferences are for treatment in a joint decision making process 
(Cushing and Metcalfe, 2007). There are no current data on whether patients and parents 
are being offered a choice of emollient but as already mentioned there are a number of 
reasons why patients may potentially not be using their emollients as prescribed and this 
can largely be solved through negotiation and agreement with the patient.  
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It is regularly cited that the frequency of emollient application is central to the efficacy of 
the product; however, few trials report either the volume or frequency of application 
recommended. NICE guidelines recommend frequent use in large quantities due to their 
short lived effect, suggesting 250g per week or more (NICE, 2007). There is a lack of 
evidence to suggest whether patients are generally adherent to emollient therapy however 
there is a limited body of evidence to suggest that if emollients are used correctly this can 
have steroid sparing effect (Grimalt et al., 2007, Lucky et al., 1997) which may be 
important due to the reasons listed below.  
 
In addition to regular emollient use, topical steroids are generally required as an adjunct to 
treat exacerbations or in the case of frequent exacerbations, may be used once or twice 
weekly to prevent flare ups (NICE, 2007). There is considerable evidence supporting the 
improved outcomes associated with steroid use compared to emollient alone (Hanifin et 
al., 1998, Lupton et al., 1982, Stalder et al., 1994). Whilst the benefits are clearly 
demonstrable, steroid induced adverse effects can be very damaging with children being 
more susceptible than adults (BNF 60, 2010). Adverse effects include local irritation and 
skin depigmentation or discolouration and extremely rarely Cushing’s syndrome and 
growth retardation and likelihood is directly associated with the frequency and volume of 
use (Hengge et al., 2006). Such risks have been demonstrated to cause carers and 
parents to become anxious about the use of topical steroids on children (Woodford et al., 
2001, Zuberbier et al., 2006), resulting in non-adherence to prescribed recommendations 
either in the form of infrequent or non-use (Charman et al., 2000). Particular lay beliefs 
that have been reported include ‘they should only be used to treat severe eczema’ and 
that they are ‘too dangerous’ to be used on children (Fischer, 1996). The frequency of 
emollient application can be reduced by the appropriate use of emollients even when 
there is no exacerbation of eczema symptoms. However, data has been published that 
show in one area of Scotland over half of those children under 6 years old prescribed a 
topical steroid were not prescribed an emollient (Santer et al., 2006).  
 
2.1.2 Educational interventions 
The problems associated with adherence to eczema therapy such as patient acceptability 
of emollients and lay perceptions of the risks and benefits associated with topical steroid 
use have resulted in a number of interventions to address the issue of non-adherence to 
therapy with educational interventions the most frequently reported. A recommendation 
taken from the NICE guidelines for eczema management in children is outlined below: 
 
“Healthcare professionals should spend time educating children with atopic 
eczema and their parents or carers about atopic eczema and its treatment. They 
39 
 
should provide information in verbal and written forms, with practical 
demonstrations which are reinforced at every consultation, and should cover: how 
much of the treatments to use, how often to apply treatments, when and how to 
step treatment up or down and how to treat infected atopic eczema (NICE, 2007)”. 
 
There is little good quality research to assess the effectiveness of an educational 
intervention on outcomes associated with atopic eczema in children (National 
Collaborating Centre for Women's and Children's Health, 2007b). In Germany, two RCTs 
have demonstrated the benefit of parental and children’s education on the long-term 
control of their disease (Staab et al., 2006, Staab et al., 2002). The 2002 study included 
children with a confirmed diagnosis of atopic dermatitis of more than four months duration 
with a SCORAD score of >20 (Staab et al., 2002). The SCORAD index measures the 
severity of eczema/dermatitis with a score <15 indicating mild disease, 15-40 moderate 
and >40 indicating severe disease (European Task Force on Atopic Dermatits, 1993). No 
power calculation was conducted for this study. The participants completed an initial 
questionnaire that included questions on medical history, health-related quality of life and 
coping. Participants were then randomised to the control or intervention groups. The 
intervention consisted of a six-week educational programme provided by paediatricians, 
dieticians and psychologists. The sessions ran once a week in the evening and lasted 
approximately 2 hours. As well as education, parents were asked to share personal 
experiences and were given the opportunity to practice new skills. There was no detail 
provided with regard to the location of study and how many of the multi-professional team 
were present at each session.  
 
At the one-year follow-up, 145 participants were included in the analysis. The SCORAD 
score had decreased by 20 points in the intervention group and 16 points in the control 
group, however, the intervention group showed an increased ability to adapt to disease 
severity as shown by an increased use of steroids for inflammation and 82% of 
participants still using regular skin care therapy compared to 67% in the control group. 
The research also suggested that this type of intervention may have a positive effect on 
the coping ability of parents of children with the disease.  
 
In Staab’s 2006 study, the structured education programme was more clearly defined and 
was age-related (Staab et al., 2006). Participants were recruited from seven hospitals and 
were randomised to control or a multi-professional team intervention. The three target 
groups for the intervention were parents (children from 3 months to 7 years), parents and 
children (8-12 years) and adolescents (13-18 years). The power calculation conducted for 
this study indicated that each group required 125 participants, a total of 750 for the whole 
study.  
40 
 
 
The programme followed a similar pattern to their previous study but in this study the 
multi-professional team underwent a 40-hour training programme to qualify for the study. 
Each of the consultations followed a manual that had been developed previously to 
ensure that all of the core topics were covered. These topics included basic medical 
information about atopic dermatitis, stress management, dealing with itching and 
scratching and sleep disturbances, avoidance of trigger factors, food allergies and coping. 
This was accompanied in the final consultation with a self-management plan. 
Consequently, this ensured the fidelity of the intervention across all sites and all education 
providers.  
 
Staab recruited 992 participants of which 823 (446 randomised to intervention and 377 
control) were included in the final one-year analysis. The results from this study indicate a 
significant improvement in eczema severity scores (a reduction of between -16.0 to -19.7 
in the intervention groups vs a reduction of -5.2 to -12.2 in the control group) as well as an 
improvement in the parent’s quality of life as a result of the intervention in all age groups. 
In all age groups this was the difference between the severe and moderate form of the 
disease. This study demonstrated that tailored, age-dependent education, aimed at 
parents, parents and children or adolescents, was significantly more effective than usual 
care.  
 
In the UK, the only RCT available in this area of research is by Chinn et al. This examined 
the effect of a single dermatology nurse consultation on children’s quality of life (Chinn et 
al., 2002). Participants were identified by screening the medical records at the local 
medical practice for those patients with a registered diagnosis of atopic eczema up to the 
age of 16 years. Each eligible family was posted two questionnaires: the family dermatitis 
index and an age-appropriate, validated quality of life index, plus a consent form. 
Participants returning a completed consent form and questionnaires were randomised to 
receive the intervention or usual care. Those in the intervention group were asked to 
attend an appointment with the dermatology nurse within two weeks. Both groups were 
then posted a follow-up questionnaire at six and 14 weeks.  
 
The content of the consultation focused on the participant’s understanding of eczema, 
practical demonstrations of application technique, avoidance of allergens and irritants, 
advice on bathing and the use of emollients at school. This was re-enforced with written 
information and the participants were offered continued support via telephone or further 
appointments.  
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The study demonstrated no significant improvement in quality of life of the 235 children 
that participated. This may be due to the ‘one-off’ nature of the intervention or may imply 
that education is not enough and that an intervention that utilises a particular consultation 
technique e.g. motivational interviewing may be more beneficial.  
 
In relation to the role of the pharmacist no RCT data are available, however, one UK study 
demonstrates an increase in the frequency of emollient application leading to a reduction 
in irritability and itch as a result of a pharmacist intervention (Carr, 2007). This study 
involved parents attending an appointment with a pharmacist, when the pharmacy was 
quiet e.g. lunchtime, to discuss their children’s eczema management using a standardised 
approach. The study was conducted in ten community pharmacies. The pharmacist 
discussed current treatment, patterns of use of emollients and tested the parent’s 
application technique on their children. The intervention lasted approximately 10 to 15 
minutes. Fifty participants were recruited and from the baseline questionnaire it was 
identified that only a small number (20%) had been shown how to apply their emollients 
by a GP or nurse and only 10% were actually applying them correctly. This also identified 
other areas where parents were confused about their child’s treatment e.g. mixing up 
steroid and emollient creams.  
 
The intervention demonstrated a small reduction in itching (mean difference: 1.48 (0.65 – 
2.30) on a 0-10 scale with 0 meaning no symptoms and 10 the worst symptoms) and 
irritability (mean difference: 1.23 (0.06 – 2.09) on the same scale) as well as increasing 
the correct use of emollients. Parental feedback described the service as extremely 
helpful or quite helpful.  
 
Following on from successful RCTs in Germany and a lack of robust evidence in the UK, 
this chapter will focus on the development and testing of an RCT aimed at improving the 
management and support for patients with atopic eczema. The intervention will focus on 
aspects of the studies mentioned above whilst factoring in current NICE guidance in 
relation to eczema educational interventions.  
 
For this project we will feasibility test an RCT methodology, in line with the conclusions 
from the previous chapter to enable us in the future to determine the effect of a community 
pharmacist-led eczema management support service in the community pharmacy setting.
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2.2 Aims and objectives 
2.2.1 Aims 
 To feasibility test and pilot a randomised controlled trial methodology to examine 
the effects of a community pharmacist-led eczema management support service. 
 To determine the acceptability of conducting RCT research in the community 
pharmacy setting. 
 
2.2.2 Objectives 
Trial the methodological approach and service design in order to ascertain the: 
 recruitment rate by pharmacists 
 appropriateness of the training programme  
 suitability of the inclusion criteria and randomisation protocol  
 appropriate questionnaire design for completion by parents/guardians 
 appropriate outcome measures  
 acceptability and completion rate of study documentation 
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2.3 PLEEZ method 
The protocol for PLEEZ and supporting documentation is included in appendix one. The 
flow of participants through the study is illustrated by figure 2.1. Research governance and 
ethical committee approval were obtained from Hertfordshire NHS Research Ethics 
Committee (appendix two) and NHS Norfolk Research and Development Department 
(appendix three) prior to commencing data collection. This study was funded by a grant 
from Numark Ltd, a representative organisation of independent pharmacies.  
 
2.3.1 Pharmacy recruitment 
Eligible Numark pharmacies in one primary care trust PCT area with a consultation room 
were identified and approached by me. Pharmacies were remunerated for all activities 
associated with the study including participant recruitment, delivering the intervention and 
data collection. Pharmacists and pharmacy staff received a free dinner as a thank you for 
attending the training evening.   
 
2.3.2 Communication with the primary care team 
All prescribers associated with the participating pharmacies were contacted by telephone 
or e-mail by myself prior to trial commencement to provide information on the study and 
obtain consent for their patients to be approached for trial participation. Any pharmacist 
interventions delivered as part of the trial were communicated to the primary care team 
(general practitioners and / nurses responsible for the eczema management of a patient) 
via a notification form.  Prescribers were familiarised with this notification form prior to trial 
commencement in order that they were aware of what to expect to receive from the 
pharmacist as a result of a consultation with the patient and parent/guardian. 
 
2.3.3 Pharmacy team training 
Participating pharmacies identified up to two members of the team to be responsible for 
the study (excluding the pharmacist). These team members attended the training session 
conducted by me and a fellow researcher, which covered the study protocol, participant 
recruitment (including gaining consent) and data collection.   
 
2.3.4 Pharmacist training 
Pharmacist training involved completion of a CPPE developed common skin condition 
training package prior to attendance at a training evening. The learning outcomes for the 
CPPE pack were: 
 
 identify skin conditions that must be referred for diagnosis and/or treatment 
 advise confidently on effective use of over the counter (OTC) and prescription-only 
(POM) products 
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 access local, regional, national and international information resources and support 
 describe the possible roles of the pharmacist in the multidisciplinary dermatology care 
team (CPPE, 2007) 
 
Eczema focused training developed in conjunction with the Norfolk and Norwich NHS 
Foundation Trust and NHS Norfolk was provided to pharmacists by a NHS Norfolk 
eczema specialist nurse. The nurse re-enforced topics covered by the CPPE training 
package in relation to eczema and also provided samples of creams and ointments for the 
pharmacists and pharmacy staff to try. The nurse also provided practical advice such as 
the definition of ‘sparingly’ in relation to the application of steroid creams. A practical 
demonstration of application technique took place with the pharmacists and staff given the 
opportunity to practice the technique for themselves.  
 
Training in consultation skills was provided on the same occasion and was underpinned 
by techniques designed to explore patient beliefs and concerns as well as motivating 
adherence to prescribed therapy. The training included an overview on some basic 
consultation techniques such as: 
 
 open questions 
 reflective listening 
 decision balance/summarising 
 key question 
 self-efficacy for treatment. 
 
The training also covered the structure of the consultation from agenda setting to the time 
frame which lasted approximately three hours.  
 
Additional training was provided to the pharmacists on the study paperwork and consent 
in the subsequent time leading up to the commencement of the trial. This was in response 
to feedback that the pharmacy staff did not feel particularly confident about roles asked of 
them for the study. This was provided by me on the training evening and as required by 
the phamacists. 
 
2.3.5 Inclusion criteria 
Due to the increased prevalence of eczema in this age group, children aged 0-10 years 
were targeted as potential participants. A dermatology registrar at the Norfolk and Norwich 
University Hospital assisted with defining the inclusion criteria for the study. The majority 
of feedback concerned the inclusion criteria of a confirmed diagnosis of eczema. Many 
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patients may be using topical steroids and emollients for conditions other than eczema 
and to recruit participants solely based on their prescribed medication without confirming 
their diagnosis would be inappropriate for this particular intervention. The decision was 
also taken to narrow the recruitment criteria to include only those patients receiving topical 
treatment. This was decided based on feedback that patients on systemic therapy would 
generally be managed by the dermatology team at the hospital rather than the GP.  
 
A final criterion for inclusion in the study was the requirement that patients had to have 
been receiving medicines from the pharmacy for three months prior to recruitment due to 
the intention to collect data on adherence to emollient and steroid therapy in the three 
months preceding study enrolment.  
 
2.3.5.1 Summary inclusion criteria 
 Child aged 0-10 years 
 Currently receiving topical treatment for diagnosed eczema 
 Provides written informed consent 
 Has been attending the pharmacy with prescriptions for eczema medication for at least 
three months before recruitment 
 
2.3.6 Exclusion criteria 
There were limited exclusion criteria for the study; however two were important for 
practical reasons. The inability to speak or read English was included as it was seen as 
impractical to provide the pharmacies with appropriate translation equipment/support for 
this particular group of patients.  
 
Following feedback from the dermatology registrar, the decision was taken to exclude 
other skin conditions and infected eczema as these would complicate the intervention and 
it was not within the remit of the intervention to be actively treating infected eczema, rather 
addressing adherence issues on the part of the patient.  
 
2.3.6.1 Summary exclusion criteria 
Unable to understand written and / or spoken English 
Any other diagnosed skin conditions or infected eczema 
 
2.3.7 Participant recruitment 
All parents or guardians who presented at the pharmacy with a prescription for an 
emollient or a steroid topical preparation for their child, were asked if the patient had been 
diagnosed with eczema by a doctor.  Potential participants who had been previously  
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prescribed these products had their pharmacy records ‘flagged’ to alert staff when they 
presented at the pharmacy that they may be suitable to invite to the study. The pharmacy 
staff or pharmacist approached the potential participant and provided them with an 
information sheet: one aimed at the parent/guardian and the other aimed at the child. 
Potential participants were free to take the information sheet away with them to consider 
participation.  All parents or guardians who consented to participate were asked to 
complete a written consent form on behalf of their child and if the child was aged 6-10 
years the child was asked to sign an assent form. This was again completed by the 
trained pharmacy staff or the pharmacist. All pharmacists had the option of sending a 
letter to potential participants alerting them to the service as a result of identifying them 
from their pharmacy medication record.  
 
2.3.8 Sample size 
The aim of this study was to recruit 100 participants (50 in each group). This data was to 
be used to inform formal sample size estimation for a larger RCT designed to determine 
whether the intervention has a significant impact on the primary outcome measure of 
Children’s Dermatology Life Quality Index (CDLQI). The effect size of the primary 
outcome measure from this study would be used to estimate the sample size necessary 
for a larger study to identify a difference between intervention and control with 90% power 
and 5% significance. 
 
2.3.9 Randomisation 
Once participants had provided informed consent they were randomised by an automated 
telephone randomisation service.  The pharmacy staff telephoned the automated 
randomisation service where some basic details were recorded and the participant 
allocated to the intervention or control group.  The allocation was stratified by pharmacy to 
ensure approximately equal numbers of intervention and control participants in each 
pharmacy.  Due to the potentially small number of participants, randomisation was 
conducted in permuted blocks of 4 or 6. All participants were allocated a study number 
and the encryption form linking the patient details to the study number was kept 
separately under each pharmacy’s usual storage procedures.  Only anonymised data 
were sent to myself as I was not directly involved in the care of the patient. 
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Patient 
declines 
Patient invited to take part in the 
study 
Randomisation 
Complete questionnaire Complete questionnaire 
Consultation with pharmacist 
within two weeks about child’s 
eczema 
Sent another questionnaire in 
the post three months after 
completing the first 
questionnaire 
Usual care 
Patient consents 
Telephone call with pharmacist 
after one week to see how 
things are going 
Sent another questionnaire in 
the post after three months 
Non-responders sent 
another questionnaire after 
two weeks 
Additional data collected from 
pharmacy records 
Data Analysis 
Intervention Control 
Figure ‎2.1 PLEEZ Study design 
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2.3.10 Patient questionnaire 
Participants in both the intervention and control groups completed a baseline 
questionnaire.  This questionnaire was designed specifically for this project and includes 
previously validated questionnaires on adherence (Morisky et al., 1986), quality of life 
(Lewis-Jones and Finlay, 1995), beliefs about medicines (Horne et al., 1999) and 
satisfaction with information about medicines (Horne et al., 2001) in addition to some 
basic demographic questions. 
 
2.3.10.1 The Beliefs about Medicines Questionnaire (BMQ) 
There are two versions of the BMQ: specific and general. They are both designed to elicit 
patients’ necessity for and concerns about their medicines or medicines in general. This 
study used the specific version of the questionnaire. It contains ten items that are rated on 
a 5-point likert scale from 5 = strongly agree to 1 = strongly disagree (Horne et al., 1999). 
The questions consist of five that are aimed at identifying the necessity with which the 
patient views their medicine and five that identify their concerns. These are then scored 
according to their group and a difference between the groups (necessity and concerns) is 
calculated. Once calculated, this difference is a good indicator of non-adherence in 
chronic conditions (Horne and Weinman, 1999), specifically intentional non-adherence as 
patients who attribute more weight to the concerns about taking their medicines rather 
than the necessity for them are more likely to not take them as prescribed (Clifford et al., 
2008). This finding has been characterised in several disease states e.g. rheumatoid 
arthritis (Neame and Hammond, 2005) and severe mental disorder (Jónsdóttir et al., 
2009) and drug specific regimens e.g. the use of antidepressants (Russell and Kazantzis, 
2008) and inhaled corticosteroids (Menckeberg et al., 2008).  
 
For this study, two copies of the BMQ were placed in the questionnaire; one for topical 
steroids and one for emollients. 
 
2.3.10.2 The Morisky Adherence self-report scale 
The Morisky medication adherence scale is a validated scale designed to measure 
adherence. Two versions exist: a four item questionnaire (Morisky et al., 1986) and an 
eight item questionnaire (Morisky et al., 2008). All questions contain a yes/no answer 
apart from the last question on the eight item version which is a 5-point likert scale. The 
questions are phrased in a way that discourage patients from answering in the affirmative 
automatically, thereby encouraging them to think harder about each question to produce a 
more accurate response. The eight item questionnaire has been shown to be a more 
sensitive measure than the four item version (Morisky et al., 2008) and has been 
demonstrated to provide a consistent result when compared to other adherence measures 
such as pharmacy fill rates (Krousel-Wood et al., 2009). The usefulness of the measure 
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has been demonstrated in a variety of settings from ulcerative colitis (Bernick and Kane, 
2010) and hypertension (Krousel‐Wood and Frohlich, 2010) to bipolar disorder (Jarman et 
al., 2010) however, at the time of conducting the study large scale validation data for the 
8-item version was unavailable. Therefore, in this study I decided to use the validated, 
four-item questionnaire which also minimised participant questionnaire burden and thus 
aimed to maximise response rate.  
 
For this study, two copies of Morisky were placed in the questionnaire; one for topical 
steroids and one for emollients. 
 
2.3.10.3 The Children’s Dermatology Life quality index (CDLQI) 
The Dermatology Life Quality Index is an extensively used tool to measure how symptoms 
affect the participant’s quality of life (Finlay and Khan, 1994). It has been used in a wide 
variety of different skin conditions and translated into numerous languages for use around 
the world (Basra et al., 2008). It has been developed into a version that is suitable for use 
in children (Lewis-Jones and Finlay, 1995) and infants (Lewis‐Jones et al., 2001) along 
with a cartoon version (Holme et al., 2003). The children’s version contains ten questions 
each with a possible answer of ‘not at all/ not relevant’, ‘a little’, ‘a lot’ and ‘very much’. It is 
scored out of 30 with higher scores indicating greater impairment to quality of life. It is also 
recommended for use by clinicians in the most recent NICE guidance for atopic eczema 
when diagnosing and assessing eczema severity (NICE, 2007).  
 
2.3.10.4 The Satisfaction with Information about Medicines Scale (SIMS) 
This is a validated questionnaire that helps determine a patient’s satisfaction with the 
information they have received regarding their prescribed medication.  It is a 17-item tool 
which asks patients to rate the amount of information they have received about their 
medicines as ‘too much’, ‘about right’, ‘too little’, none received’ and ‘none needed’ (Horne 
et al., 2001). The answers ‘too much’, ‘too little’ and ‘none received’ are attributed a value 
of 0 and the answers ‘about right’ and ‘none needed’ are given a value of 1. A high score 
then indicates a high level of satisfaction with the information the patient has received 
about their medicines. This scale can be further divided into two subscales: action and 
usage of medication (questions 1-9) and potential problems of medication (questions 10-
17). The version of SIMS that was used in this study did not contain the questions 
referring to alcohol intake and sexual activity as this was aimed at children and therefore 
would not have been appropriate. 
 
2.3.11 The intervention 
Participants randomised to the intervention group had an appointment for a consultation 
arranged with the pharmacist at a mutually agreeable time within the following two weeks 
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post randomisation. The participant and parent or guardian were taken to the consultation 
room with the pharmacist for the eczema management support session. The pharmacist 
used the previously completed baseline questionnaire to inform the consultation which 
was targeted at the participant’s needs, thus consultations comprised of core content and 
possibly additional aspects in response to individual need. Table 2.1 summarises the 
content of the consultations and is based on previous published research and current 
NICE guidance (NICE, 2007). If the parent/guardian expressed an interest in trying 
another cream/ointment for preference, the pharmacist was able to provide the 
parent/guardian with the smallest samples of NHS Norfolk formulary listed creams. 
 
One week post consultation, the pharmacist contacted the participant to discuss their 
progress with implementing any recommendations, offer any further advice and co-
ordinate any prescription changes if needed. If changes were necessary or participants 
preferred a different emollient, the pharmacist was provided with a notification form to 
send to the GP. Multiple visits to the community pharmacist were seen as potentially 
difficult to conduct so therefore this method was seen as a compromise that may have 
made study implementation easier at the outset.  
 
Core items discussed with all participants Additional items addressed in response to 
individual need 
Current topical eczema management Demonstration of steroid and emollient 
application technique 
Frequency and volume of emollient use Advice regarding future management 
strategies 
Frequency and volume of steroid use Lifestyle advice and food allergies 
 
Discussion of application technique Provision of emollient samples to try for 
preference 
Table ‎2.1 Intervention content 
Pharmacists were paid per patient that was recruited, which included the intervention and 
paperwork completion. This money was paid to the pharmacists via their membership 
subscriptions with the Numark organisation and not via the University of East Anglia.  
 
2.3.12 Pharmacist data collection 
A bespoke data collection form was developed for pharmacists to document the areas of 
discussion with the parent / guardian together with data from patient medication records to 
determine the use of eczema related products over the previous three months and the 
three months during the trial.  
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2.3.13 Follow-up data collection 
After three months, a second questionnaire containing the same measures as the 
baseline questionnaire was sent to both the intervention and control group participants by 
the pharmacy concerned with their care. The questionnaires were sent back by the 
participants directly to me, who informed the pharmacy upon receipt. Non-responders 
were sent a second posting after two weeks.  
 
2.3.14 Data analysis 
For the primary outcome measure (CDLQI) the magnitude of difference and variance 
between intervention and control groups was analysed. The study was not powered as 
this was a feasibility study. Morisky reported adherence, was dichotomised into 
adherence/partial adherence. Therefore, if four ‘no’ answers were entered into the 
questionnaire, then the patient was deemed to be adherent. If there were one or more 
‘yes’ answers, then the patient was classed as partially adherent (Morisky et al., 1986). 
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2.3.15 Amendments to study design 
This study was commenced at the start of my PhD and the basic protocol and overall 
study design had already been developed prior to my joining the research team.  
 
During the initial phases of the study the pharmacists involved highlighted problems with 
the protocol and documentation and it became clear that recruiting the required number of 
participants was going to be difficult. Therefore, I decided to submit applications to the 
ethics committee for changes to the study protocol. Approval was obtained for each 
amendment (appendices four to seven).  
 
Amendment number 1 
This amendment focused on aspects of the study that participating pharmacists and I 
highlighted that had been missed from the original documentation. This included 
amending the information sheet to include details about the follow-up telephone call from 
the pharmacist, the addition of two more boxes on the data collection form to ascertain 
what the pharmacist had discussed with the patient during the consultation. It was also 
decided to invite two members of the pharmacy staff, instead of one, to the training 
evening to account for sickness during the study period. 
 
Amendment number 2 
This amendment was aimed at increasing uptake of the service. It extended the time 
available to pharmacists to recruit participants and also allowed them to send a letter to 
patients identified from the pharmacy medication record, informing them of the service.  
 
Amendment number 3 
This amendment extended the recruitment criteria to include adults over the age of 18. It 
introduced further information sheets, consent forms and questionnaires revised to reflect 
this potential new group of participants. It also increased the data collection period for the 
study further.  
 
Amendment number 4 
The final amendment for the study was submitted after the main study had been halted 
due to low recruitment of participants. This amendment allowed me to invite pharmacists 
to a focus group to determine the reasons for a low recruitment rate and how this could be 
improved for further research projects. A new information sheet and consent form was 
developed for the pharmacists (appendix eight).  
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2.4 Pharmacist focus group 
During the time when the eczema RCT was still running, I had conversations with each of 
the participating pharmacists to gain a sense of whether they thought I could do anything 
to increase the numbers of participants being recruited to the study. These conversations 
highlighted considerable diversity between different pharmacists in what they thought 
were the problems with the study. It emerged that not all of the pharmacists were 
approaching the research in the same way and in their practice they also had different 
ways of fitting it in to their daily routine, with varying degrees of success. Therefore, it was 
decided to ask them all to take part in a group discussion to examine areas of agreement 
or differences in engaging with the research and their reasons for these.  
 
2.4.1 Focus group aims 
To characterise the views of pharmacists involved in a community pharmacy RCT in terms 
of why they participated in the research, their views on the mechanics of the study and 
how they think this kind of research fits into community pharmacy practice. 
 
2.4.2 Focus group method 
Ethics and Governance approval was received prior to conducting the focus group. A 
group discussion (or focus group) was chosen as a means to encourage interactive 
discussions between participants. At this point, I wanted to elicit the views of pharmacists 
on participating in an RCT and how the project methodology could be refined to reflect 
these. This fits the ‘problem-solving’ notion put forward by Kamberelis & Dimitriadis in 
suggesting that “problems cannot be solved by individuals alone” (Kamberelis and 
Dimitriadis, 2007). Opening and introductory questions were used along with open 
questions to facilitate the focus group discussion as described in Krueger and Casey 
(Krueger and Casey, 2009) with the facilitator joining in the conversation.   
 
2.4.2.1 Inclusion criteria 
The inclusion criteria for the focus group were as follows: 
 Community pharmacist 
 Working in the independent sector 
 Participated in the original eczema RCT 
 
2.4.3 Facilitation 
The focus group was moderated by two members of the research team not associated 
with the day-to-day running of the RCT project and members of a wider research group 
(the UEA Medicines Management Research Team). I decided not to take part in the focus 
group as this may have affected the participants’ responses to questions about the 
researcher’s own conduct during the study. Both of the researchers present for the focus 
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group had observed and acted as secondary facilitators at previous sessions in other 
studies. The session was conducted at the University and the participants were provided 
with refreshments.  
 
2.4.4 Topic Guide 
The focus group facilitator was given a set of questions by me to ask the pharmacists 
during the focus group. The questions had been piloted with a pharmacist who was 
unable to attend the focus group to determine if they were likely to provide the kinds of 
answers I was seeking in terms of reasons for the study failing. These questions sought to 
elicit a wide range of reasons for taking part in the trial, the barriers experienced to their 
participating fully in research and the benefits that they expected and actually received 
from taking part in the research. The following questions were asked to the group: 
 
 What was your initial motivation to take part in the study? 
 What are your thoughts on the training provided? 
 What are your thoughts about the support that you received? 
 What was your general impression of the study? 
 More generally, what are your thoughts on the current trend of pharmacists providing 
more services while still maintaining their original functions e.g. dispensing? 
 
The participating pharmacists were given prior information about the general topics to be 
discussed in the participant information sheet and were each asked to sign a consent form 
before the focus group could begin. The session was audio-recorded, transcribed by 
myself and then checked by the assistant facilitator for accuracy. The transcript was then 
analysed independently by myself and a fellow researcher using thematic analysis 
directed at identifying any common themes expressed over the course of the focus group 
discussions.  
 
2.4.5 Focus group analysis 
The transcript was independently coded by me and a fellow researcher according to the 
principles of thematic analysis (Braun and Clarke, 2006). We met to discuss the findings 
and agree final themes. Any disagreement was discussed and a consensus reached 
based on referral back to the original transcript.  
 
2.4.5.1 Thematic analysis 
Thematic analysis is one of the most widely used frameworks for analysing qualitative 
data, especially for novice researchers as it minimally organises the data in an attempt to 
understand what is being said by the participants (Braun and Clarke, 2006). Until relatively 
recently, thematic analysis, although used ubiquitously, was poorly defined. Braun and 
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Clarke in 2006 attempted to define thematic analysis as the process described below in 
order to standardise the approach and make it more accessible to novice researchers. 
 
The process of thematic analysis as described by Braun and Clarke:  
 
1. Familiarise yourself with your data e.g. transcription and reading 
2. Generating initial codes 
3. Searching for themes e.g. organising codes into groups, starting to identify themes 
4. Reviewing themes e.g. checking themes match with the originally generated codes 
5. Defining and naming themes 
6. Producing the report 
 
It is stated that constant reference at all stages to the original transcript is essential as this 
will help the researcher determine the level of themes and subthemes and confirm that 
these are relevant to what was said in the transcript and have not been taken out of 
context during the coding process. The use of thematic maps is highlighted as a process 
that can be used to develop themes and determine where they lie in the bigger picture of 
the research question.  
 
Computer software was not used to conduct the analysis. Coding started with the first line 
of the transcript and continued on every line until the last. Not every line was individually 
coded because some lines were included in more than one code or were encompassed in 
codes spanning more than one line e.g. long passages of text; however, a consistent 
effort was made to code as much as possible. This returned 219 codes in total. These 
were then typed up with a reference number to consistently locate which part of the text 
they came from and cut out to set each code onto its own small piece of paper. These 
codes were then arranged to reflect their degree of conceptual commonality with others 
e.g. all the ‘time-related’ codes were grouped together. This initially produced eleven 
themes, some of which were subsequently further combined where differences did not 
appear as clear. The overall theme for each collection of codes was decided without 
reference to the original questions posed during the focus group. A second researcher 
also coded the transcript and identified themes independently of myself. We met to 
discuss emerging themes and to ensure all themes had been identified. 
 
To help highlight both commonalities and differences identified in the analysis between 
the pharmacists’ views, selected quotes are presented in the results section.  
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2.5 PLEEZ results 
2.5.1 Feasibility-RCT results 
Seven pharmacists and pharmacies were recruited to the study, two in a rural location, 
two in a small town and three in a city. After nine months and a lack of recruited 
participants, the study was halted. Nine participants, from the initial target of 100, were 
recruited of which five were in the intervention group and four in the control group from 
just three pharmacies (six in one pharmacy, two in a second and one in a third pharmacy). 
Table 2.2 describes the study demographics. The recruitment period lasted from mid-
September 2009 until May 2010, however, all of the recruitment of participants occurred 
between the start and mid-December 2009.  
 
Follow-up data from the returned questionnaires, were only available for four control 
participants (100%) and three out of the five (60%) intervention participants. The outcome 
measures demonstrated no improvement for the control participants. All three intervention 
participants, however, showed an improvement in adherence, as measured by the 
Morisky scale (Morisky et al., 1986). One patient also demonstrated improved knowledge 
about their medicines after the consultation with the pharmacist. All questionnaires that 
were completed at baseline and returned to me were completed in full. The data from the 
baseline questionnaires are detailed in table 2.3 with further examination of the combined 
(intervention and control) SIMS results in figure 2.2.  
 
Data collection by other means failed due to the pharmacists not completing the 
appropriate paperwork as per study design. This paperwork included the pharmacist data 
collection form and as such aspects of the study e.g. content of consultation and level of 
emollient and steroid use could not be characterised.  
 
Participant demographics Measure Control Intervention 
Number of participants Number 4 5 
Age (months)  Mean (SD) 21.2 (12.4) 33.0 (30.4) 
Gender Number (%) 2 (50%) male 3 (60%) male 
Family history of eczema Number (%) 1 (25%) 4 (80%) 
GP or nurse contacts in the previous 
three months 
Mean (SD) 1.0 (0.8) 1.7 (3.3) 
Table ‎2.2 Study demographics 
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Questionnaire Measure Control Intervention 
CDLQI (n=4) Mean score (SD) 4.8 (4.5) 3.9 (2.7) 
BMQ differential – Steroid (n=3) Mean score (SD) 0.3 (3.8) 4.2 (5.7) 
BMQ differential – Emollient (n=4) Mean score (SD) 8.25 (2.5)  4.8 (5.3) 
Morisky – Steroid (n=3) % adherent 0 20 
Morisky – Emollient (n=4) % adherent 50 20 
SIMS (n=4)(max = 15) Mean score (SD) 6.25 (3.8)  11.4 (2.9) 
Table ‎2.3 Results from the PLEEZ questionnaire for control and intervention at baseline
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Figure ‎2.2 % of patients reporting they had received about the right information or that none was needed for each of the SIMS questions at baseline. 
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2.5.2 Focus group results 
Four pharmacists agreed to participate in the focus group, three declined. The three 
participating pharmacists who declined cited strong family or personal reasons for not 
doing so. Of the pharmacists who did take part, there were equal numbers of men and 
women. All participating pharmacists were aged between 40 and 60 years.  One worked 
in a city pharmacy, one in a pharmacy located in a small town and two in villages.  
 
The focus group produced seven themes: GPs, the balance between professions, 
paperwork, trial design, timing, frustration and impact and reasons. There was a sense of 
a lack of engagement by the GP practices which was reflected by the experience of 
pharmacists within the group: 
 
“the bizarre thing is that we have a very good working relationship with the surgery 
but when it came to this particular trial obviously went to the practice manager first 
with that, then had to go the partners but the partners weren’t interested... they 
were just saying oh yes we’ll get round to it, we’ll get round to it ....and they never 
got round to it because they didn’t see, they said yeah go see a pharmacist, 
whatever they want to do, fine we’re behind it  but to actually get the senior partner 
and a quorum decision to say yes this is, and send someone to talk about the trial, 
it was not a priority” (Ph3 male, pharmacist in a small town)  
 
“it was a bit like them [GPs] flicking a fly [pharmacists] off the shelves… it was of 
no consequence to them” (Ph2, female, pharmacist in a village) 
 
The purpose of gaining consent from the GPs was to involve them in the project from the 
start. As part of the project they may have received documentation requesting a change to 
a patient’s regimen and therefore it was important to inform them of this before 
progressing with the study. However, the general view of all the participating pharmacists 
was that because eczema, as a disease, was not high on their medical practice’s list of 
priorities, then it was not seen by the GP as warranting the time taken to actually give 
consent to let the pharmacist approach their patients. In most cases it took repeated 
telephone calls and e-mails to obtain consent from the medical practice. 
 
Other factors relating to GPs included having a lack of interest in research and 
pharmacists expressing disagreement with GPs’ priorities such as “putting money before 
patients”. It was suggested by one pharmacist that when it came to their providing a 
service to patients in the community pharmacy, unless the GP was paid for it as well, GPs 
did not want to engage with it, as with medicine use reviews (MURs). 
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Most of the pharmacists also commented on the balance of power between the two 
professions, saying that the GPs had an unfair advantage when it came to recruiting 
patients for an NHS service that both professions were conducting e.g. health checks, and 
that the pharmacist was probably not being considered by patients as the most suitable 
person to conduct this type of service. 
 
“…there’s only a finite number of people you can do and the surgery have actually 
written to their patients about it all they’re going to respond to the surgery more to 
the surgery than the pharmacy” (Ph3) 
 
However, two out of the four pharmacists present also stressed the need to work 
collaboratively with GPs to decrease their workload and so to free up time for more urgent 
clinical problems. They saw this as being achieved through such services as minor 
ailments in the community pharmacy.  
 
“…by the time they’ve [GPs] got to them it’s [eczema] flared up, that’s the problem, 
they’ve only gone there [surgery] because it is a real problem, but if we can get it 
the other way round they [GPs] would need to see them half the time would they?” 
(Ph1, female, pharmacist in a village) 
 
In relation to the trial design and paperwork, all the pharmacists expressed the view that 
they wanted the patient/ potential participant to be able to have as near usual a pharmacy-
based experience as possible. This meant coming in and having the kind of conversation 
with the pharmacist they would usually have, without the need for any paperwork. They 
also felt that the length, layout and colour scheme of the paperwork was a disincentive to 
taking part in the study.  
 
“... sheer amount of paperwork and I think it’s coming at a time when whatever we 
do is paperwork and it’s a bit of a turn off really” (Ph2) 
 
“think of it on the side of the patient or the guardian they don’t understand consent, 
they don’t understand the paperwork, they just want to walk into the pharmacy like 
they do every single day and speak to the pharmacist and be given the advice that 
we were giving, they don’t want this, oh can you fill this form in before we talk 
about this.... straight away turns em off” (Ph3) 
 
One of the pharmacists recognised the need for most of the paperwork but went on to 
point out practical problems with its layout, colour scheme and content.  
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“I don’t wanna be sitting there thinking is it one of these forms, even getting them 
to fill out one form, and then going oh you’ve got the wrong form. I think that side 
of things could have been better” (Ph3) 
 
When providing pharmacy services, pharmacists are generally used to obtaining verbal 
consent from the patients, however, this study required written consent, and this was not 
something that any of the pharmacists were used to. Three pharmacists went on to 
express a need for this process to be made as easy and simple as possible so that they 
and the participant can get on with the intervention and the participant does not lose 
interest. The everyday practice of community pharmacy is that patients will often only 
come in for a matter of moments to pick up their prescription, so that they saw keeping 
patients in the pharmacy for a substantial amount of time to read and sign all of the 
informed consent forms as a considerable disincentive for the potential participant.  
 
“look with MURs [medicine use reviews] we have a verbal consent before we start 
and it makes it much easier” (Ph1) 
 
“I think from my point of view erm a little bit of naivety from myself because I’ve not 
really been involved with the, the erm the mechanics of the trial before, so 
therefore as pharmacists we are very much hands-on, we’re dealing with patients 
all the time, we’re responding to symptoms, we’re doing it there and then, that’s 
what the patient wants, suddenly to have the bureaucracy of the trial which is 
obviously is necessary.... I wasn’t expecting that.” (Ph3) 
 
This quote illustrates the discomfort of this pharmacist with introducing a new and 
unfamiliar procedure into their usual interaction with patients, and something that they did 
not see as being part of care to patients. 
 
This particular study focused on children with eczema as this is known to be the age 
group with the highest prevalence (Harris, 2007, Kurukulaaratchy et al., 2003). However, 
all the pharmacists who participated in the focus group found this to be very restrictive in 
excluding adults and alongside the other inclusion/exclusion criteria e.g. the requirement 
to have received medicines from their pharmacy for three months prior to recruitment, saw 
this as further reducing an already small number of potential participants who might be 
approached. 
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“it was the age to start with... the very first idea of this study I thought there would 
be lots of people but when you actually look at it, there wasn’t , I think I had 7, I 
had a list of 7.” (Ph1) 
 
The study protocol had suggested that counter assistants could recruit patients to the 
study, which one of the pharmacists felt was a mistake.  
 
“actually engaging our staff to actually gain the consent and how to ask patients, 
influencing in the right way as trials needed, y’know asking you staff to do the 
initial consent was quite difficult y’know” (Ph4, male, pharmacist in a city)  
 
Because the pharmacist had decided to recruit the patients to the study as well as 
conducting the intervention he saw this as increasing his workload in an already busy 
pharmacy which meant he had to withdraw from the study at an earlier stage.  
 
Another area of concern for some of the pharmacists was the lack of any intervention for 
the control participants. The pharmacists (not used to participating in this type of study) 
felt uncomfortable providing the intervention for only half the participants and felt it 
necessary to say to the patient they would provide them with the intervention once the 
study had finished. 
 
“it’s very difficult to get them to do all the sign up and then say I’m awfully sorry but 
I can’t do you at the moment... we sort of decided that if we had any that went erm 
that weren’t randomised to be seen immediately, we would say well y’know we’ll 
do yours after the trial and have the discussion” (Ph2) 
 
The timing of the study was another theme that could now be seen to surface throughout 
the course of the focus group discussion. The time of year when the study was being 
conducted at “it was the middle of the summer holiday” (Ph1) then when there were 
delays to starting “…made it running on towards Christmas then” (Ph2). There are times 
in the year when community pharmacies are naturally busy e.g. in the approach to 
Christmas, or quiet e.g. in the summer holidays and this could affect whether a) the 
pharmacist has time to engage fully with a study or b) there are any patients to recruit to 
the study. The employment status of these particular pharmacists may also have had an 
impact on the issue of timing. All of these pharmacists owned their own pharmacy and as 
such would have had constraints on their time that other pharmacists (those that work for 
multiple chains) would not have had. 
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The pharmacists also experienced frustration from delays to the research process, they 
felt they just wanted to get on with doing the research. The pharmacists’ frustration arose 
from the time it took for the amendments to be approved, the volume of paperwork that 
they had to deal with, the issues surrounding the perceived lack of services to the control 
group, the consenting process and sense of some of the pharmacists that they were 
competing for patients with dispensing doctors, so again there was the non-level playing 
field “all the time we’re up against this doctor dispensing bit” (Ph2).  
 
Finally, all the participating pharmacists clearly articulated how they found being part of a 
research study a valuable experience which had even benefitted their practice and 
increased their awareness of the necessity of research in community pharmacy as well as 
building their enthusiasm. All the pharmacists saw becoming involved as offering a 
chance to engage with a different population that they did not see very often, here, 
children and young parents. The pharmacists also saw the condition of eczema as not 
being managed particularly well by the current care team so that offering or evidencing the 
intervention might lead to them having a positive effect on the patient-participants’ 
condition. 
 
“I had seen so many prescriptions and and I could see that it really wasn’t being 
erm used that the products that they were being prescribed were not being used 
and you could also tell by the repeat forms, what they were picking and using and 
then if they’d come back for steroids because they weren’t using emollients, I 
think, and actually this was an opportunity to actually get them to sit down and talk 
to them and do something positive for them” (Ph1) 
 
The pharmacists also noticed an impact on their practice, using the RCT study training 
evening to gain knowledge to apply to other patients not in the study.  
 
“you know I feel the same, I didn’t get any patients out it and I had to hand it back 
but the fact that I learnt what I learnt from the [training] evening into help not just 
the child but maybe the adults having some of the problems” (Ph4) 
 
“I do find I actually spent more time with the patients who did not come forward for 
the trial and I am making more of a difference that way, so for me personally I’m 
doing better than I was beforehand and hopefully my patients are better for it, so 
you see the rationale a bit more because you’re looking at the whole picture now 
rather than just an odd script that coming through the door. So we’ve, I’ve 
benefitted from it and patients I have dealt with have benefitted from it but not the 
trial” (Ph1). 
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All of these points demonstrate that these particular pharmacists, after participating in a 
study, acknowledge the benefits to their practice even after the study had finished and 
one pharmacist even stated “it hasn’t dampened my enthusiasm for trying it again” (Ph1). 
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2.6 PLEEZ discussion 
This feasibility study recruited nine participants over a nine month period with all 
participants recruited from three pharmacies in the initial three months of the study until 
mid-December. This demonstrates that although possible to conduct an RCT in 
community pharmacy there was a failure to recruit a large enough number of participants. 
This may be due to a variety of factors, including study design, but largely centred on the 
process of recruitment itself. No information was collected on how many patients were 
approached to participate in the study and therefore a recruitment rate cannot be 
determined. I also had no access to the number in the patient population and as such a 
recruitment rate for the available population is not calculable for this study. In future an 
analysis of community pharmacy patient medication records or GP medical systems prior 
to study implementation would be able to identify this information. This lack of recruitment 
demonstrates a problem with the inclusion criteria that is discussed more fully later in this 
section. This may indicate that an independent researcher, present in the pharmacy, may 
be more appropriate than expecting a pharmacist to recruit patients and document 
refusals.  
 
The results from the small number of questionnaires do provide some reassurance that it 
was appropriate to target this group of patients. In both groups at baseline, a high 
proportion of participants stated that they had unmet needs for information about their 
child’s therapy relating to side effects, interactions, what to do if they forgot to use the 
cream/ointment and the length of treatment required for their child.  
 
All the questionnaires were fully completed when returned to me which implies that their 
design was appropriate for this group of participants. The outcome measures selected 
also provided a wide range of characteristics affected by eczema and demonstrated a 
slight change between baseline and follow-up with the exception of the health-related 
quality of life measure which did not demonstrate a change. However, the baseline values 
for both groups were small, indicating a low impact on quality of life at the start and in 
order to demonstrate a benefit it may be prudent to target patients with more severe 
eczema with this type of intervention, however this may make recruitment more difficult.  
 
None of the other study documentation (pharmacist data collection form or GP referral 
form) was completed and this may be due to a lack of understanding on the part of the 
pharmacist as to what was required of them or it may be a lack of time available to them 
to complete the paperwork. Both this and the problems with recruitment could be rectified 
by placing an independent researcher in the pharmacy at the same time as the study is 
being conducted. As well as recruiting patients and consenting them for the study this 
researcher could collect the necessary data from the pharmacy. However, this was not 
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possible in this study due to the part-time nature of myself and the lack of funding for such 
support.   
 
Focus group discussions demonstrated that participating pharmacists had similar ideas 
about what they wanted for their patients who may participate in a community pharmacy 
study. An overarching theme threading through the focus group data was that pharmacists 
wanted the patient taking part in the research study to have as near “usual” experience of 
community pharmacy as possible.  However, this may be a surprisingly unambitious 
aspiration considering that the usual experience of patients in community pharmacy 
settings consists of one-off opportunistic interventions, usually over-the-counter in front of 
other customers/patients. The trial intervention was based on using a consultation room 
and attempted to move the pharmacist into a more clinical/advisory role away from the 
dispensary or counter, almost formalising the consultation with the patient. It centred on 
building rapport with a patient and advising them after a lengthy discussion related to their 
eczema medicines. This is not normal practice for some pharmacists including some of 
the pharmacists who participated in our study and may suggest that future interventions 
need to include more support (both in terms of training and locum support) for participants 
in managing such changes. 
 
The level to which these pharmacists could engage with these ‘lengthy’ consultations with 
patients was limited. Evidence has shown that pharmacists are experiencing ever growing 
pressures at work from the increase in prescription items and the requirement to provide 
this type of enhanced service (Hassell et al., 2011). In the previous 10 years the number 
of prescription items has increased by over 157% to 850 million items whilst the number of 
pharmacies has only increased by 12.3% (The NHS Information Centre, 2011a). This 
implies the time available to pharmacists to participate in research maybe limited and is 
likely to be given a lower priority than their day-to-day activities. Thus, researchers should 
be cognisant of this and make arrangements for the adequate locum-cover or researcher-
support of a pharmacist who is participating in a study to increase their commitment to the 
research. This researcher could act as the recruiter for the study in the pharmacy in order 
that the pharmacist does not have to engage in the consenting process. This may also 
remove certain issues surrounding selection bias if the pharmacist was to recruit their own 
participants. However, this support must be at a level that can be realistically implemented 
within the current funding arrangements for community pharmacy if the service was to be 
commissioned by the NHS.  
 
Pharmacists in our study also expressed reservations about its design. Using RCT 
methodology may provide the best quality evidence (Gomm et al., 2006); however, it may 
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not be appropriate in a particular setting due to practical aspects associated with 
implementation.  
 
The randomised controlled trial (RCT) methodology is classed as the ‘gold standard’ when 
it comes to proving the effectiveness of a healthcare intervention in the setting in which it 
is conducted (Gomm et al., 2006). The RCT is the only design which guards against most 
of the methodological errors associated with confounding and bias. RCTs can be blinded 
(where the participant does not know which treatment they are receiving), double-blinded 
(where the participant and physician do not know the allocation) or not blinded at all. 
There is evidence to demonstrate that studies that are not blinded tend to over-estimate 
the effect size of the intervention by around 17% (Schulz et al., 1995). In community 
pharmacy research, it is often not feasible to blind participants or pharmacists and 
therefore most studies in this setting remain unblinded. To ensure that RCTs are 
conducted on a methodologically sound basis the CONSORT (Consolidated Standards of 
Reporting Trials) statement was developed and provides a checklist that aims to assess 
the rigour of an RCT from the randomisation method to reporting of the results (Moher et 
al., 2001).  
 
It has been suggested in the literature that more thought be given to using observational 
studies and other research methods that are easier and more practical in nature to 
implement than the RCT (Black, 1996). For this particular type of research in this setting, 
a before and after study or a stepped-wedge design may have been more appropriate. A 
stepped wedge design is one where all participants receive the intervention; however the 
timing of the intervention depends on which group the participant is randomised to (Brown 
and Lilford, 2006). Each group starts the intervention at a different time point with all those 
except the initial group having a control period of varying length before the intervention is 
provided.  
 
Being naïve about the study design was a fault that one pharmacist identified himself and  
indicates not only a shortfall in the training provided to these particular pharmacists but 
also to a lack of pharmacist’s general knowledge about methodologies available to 
researchers. Therefore, greater training needs to be given to pharmacists who participate 
in studies that are using unfamiliar research designs to explain the necessity of the 
processes involved and more support to implement these processes in the working 
environment. This training should include basics such as the need for consent, why 
certain research designs are being used and what type of evidence they will provide for an 
intervention. This was not included in the training provided to our pharmacists. 
Pharmacists may then be able to engage much better with these studies in the future. 
68 
 
There may also be a need to investigate, more widely, the knowledge and understanding 
of research methods by the general population of pharmacists.  
 
In this study the randomisation database itself worked successfully, however, the problem 
occurred with the pharmacists’ unwillingness to accept the decision of the randomisation 
system and to provide the service at a later date. This could have been identified through 
an appropriate qualitative study before commencement of the full study. If an independent 
researcher had been present to recruit participants this may have ameliorated 
pharmacists’ views towards this particular research design and the effect it would have 
had on their patients.   
 
For the practical aspect of the study, lack of engagement from, and poor communication 
with the GP medical practice is a common problem encountered by community 
pharmacists (Blenkinsopp et al., 2007b, Bradley et al., 2008, Bush et al., 2009). Many 
research studies either need to gain consent from a particular practice to approach 
patients, due to the nature of the intervention with medication (as in our study), or need 
the practice to identify potential participants on their behalf. Problems seem to arise 
because GPs may not see the need to become involved and would prefer to leave the 
pharmacist to do what they would normally do i.e. approach patients as they see fit. 
Therefore, they do not see the need for consent to be given and this can create barriers in 
the initial phase of any community pharmacy study. This can potentially be addressed by 
closer working between the research team, the medical practice and the community 
pharmacist to identify groups of patients that would benefit from this type of intervention in 
the future. In retrospect, there was little need to gain consent from the medical practice for 
this study as it was low risk and mirrored services that are already being conducted in 
community pharmacy e.g. MURs.  
 
One aspect of the study that could be seen to impact on the level of engagement from the 
medical practice was the choice of disease state i.e. eczema. This condition is not 
featured on any targets e.g. Quality and Outcomes Framework (QOF), that medical 
practices have to achieve and there is evidence to suggest that in one group of patients 
(those with diabetes mellitus) that the QOF incentive system improves clinical and 
process outcomes (Khunti et al., 2007). This may imply that prescribers become more 
interested in those patients for whom they are financially rewarded for treating. This, 
together with the potential perception that pharmacists are already conducting this type of 
intervention, may not have helped in gaining consent to approach their patients. 
 
The pharmacists highlighted that although anecdotally at the start they thought they had a 
lot of patients that would meet the inclusion criteria, at the time of recruitment into the 
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study this number was far lower than originally anticipated. Eczema affects approximately 
16.5% of the population from 0-12 years of age (NICE, 2008) and therefore the actual 
number of patients available to the study was not an issue. Pharmacists may have found it 
difficult to approach patients within the confines of the protocol, which may be as a result 
of poor preparatory work in helping them to identify patients that may be suitable for the 
study.  Appropriate mechanisms, that were not used in this study, should be in place when 
designing research studies to determine the potential number of participants before the 
study commences. One way of achieving this would be to use the QOF database (for 
more prevalent conditions) to ascertain exact number of patients that are registered with a 
particular condition at the outset of the design stage. This would also allow a recruitment 
rate to be calculated. Another method would be to involve the medical practice by asking 
them to perform a search of their records to create a list of patients that could be targeted 
by them to attend the clinic. This would also be useful in determining a response rate.  
 
Issues surrounding documentation for the study could be seen to be related to the study 
design in that the pharmacists should have received much more training and help on how 
to use it appropriately. However, it also points to a need to test study documentation prior 
to commencement to determine if any alterations can be made to allow the participating 
pharmacists and patients to complete it quickly and easily. It is not practical to expect 
pharmacists (or any healthcare professional) to commence a study protocol without the 
appropriate support from the research team in the initial phases of the research. In future 
studies it may be prudent to have a researcher present when the pharmacist is in the early 
stage of recruiting patients and providing the intervention so that if any support is required 
it can be provided instantly. Once the pharmacist is familiar with the paperwork and 
processes, the support can be slowly reduced but should always be available should they 
require it.  
 
In terms of data collection, the questionnaire used for the study was also highlighted as 
part of the pharmacists’ problems with the paperwork and none of the data from the 
pharmacy medication record or consultation was collected even though they were paid for 
data collection. The questionnaire contained BMQ, Morisky, SIMS and CDLQI which may 
have made the questionnaire too long and may have put pharmacists off recruiting 
participants with the thought of having to ask participants to complete it. In future it may be 
prudent to reduce the questionnaire length so that it contains the minimum required for the 
study so that participants can complete it quickly before any consultation. No other data 
were collected by the pharmacists. This, again, points to the need for increased 
researcher support at the time of providing the intervention so that either the pharmacists 
can be reminded of what data need to be collected and have the time to do so or the 
researcher can obtain the data independently of the pharmacist.   
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The training aspect of the study that focused on eczema was well received; referenced by 
comments from the pharmacists that stated they felt in a better position to advise patients 
of all ages not just children. This means that the training they received was at a general 
level and therefore they felt they could use it for all patients. The study documentation 
training fell short of the pharmacists’ needs and no reference was made to the 
consultation skills training. More should be made of these elements in future along with a 
longer session, on more than one occasion, to facilitate this.  
 
There is little research examining how pharmacists approach research and what problems 
they encounter in terms of participation although Cvijovc et al. explore this in a Canadian 
context. These problems include a perceived lack of time, fear of modifying established 
work patterns and a perceived lack of value attributed to research participation (Cvijovic et 
al., 2010). In this study pharmacists stated they had a lack of time to conduct the 
research, however the research team explored this and discovered that the research took 
very little time to complete. This excuse of time was reportedly given to mask the other 
underlying issues with the Canadian study already mentioned. Whilst giving time as a 
reason for non-completion of the study, our pharmacists also elaborated in some depth on 
other reasons that may be responsible for the failure of this study. However, it was also 
clear that they remained enthusiastic about the idea of taking part in research in general, 
even though some of them had not known what to expect at the outset.  
 
Examining the problematic issues raised in the context of their usual practice may provide 
some very practical guidance for redesigning such trials in the future. These problems 
also fit with the current literature explaining why patients do not want to participate in 
community pharmacy research, as described in chapter one. Patients cite reasons for 
non-participation in a community pharmacy research project as confusion or lack of 
understanding of the research, unavailability and most importantly the impact on the 
relationship with their GP (Petty et al., 2001). It may therefore point to an issue regarding 
relationships, not only the GP-pharmacist but also GP-patient and patient-pharmacist as 
to why community pharmacy RCTs are potentially difficult to conduct and these should be 
investigated further.  
 
Even though this study examined a limited amount of data from a focus group whose 
membership was restricted to pharmacists from the independent sector it still produced 
rich data on the varying reasons for a lack of recruitment of participants for this particular 
study. The small number of independent pharmacists that participated were able to offer a 
diversity of views which helped identify a range of related problems in the study that they 
had encountered. This process has made visible the reasons for conducting the focus 
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groups: determining whether I could have increased the number of participants, what the 
problems were and how the individual pharmacists fitted the study into their daily routine 
and these were largely answered by the focus group discussion and its subsequent 
analysis of the data it produced. It may be prudent in future research to conduct this type 
of focus group before the main research project even enters the design phase. However, 
this will still only produce certain insights into practical aspects of conducting research that 
can be ‘predicted’. It will not allow researchers to anticipate and predict everything and 
that is why feasibility testing, piloting and subsequent follow-up will remain an important 
aspect of the research framework for developing complex interventions.  
 
With a lack of time and the opportunistic nature of the pharmacist’s interaction with 
patients it is clear to see that this study was always going to struggle to recruit 
participants. The recruitment process of approaching patients ad-hoc – when they had 
spare time to do so, determining the correct paperwork, explaining the study and obtaining 
informed consent, all before speaking to the patient about their eczema, may have been 
too much. In future, more thought needs to be given to the important stage of a research 
study. In this project, the presence of a researcher in the pharmacy may have helped 
address some of these problems. In the community pharmacy setting this study has 
demonstrated that it may be impractical to expect the pharmacist to act as recruiter and 
the intervention provider at the same time.   
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2.7 PLEEZ conclusion 
In deliberately setting out to test study processes this project would have benefitted from 
even greater preparation such as an appropriately designed feasibility study to assess 
aspects of the study such as recruitment rate, documentation, support requirement and 
practical implementation of the project in the community pharmacy setting and then 
conduct a separate pilot designed with information from the first study. This study 
attempted to combine both into one. The patient outcomes may be encouraging but 
further research will need to be conducted to determine the effect of this kind of 
community pharmacy service. 
 
The reasons for conducting the study in this group of patients: concerns about treatment, 
the need for appropriate therapy management and the need for education have all been 
confirmed by the participants that were recruited to the study and their answers to the 
initial questionnaire. In conducting this study the potential reasons why community 
pharmacy research may prove difficult have been highlighted. 
 
The pharmacists raised several practice specific problems that prevented them from 
participating fully. This did not, however, alter their enthusiasm for the study or the impact 
the study training had on their other patients that were not recruited.  
 
One important theme that emerged was the need for greater researcher support either in 
the form of extra training or being present with them in the pharmacy to recruit potential 
participants or collect the necessary data. It is important that when designing such studies 
researchers understand the ‘real life’ pressures that community pharmacists are under 
and take steps to alleviate further pressures applied by participation in research. The 
inclusion of greater support may also remove a component of selection bias and allow 
researchers to obtain full sets of data.  
 
In terms of the study design, pharmacists clearly had concerns regarding the nature of a 
control group and felt uneasy about it. Better training in the area of research methods to 
enable pharmacists to understand the necessity of certain methodologies may help 
alleviate some of these anxieties. Alternatively, changing the research design to one that 
may be more appropriate could be an option in future studies. 
 
Better communication with the medical practice by both the community pharmacist and 
the researcher is central to a successful study. In this case it may have resulted in better 
identification of likely numbers of participants that were available for the study. As such it 
is important to identify at the outset, not only the number of participants but also their 
needs for any kind of intervention. This may take the form of meetings with the specialist 
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nurse or GP at the practice to gain an idea of the scope of the problem in a particular 
group or it may be in the form of an audit to determine where any intervention would be 
best targeted. 
 
This point of determining where an intervention should be targeted goes further than 
collecting data, either quantitative or qualitative, from the medical practice. Current 
literature and comments from the pharmacists in our focus group indicate that patients 
may have views on which healthcare professional they prefer to be treated by and which 
one they are most likely to engage with in order to improve their health. Further work 
should therefore be undertaken to determine how this triumvirate relationship between the 
pharmacist, patient and GP affects the extent to which patients are likely to engage with 
services provided by the community pharmacy. This allows the research team to begin 
designing novel services with patients in mind, something that is high on the agenda of 
funding bodies such as the National Institute of Health Research (NIHR, 2012).   
 
If this project were to be conducted again, the main amendment would be the presence of 
an independent researcher to recruit participants and complete study paperwork. This 
would mean the pharmacist could focus on the consultation and aspects of the data 
collection process would not be missed. This revised study would also not contain a 
control group as it would be testing the feasibility of the service/research and not 
examining a difference in effect between two groups. There would also be greater 
involvement of the medical practice with potential signposting of patients to the service 
either by mailing those identified through their medical records or referral from the GP.  
 
All of these aspects, views and data can then be used to design an intervention that is 
appropriate for the patient and one that they are likely to engage with. It should be one 
that does not duplicate work being conducted by the medical practice, targets the 
appropriate group of patients and most importantly is successful when initiated in the 
unique setting of the community pharmacy. The strategy for designing a new community 
pharmacy intervention will factor in these considerations along with the most recent MRC 
guidance on complex interventions. This strategy is illustrated in figure 2 and is one that 
will be used for the remainder of this thesis
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PLEEZ Eczema Service 
Pilot/feasibility study 
 
MRC Guidance on Developing Complex Interventions 
Literature review 
 Examine current pharmacy literature to 
inform future service and research design 
Patient focus groups 
 Determine patient views on pharmacy 
service provision 
Prescribing audit 
 Determine where services can be best 
targeted 
Community pharmacy enhanced service 
Feasibility study 
Figure ‎2.3 Strategy for developing an enhanced pharmacy service as a result of the PLEEZ Eczema service project. 
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3 Type 2 diabetes: a perfect disease for community pharmacy? 
In the development stage of a novel complex intervention, the MRC states that 
researchers should identify the appropriate evidence base in order to develop theory and 
processes to inform the study design (Medical Research Council, 2008). One way of 
achieving this is to conduct a systematic review of the literature, which is the focus of this 
and the next chapter.  
 
Chapter two demonstrated that in the community pharmacy setting a number of factors 
need to be considered when choosing a disease state on which to focus a novel 
intervention. There needs to be a large enough population affected to ensure a high 
recruitment rate, it needs to be predominantly treated in primary care and it should be high 
on the medical practice’s list of priorities in order for them to engage in the research.  
 
Type 2 diabetes meets all these requirements: accurate figures can be obtained about 
local prevalence, if patients are not prescribed insulin then it is generally treated in primary 
care; and as part of the Quality and Outcomes Framework (QOF) it is a high priority for 
the medical practice. With the complexity of the condition and therefore the number of 
areas the pharmacist may be able to target together with the number of visits this group of 
patients make to the pharmacy to collect their medicines; we decided to focus on 
designing an intervention for this condition. 
 
3.1 Prevalence and cost to the NHS  
There are an estimated 17.5 million people diagnosed with a long-term condition in the UK 
(Department of Health, 2005a); of which 2.3 million (4.3% prevalence) have diabetes (The 
NHS Information Centre, 2011c). The prevalence has risen from 3.6% to its current figure 
since 2005/6 and is predicted to rise further over the next few years as a result of the 
obesity epidemic with the estimated number of people with diabetes reaching 3.2 million 
(5.9% prevalence) by 2020. According to the United Kingdom Prospective Diabetes Study 
(UKPDS) it affects proportionally more Indian-Asians (10%) and Afro-Caribbeans (8%) 
than are present in the normal population (4% and 2% respectively) (Davis, 2008). The 
majority of patients (85%) are diagnosed with type 2 diabetes which is largely controlled 
by oral medication.  
 
The expenditure on type 2 diabetes in the NHS is estimated to be £1.3 billion with total 
costs to society estimated to be five times this figure through loss of income due to time 
off work and caring for those who have the severe form of the condition (NICE, 2009a). In 
2010/11 the total cost of prescribing for diabetes (both type 1 and type 2) reached £725.1 
million an increase of 11.7% on the previous year with the number of items prescribed 
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rising by 7.8% to 38.3 million (The NHS Information Centre, 2011c). This figure is, in part, 
comprised of the following: 
 
 £259.1 million on antidiabetic drugs – a 30.6% rise from the previous year 
o 14.1 million prescriptions for metformin – an increase of over 70% from 2005/6. 
 £152.6 million on blood glucose monitoring – an increase of £10 million on 2009/10 
 
3.2  Causes and complications 
Type 2 diabetes is caused by the reduction of insulin production or the resistance to 
insulin in the periphery. In terms of insulin production, pancreatic beta cells are generally 
performing at a suboptimal level and are not producing the required level of insulin for the 
body. As well as converting glucose to glycogen, decreasing gluconeogenesis and 
decreasing glycogen breakdown, insulin also performs a central role in the movement of 
glucose across the cell membrane in the peripheral tissue. Insulin activates its receptor on 
the membranes of muscle and fat cells which enables the GLUT-4 glucose transporter to 
facilitate the movement of glucose inside the cell. In type 2 diabetes, these receptors can 
become resistant to insulin which will lead to reduced glucose intake into the cells, leaving 
them with a deficit of energy and increased blood glucose concentration (Kumar and 
Clark, 2002a).  
 
This is a condition that usually develops over a long period of time, to the extent that 
patients will not always be aware that they have the condition and is the reason for the 
large number of people that have the condition but are not aware of it, the so-called 
‘missing million’ (Diabetes UK, 2010). These patients will have an increased frequency of 
hyperglycaemia but may have few or none of the classic symptoms (Walker and Edwards, 
2003). The common symptoms of type 2 diabetes are polyuria, polydipsia, blurred vision 
and very often weight loss despite an increase in appetite. The other symptoms that can 
present include chronic skin infections, pruritus or vaginitis. Caught at this stage it can be 
treated effectively to reduce the incidence of complications. However, in some cases 
patients may have started to develop complications and still have no idea that they have 
the condition. If a patient is asymptomatic the only method of ascertaining whether they 
have type 2 diabetes would be to perform a blood glucose test. This may be an 
opportunistic random test carried out, for example, in a pharmacy or as part of a routine 
medical practice visit for an unrelated condition. If the results of the random test fall 
outside the normal expected range then a fasting test should be performed to ascertain 
whether the patient has the condition. The internationally recognised reference ranges to 
indicate a diagnosis of diabetes are (WHO and IDF, 2006): 
 
 Random plasma glucose concentration >11.1mmol/L 
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 Fasting plasma glucose concentration >7.0mmol/L  
 
It is always advisable to perform the test twice on separate occasions and there may be a 
need to perform a further 2-hour post glucose load test. This is a test where the patient is 
given 75g of anhydrous glucose and 2 hours later the blood glucose concentration is 
tested. Anything over 11.1mmol/L indicates a diagnosis of diabetes.  
 
There are many complications arising from having poorly controlled diabetes and these 
can fall into two categories: macrovascular and microvascular. The macrovascular 
complications include increased risk of myocardial infarction, stroke and foot amputation. 
Hypertension is also a risk factor for these complications and as such it is important to 
simultaneously maintain blood pressure control in the care of diabetes patients to reduce 
the risk further. 
 
Increased microvascular blood glucose concentrations over a long period of time can lead 
to damage of the small blood vessels in the retina, renal glomerulus and nerve sheaths 
which can lead to microvascular complications such as neuropathy, nephropathy and 
retinopathy respectively (Kumar and Clark, 2002a). Neuropathy is usually associated with 
complications in the feet and can lead to pain and weakness in the legs and feet. In men it 
is also associated with impotence. Nephropathy, caused as a result of enlargement of the 
kidneys and high glomerular filtration rate (Walker and Edwards, 2003), may lead to renal 
insufficiency whilst retinopathy usually presents with a simple blurring of the vision and if 
left untreated may lead to blindness. Developing retinopathy as a result of diabetes is one 
of the leading causes of blindness in the UK in the under-65s (Kumar and Clark, 2002a). 
 
In terms of secondary care, patients with diabetes are more likely to be admitted to 
hospital as an emergency and once there will stay longer than a general inpatient by an 
average of three days and of those patients admitted specifically for their diabetes, 47% 
were admitted with active foot disease (a complication arising out of poor glucose control) 
requiring extensive treatment (The NHS Information Centre, 2012). Therefore, in order to 
reduce admissions, length of stay and complications it is important that patients with type 
2 diabetes receive the appropriate preventative care from the NHS in order to reduce 
further (more costly) intervention.  
 
3.3 Evidence and guidelines for treatment 
In order for patients to reduce the complications experienced as a result of having type 2 
diabetes the National Institute for Health and Clinical Excellence (NICE) has developed 
guidelines for the treatment of type 2 diabetes and places targets on clinical outcomes 
such as blood glucose and blood pressure which are listed below (NICE, 2009b): 
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HbA1C:   <59 mmol/mol or 7.5% 
Blood pressure:  <140/80 mmHg or <130/80 mmHg if kidney, eye or cerebrovascular 
damage is present. 
Total cholesterol: <4.0 mmol/L 
LDL-cholesterol: <2.0 mmol/L 
 
Any reduction in HbA1C levels (the long-term measure of blood glucose control) can 
improve the risk of developing microvascular and macrovascular complications (Stratton 
et al., 2000) and that early control particularly, can help reduce the long-term 
complications developed as a result of having the condition (Holman et al., 2008). There is 
however, now an evidence base for not intensively treating diabetes to a level below 48 
mmol/mol or 6.5%. Research has demonstrated that intensive treatment leads to 
increased all-cause mortality and CV-related deaths along with increased episodes of 
hypoglycaemia (ADVANCE Collaborative Group et al., 2008, ACCORD Study Group et 
al., 2008) and significant weight gain (ACCORD Study Group et al., 2008).  
 
The drug of choice for first line treatment is metformin, which is particularly effective for 
obese patients as it is known to cause anorexia. Alternatively, sulphonylureas e.g. 
Gliclazide can be used in those patients for whom weight is not a problem. NICE 
recommends a stepwise approach to the management of blood glucose; once a patient’s 
HbA1C level increases above a certain threshold it directs the prescriber to initiate further 
therapy. This can be a combination of metformin and sulphonylurea or the addition of one 
of the following:  
 
 thiazolidinedione e.g. pioglitazone;  
 dipeptidylpeptidase-4 inhibitor e.g. sitagliptin or vildagliptin;  
 acarbose;  
 glucagon-like peptide-1 mimics e.g. exenatide or liraglutide;  
 or insulin (as a final option) 
 
which can result in a patient being prescribed several medicines in an attempt to control 
their blood glucose. 
 
Unless prescribed insulin, it is not routinely recommended for patients with type 2 diabetes 
to self-test their blood glucose levels (NICE, 2009b). This is based on evidence stating 
that self-monitoring of blood glucose, with its significant cost implications, only leads to a 
moderate reduction in blood glucose and can lead to increased anxiety and depression 
(Farmer et al., 2007, O'Kane et al., 2008, Simon et al., 2008). However, patients may find 
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it a comfort to test their blood glucose once or twice a week to determine an approximate 
reading for their own knowledge. It may also prove useful for newly diagnosed patients 
who are in the process of discovering how their diet and lifestyle can affect their blood 
glucose levels. This group of patients may then be receiving prescriptions for test strips 
along with the associated lancets and testing machines. Patients may not always know 
how to use these machines and therefore the pharmacist may be asked to guide them on 
their use.  
 
The importance of good blood pressure control cannot be understated in patients with 
type 2 diabetes (Stearne et al., 1998) as it has been demonstrated to provide a similar 
reduction in the development of the same complications associated with the control of 
blood glucose (Sehestedt et al., 2011), however there may be differences in which one is 
better to treat intensively on the disease development and progression in each patient 
(Bartnik and Cosentino, 2009). The standard treatment for patients with type 2 diabetes 
and hypertension is to initiate an angiotension-converting enzyme (ACE) inhibitor or 
equivalent if these are not tolerated. Again, NICE state a stepwise approach to the 
management of hypertension in these patients and for those that are severely affected 
then it may result in four or more medicines being prescribed concurrently.  
 
There are a further two medicine-related interventions in these patients: lipid-lowering 
drugs and anti-thrombotics. The evidence base for total cholesterol and LDL-cholesterol 
reduction in patients with type 2 diabetes is clear. For every mmol/L reduction in low-
density lipoprotein cholesterol (LDL-C) there is a reduction in all-cause mortality by 12%, 
CHD death by 19%, stroke by 17% and the incidence of a first major coronary event in the 
diabetic sub-population by 26% (Baigent et al., 2005). It has been demonstrated that 
statins have a significant effect at lowering the LDL-C level in patients with type 2 diabetes 
(Haffner et al., 1998, Shepherd et al., 2006) and therefore NICE recommends that each 
patient should be prescribed a statin as a matter of routine to lower their cholesterol.  
 
The evidence base for anti-thrombotic therapy is not as clear and there may be little 
benefit of prescribing aspirin to patients who have not yet experienced a myocardial 
infarction or stroke (De Berardis et al., 2009, Zhang et al., 2010). However, many patients 
are prescribed it as the evidence base has developed over recent years and NICE 
currently recommends prescribing it as primary prevention in those patients over 50 and 
those under 50 with significant other cardiovascular risk factors.  
 
In combination with all of these medicines to treat the ‘core’ elements of type 2 diabetes, 
patients may often be prescribed other medicines to treat co-morbid conditions or 
complications as a result of having the disease. These can include treatments for 
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neuropathic pain e.g. paracetamol or amitriptyline or impotence e.g. sildenafil (NICE, 
2009b).  
 
Even with all of these treatments available only 66.5% of patients achieved a target HbA1C 
of 59 mmol/mol, 60.7% achieved a blood pressure of 140/80 mmHg and 40.9% reached a 
target of 4.0 mmol/L for total cholesterol (The NHS Information Centre, 2011b). Medical 
practices are encouraged to achieve these targets via the implementation of the Quality 
and Outcomes Framework (QOF), an incentive scheme run by the NHS. Medical 
practices are incentivised monetarily for such aspects of diabetes care as (BMA and NHS 
Employers, 2011): 
 
 compiling a list of those patients within the practice that have been diagnosed with 
diabetes 
 performing clinical tests at regular (pre-specified) intervals 
 the number of patients achieving national targets for measures such as blood glucose, 
blood pressure and lipids 
 the medication prescribed to patients with certain complications arising from the 
disease 
 the number of patients to have received the influenza vaccine. 
 
The number of medicines prescribed may indicate that adherence to regimens may be a 
problem in this group of patients and that this may be contributing to a lack of control. This 
is an area that the community pharmacist, who will be seeing the patient regularly when 
they collect their medicines, may have an impact on.  
 
3.4 Adherence to treatment 
It is estimated that 50% of patients do not take their prescribed medication correctly  
(Sackett and Snow, 1979) and research has shown that this causes, or is the reason for, 
between 11% and 30% of drug related hospital admissions (Col et al., 1990, Wasserfallen 
et al., 2001). Non-adherence is the term used to describe the extent to which a patient’s 
behaviour does not correspond with agreed recommendations from a healthcare provider 
(WHO, 2003). The reasons for such patient behaviours have been widely researched and 
it is believed that it arises from both unintentional and intentional actions (Vermeire et al., 
2001). 
 
Intentional non-adherence is where a patient has decided not to take their prescribed 
medicines due to factors such as side effects, perceived lack of effect of treatment or 
disbelief in their diagnosis. Unintentional non-adherence occurs when factors such as 
dexterity, lack of mobility or lack of understanding prevent the patient from either collecting 
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their medicines from the pharmacy or accessing their tablets e.g. if they are contained in 
small bottles with child resistant lids. This also includes cognitive impairment such as 
memory loss in dementia patients or patients with learning difficulties. The pharmacist can 
have an impact in addressing unintentional non-adherence through the provision of a 
delivery service, large print labels and compliance aids. Efforts to address intentional non-
adherence have focused on improved physician-patient communication (Martin et al., 
2005) and other educational interventions using different consultation techniques such as 
motivational interviewing and behaviour change counselling (Easthall et al., 2012). 
However, no single intervention has been found to be better than others at tackling this 
problem (Peterson et al., 2003). 
 
Adherence can be further subdivided into primary non-adherence and secondary non-
adherence. Primary non-adherence is where patients do not collect their prescribed 
medicines from the pharmacy and secondary non-adherence is where they do not follow 
the prescribed regimen (Donovan and Blake, 1992).  
 
There are several methods for measuring adherence including self-report e.g. the Morisky 
questionnaires, prescription re-fill counts and electronic monitoring e.g. MEMS. There is 
no consensus on the gold standard for measuring adherence (Smith et al., 2010), 
however there appears to be an agreement that self-report methods are less reliable than 
pill counts or electronic monitoring (Adams et al., 1999, Guénette et al., 2005). When 
monitoring adherence, it has been suggested that two methods are used together in an 
effort to triangulate the results produced (Vitolins et al., 2000). 
 
Adherence to treatment by patients plays an important role in the metabolic control of type 
2 diabetes. Schectman et al. demonstrated that every 10% increase in adherence was 
associated with a 0.19% lower HbA1C level (Schectman et al., 2002) and a lower HbA1C 
level has been demonstrated to lead to a reduction in the incidence of diabetic 
complications (UK Prospective Diabetes Study (UKPDS) Group, 1998). 
 
In 2004, Cramer performed a review of the literature examining the adherence to diabetes 
medication and found a wide variation in results both from retrospective and prospective 
studies (Cramer, 2004). In the studies that used retrospective prescription refill data from 
health databases the mean adherence ranged from 36 to 93% and certain studies 
highlighted that once-daily regimens had higher adherence rates than twice-daily (Dezii et 
al., 2002) and monotherapy displayed higher adherence characteristics than polytherapy 
(Ciechanowski et al., 2000). In the prospective analysis, all studies used the Medication 
Event Monitoring System (MEMS) to monitor adherence. This produced a much narrower 
range for adherence of 61 – 85% of doses taken and again certain studies provided 
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evidence to suggest that adherence decreases as the number of daily doses increases 
(Paes et al., 1997). One study compared electronic monitoring with self-reporting 
adherence and found that there was a discrepancy between the two (74.5% vs 92.4% 
adherent respectively) (Matsuyama et al., 1993), with self-reporting being less valid.   
 
Evidence from Sweden suggests that adherence is good in patients with diabetes with 
almost 90% of patients classed as adherent (taking 80% of the prescribed doses) to 
treatment, as measured by large scale prescription refill data (n=171,220 patients) (Haupt 
et al., 2009). Conversely, in Scotland, Donnan et al. found that prescription refill data from 
2920 patients demonstrated that only 31% of patients prescribed only a sulphonylurea 
and 34% prescribed metformin alone were classed as adequately adherent (taking >90% 
of prescribed doses) with poorer adherence associated with an increase in the daily 
number of tablets and when co-medication was added to the sulphonylurea regimen 
(Donnan et al., 2002). This has been confirmed in 1,815 patients in the US who displayed 
lower adherence rates from prescription refill data when a second medicine was added to 
their monotherapy than when it was changed to a fixed-dose combination medicine (54% 
vs 77% respectively) (Farmer et al., 2005). This is something that is confirmed more 
widely in the literature for other conditions (Claxton et al., 2001). 
 
Therefore it has been demonstrated that adherence may be a problem in this group of 
patients, the full extent of which has yet to be determined, with self-report methods 
potentially over-estimating the figure. This research has shown that the number of 
medicines and number of daily doses a patient has to take directly impacts on their level 
of adherence. However, as suggested earlier, the extent to which a patient adheres to 
treatment may be affected by a number of other factors. Non-adherence has been 
suggested to be as a result of the patient not understanding the need for the medicine, the 
occurrence of any side effects or deciding that the medicine has no perceived effect and 
they therefore stop taking it (Grant et al., 2003). There is also some limited evidence to 
suggest that the just the perception of side effects may impact on intentional non-
adherence (Chao et al., 2007). 
 
However, in patients with diabetes there is evidence to suggest that there is strong 
motivation to take prescribed medicines as patients can observe them having an effect 
through an improvement in their blood glucose measurements (Farmer et al., 2005, 
Lawton et al., 2008). In both of these studies, experiencing side effects from medication 
was found to have a negligible effect on the extent to which a patient is likely to adhere to 
treatment.  
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Most concerns about diabetes medication appear to focus on weight gain as a result of 
taking the medicine, what to do when doses are missed, the increased cardiovascular risk 
as a result of taking certain medicines and how they will continue to manage their 
regimens if their routine changes. These were all perceived to have an effect on the level 
of a patient’s adherence to treatment (Hauber et al., 2009, Lawton et al., 2008, Farmer et 
al., 2005).  
 
Other factors that have been shown to have some impact on adherence rates in this 
group of patients are: age, lower socio-demographic status, shorter duration of disease 
and lack of complications (Bezie et al., 2006) along with a potential link between diabetes, 
depression and non-adherence (Park et al., 2004). 
 
The evidence regarding adherence to medication in diabetes patients suggests that there 
may be a problem trying to persuade patients to take their medicines as prescribed. One 
consequence of this could be the large proportion of patients that fail to achieve national 
targets for diabetes control. The evidence appears to suggest that a simplification of 
medication regimens and improved information provision aimed at addressing concerns 
over side effects, missed doses, routine changes and cardiovascular risk may help to 
improve adherence in this group of patients. These are all topics which a pharmacist, with 
appropriate counselling on medication and improved communication with the prescriber 
should be able to address in the community pharmacy setting.  
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3.5 Summary 
With the number of medicines and devices prescribed for diabetes and co-morbid 
conditions, patients with type 2 diabetes will visit their community pharmacy on a regular 
basis and this provides an opportunity for a novel intervention. As discussed, these 
patients may have significant concerns or needs for information about their medicines or 
disease that the community pharmacist may be able to address via an adherence-based 
intervention. Together with this the explicit guidelines produced by NICE for the treatment 
of type 2 diabetes also provide a background for clinical interventions that can be 
suggested to the primary care team by the pharmacist. These guidelines are stepwise and 
cover most aspects of diabetes care and there is therefore the potential for the long term 
management of patients to be moved to the pharmacist provided they remain within these 
limits. The use of the QOF incentive scheme for medical practices would also be of use in 
any future study/service. Any help that the community pharmacist can provide to this 
group of patients may also help the medical practice to achieve their targets more easily. 
It could also be an advantage when trying to engage practices in research projects that 
involve the community pharmacist.  
 
The next stage in this thesis is to examine the current evidence base for such a 
community pharmacy service from the UK and abroad.  
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 Chapter Four  
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4  Diabetes community pharmacy interventions 
4.1  Introduction 
There have been many interventions developed in the UK and internationally to assist 
patients in controlling their diabetes, most notably in the UK these have included the X-
PERT and DESMOND studies (Davies et al., 2008, Deakin et al., 2006). These have 
involved multi-professional teams in a variety of settings, and have provided encouraging 
results with regard to education provision and its effect on diabetic control. This type of 
educational intervention has been delivered and evaluated by community pharmacists 
both in the UK and internationally and the next section will examine these in more detail. 
 
4.2 Aim 
A literature search was performed to identify published research articles which examined 
the effect of a community pharmacy based service on patients with type 2 diabetes. This 
was performed to learn from other trial designs and to identify what worked successfully 
and what did not in order that this can be factored in to the design of our novel 
intervention. There was also a need to identify any UK research in this area to avoid 
duplication and determine if this work could be conducted within the current community 
pharmacy operational framework.  
 
4.2.1 Objectives 
To identify: 
 the presence of UK-based and international studies conducted in this group of patients 
in this setting 
 the trial design of each of the included studies 
 the training provision for pharmacists 
 the inclusion criteria applied to potential participants 
 the content and duration of the interventions 
 whether these types of interventions have been effective 
 the quality of the research conducted in this group of patients in this setting 
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4.3 Method  
The following databases were searched for relevant articles: OVID (AMED, Medline, 
Embase, PsychINFO), CINAHL, Scopus, Web of Knowledge and the Cochrane Database. 
These databases were selected due to their specialism in the area of medicine, nursing 
and allied health as well as being general literature databases that list the major journals 
that are likely to publish research in the field of interest.  
 
The terms used for this literature search are identified in the results section together with 
the number of articles returned by the individual databases. These terms were identified 
using previously identified articles and MeSH terms. Each term was searched for in the 
title and abstract listed on the database, apart from Web of Knowledge where the search 
was only conducted in the title and CINAHL where the search was conducted in the 
abstract only. This was due to constraints on the database search engines.  
 
Once identified, the articles were downloaded to the Endnote referencing programme for 
further screening. A first screen was used to remove duplicates and those articles that 
clearly did not fit the inclusion criteria from their title. A second, more detailed screening, 
involving the abstract was then performed using the inclusion and exclusion criteria. 
 
4.3.1 Inclusion criteria 
This literature review focuses on the role of the community pharmacist in the management 
of patients with type 2 diabetes. Therefore, it is appropriate that all those included are 
performed by a community pharmacist working in a community pharmacy and not a 
clinical pharmacist working in the community. Some studies were conducted in health 
clinics or hospitals and this does not reflect the current situation in UK community 
pharmacy. The community pharmacy setting in the UK is defined by its primary role of 
medicines supply and not clinical service provision. This places limitations on the role of 
the community pharmacist that pharmacists in other settings will not experience e.g. 
dispensing and advising customers over-the-counter. It is also a place where the 
pharmacist is the only healthcare professional present and therefore there is limited scope 
to discuss medical problems with other members of the healthcare team. It is for these 
reasons that this review will focus specifically on the community pharmacy and not the 
community pharmacist operating in other environments.  
 
Many studies also involved a pharmacist as part of a wider healthcare team and it is 
difficult to determine exactly what affect the pharmacist alone had on these patients and 
whether any effect could be attributed to the pharmacist or another healthcare 
professional e.g. certified diabetes educator. 
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Further specification required the review to contain only studies that were conducted in 
patients with type 2 diabetes. This is due to the differing nature of the two types of 
diabetes. Type 1 is generally managed by the secondary care team and it may not 
therefore be appropriate to develop a role for the community pharmacist in this area due 
to the increased complexity of any intervention which would be centred on a patient’s 
insulin management. As a result of this, pharmacists may require a significant training 
programme that may not be feasible to perform in this setting. Type 2 diabetes is 
managed largely in primary care with oral medication and the community pharmacist will 
see this group of patients regularly and will be in a position to contact the medical team 
should it be necessary.  
 
For this review, it was decided to include only studies that reported HbA1C as an outcome 
measure, either primary or secondary. This is due to the importance of this measure of 
blood glucose as an indication of control of the disease and the likelihood of developing 
complications. 
 
As demonstrated in chapter two, it may be hard to conduct RCT research in this setting 
therefore any research methodology will be accepted. Studies must also have an abstract 
available for screening. Conference presentations were also included in the literature 
review.  
 
4.3.1.1 Summary inclusion criteria 
 Intervention performed solely by a community pharmacist 
 Conducted in patients with type 2 diabetes  
 Conducted in the community pharmacy setting 
 Reported HbA1C as an outcome measure 
 Used any type of research methodology 
 Abstract available 
 
4.3.2 Exclusion criteria 
I did not have the facilities to translate articles that were published in a foreign language, 
therefore these paper were excluded if an English version could not be sourced. 
 
4.3.2.1 Summary exclusion criteria 
Articles not written or available in English  
 
4.4 Search results 
The literature search was performed up to and including December 2011. Table 4.1 
details the terms used and the number of hits returned by each of the search engines.   
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Search 
number 
Terms Database 
OVID SCOPUS CINAHL & 
MEDLINE 
Web of 
knowledge 
1 Pharmac* 1,139,640 923,123 379,881 543,625 
2 Pharmacist* 53,234 54,263 14,869 15,360 
3 1 or 2 1,139,640 923,122 37,988 543,625 
4 Community 691,113 722,024 266,529 365,163 
5 Retail 12,387 26,672 4,418 10,844 
6 High street 234 15,364 83 265 
7 4 or 5 or 6 702,794 761,683 270,668 376,253 
8 3 and 7 24,626 18,941 9,438 4,333 
9 Adult onset diabet* 1,012 13,056 353 479 
10 Type 2 diabet* 135,151 118,585 59,169 97,926 
11 Ketosis resistant diabet* 22 51 5 21 
12 Maturity onset diabet* 3,458 2,595 1,297 976 
13 Non-insulin dependent 
diabet* 
21,133 105,752 8,816 13,906 
14 Noninsulin dependent 
diabet* 
2,810  1,152 854 
15 Slow onset diabet* 9 519 4 24 
16 Stable diabet* 260 8,061 87 338 
17 Type II diabet* 15,105 20,047 5,681 10,966 
18 NIDDM 14,648 7,986 6,703 8,953 
19 9 or 10 or 11 or 12 or 13 
or 14 or 15 or 16 or 17 or 
18 
177,635 172,865 76,815 131,818 
20 8 and 19 312 319 108 22 
21 Remove duplicates 206   14 
Table ‎4.1 Search terms and results returned 
The Cochrane Database returned no relevant studies or reviews.  
 
4.4.1 Included studies 
After detailed searching, 30 articles required further reading of the full paper to determine 
appropriateness for inclusion of which eight articles were subsequently deemed 
appropriate (Correr et al., 2011, Krass et al., 2007, Mehuys et al., 2011, Oyetayo et al., 
2011, Taylor et al., 2005, Wermeille et al., 2004, Fornos et al., 2006, Krass et al., 2011). 
One study, conducted by Wermeille et al. should have been excluded as it appears that 
the actual consultation with the patient took place in the medical practice for ‘space 
reasons’. However, I felt that it would be useful to include as it was the only UK study 
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published in this area at the time of the literature search and it would be helpful to 
compare to other countries. I believe that the intention of the study team was to perform 
the project in the community pharmacy had there been a suitable space and that if this 
project was performed today it would have been possible for them to achieve this.  
 
4.4.2 Characteristics of excluded studies 
A number of studies from the US and Australia were excluded based on the setting in 
which they were conducted. Some of these studies, including DiabetesCare, the Diabetes 
Ten City Challenge and The Ashville Project (Cranor et al., 2003, Fera et al., 2009, 
Odegard et al., 2005, Krass et al., 2006, Johnson et al., 2008), were conducted in 
community medical facilities by a community pharmacist; however, this setting does not 
reflect the current UK setting of community pharmacy and they were therefore excluded. 
These three studies either used an observational design or a pre-test post-test 
methodology and between them recruited 1313 participants. Three Swedish studies were 
also excluded because they were conducted by community pharmacists in conjunction 
with a diabetes nurse and away from the community pharmacy setting (Sarkadi and 
Rosenqvist, 1999, Sarkadi and Rosenqvist, 2004, Sarkadi et al., 2005).  
 
Certain studies were excluded based on their chosen outcome measure of fasting plasma 
glucose (Turnacilar et al., 2009, Adepu et al., 2007). This is not seen as a good measure 
of the long term control of a patient as it only references a patient’s glucose level over the 
preceding 12 hours. To provide some comparability, we only included studies which 
reported appropriate clinical outcomes and consequently studies that reported fasting 
plasma glucose, health-related quality of life and intermediate outcomes such as 
knowledge or satisfaction (Malathy et al., 2011, Mitchell et al., 2011) were excluded.  
 
4.4.3 Quality assessment 
The aspects of individual studies included are described with reference to study design 
(table 4.3), training provision (table 4.4), inclusion criteria (table 4.5) and intervention 
design (table 4.6). A quality assessment is provided in each table which is used to 
determine which factors may be related to better outcomes and individual rating systems 
are described in detail in table 4.2. This rating system was developed in collaboration with 
the supervisory team to provide clarity on the different aspects of each study and to aid 
presentation of results. The system has not been validated in the literature. 
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  = Poor  = Moderate  = Good Table 
reference 
Study design Controlled 
trial 
Randomised OR 
achieved recruitment 
target 
Randomised AND 
achieved recruitment 
target 
4.3 
Training 
provision 
No input Acquired all knowledge 
face-to-face 
Addition of role play 
sessions 
4.4 
Inclusion 
criteria 
Some 
recruitment 
criteria 
Based on HbA1C Based on HbA1C and 
number of medicines 
4.5 
Intervention 
content 
Small 
number of 
interventions 
Large number of 
interventions, covered 
small number of topics 
Many interventions 
covering all aspects of 
diabetes care 
4.6 
Table ‎4.2 Definitions for the quality rating system 
 
4.5 Results 
There were differences between the studies in terms of the magnitude of change in the 
clinical outcome measures and this may have been due to the different approaches to the 
intervention and the research process. These differences are summarised in each 
subsequent table and collated in table 4.7 where they are ranked in order of overall 
quality. Study design is examined first in table 4.3.  
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Author Date Location Controlled Before/after Randomised Power 
Anticipated effect 
size 
Number of anticipated 
participants 
Number of actual 
participants 
Quality 
Correr 2011 Brazil       161  
Fornos 2006 Spain    80% 
10% relative 
difference between 
groups 
110 114  
Krass 2007 Australia   * 90% 
0.5% absolute 
reduction 
360 335  
Krass 2011 Australia   * 90% 
0.5% absolute 
reduction 
320 387  
Mehuys 2011 Belgium   * 80% 
0.5% absolute 
reduction 
256 288  
Oyetayo 2011 US       126 - 
Taylor 2005 Australia       239  
Wermeille 2004 UK       62 - 
Table ‎4.3 Study design 
*Randomisation performed by pharmacy; one  for each of the following criteria: controlled trial; randomised; achieved recruitment target. 
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Correr et al. performed a non-randomised study in Brazil that was based on a 
pharmacotherapy follow-up programme (PFU) and provides detailed information regarding 
the intervention provided to the participants and the training provided to the pharmacists. 
This study recruited six pharmacies of which two self-selected to be in the control group, 
purely based on the pharmacist’s preference which may have influenced the result as the 
more motivated pharmacists were providing the service. There was little explanation of the 
participant drop-out rate, which in this study was 40.3%.  
 
The reporting of the RCT by Fornos et al. was extensive and provided significant detailed 
information. The study had 80% power to detect a 10% relative difference in HbA1C  
between groups at follow-up, which was achieved with the appropriate number of 
participants recruited. The intervention was extensively described along with the training 
requirements for the pharmacists who also attended regular sessions where drug-related 
problems were discussed and intervention fidelity was assessed. The study also reported 
other clinical and humanistic outcomes in addition to HbA1C, which all demonstrated a 
positive effect of the intervention. 
 
The group of researchers in Australia have developed and tested a number of community 
pharmacy diabetes interventions (Krass et al., 2007, Krass et al., 2011, Taylor et al., 
2005, Armour et al., 2004) as well as patient perceptions of such a service (Mitchell et al., 
2011). Both studies provide extensive information regarding the intervention provided to 
participants and the training provided to pharmacists.  They both include detailed inclusion 
criteria and power calculations although the 2011 study over-recruited. They both also 
report other clinical and humanistic outcomes on which the interventions have a limited 
positive effect.  
 
The group’s 2005 study was similar to the subsequent two with respect to training with the 
addition that the research team visited the pharmacies to assess intervention fidelity 
(Taylor et al., 2005). It is not clear if this was performed in the 2007 or 2011 studies or 
what the outcomes of these visits were.  
 
To demonstrate that these studies can have a beneficial effect to the patient is important, 
however, it must also be affordable to the health service in which it is conducted. Only one 
of the studies reviewed also published a cost-effectiveness analysis of their service. 
Taylor et al. calculated that the additional cost of providing their service was 
approximately $A383 per patient for the first nine months of the service and that this 
achieved an HbA1C reduction of 0.46% (Taylor et al., 2005). For every 1% reduction in 
HbA1C, the risk of developing any long term complications diminishes by 21%, myocardial 
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infarction by 14% and microvascular complications by 37% (Stratton et al., 2000) which 
could lead to significant cost savings to the NHS.  
 
Mehuys et al. over-recruited for their power calculation, recruiting a total of 288 when only 
256 were required. In this study the intervention was well described, however, the training 
requirement of the pharmacists was not clear from the article. A lack of description of 
training undertaken by the pharmacists was also a problem with the article by Oyetayo et 
al. This was classed as a ‘live four-hour educational session’ but did not describe where 
this took place or what was covered. This study included no power calculation and 
experienced a drop-out rate of 65%, the reasons for which were not explained.  
 
Wermeille’s 2005 study was the only one to be conducted in the UK. It was a prospective 
pre-test post-test design that identified participants through their pharmacy medication 
records. Each participant recruited attended an interview at baseline and again at 24 
weeks and had a pharmaceutical care plan (PCP) developed for them by the community 
pharmacist. This PCP, generated after the first interview was reviewed by a second 
community pharmacist and two academic pharmacists before being discussed with the 
participant’s GP. The second interview was designed to assess whether the PCP had 
been implemented. During both interviews the participant’s knowledge was tested, 
medication adherence measured and a blood pressure measurement was taken.  
 
The training provision provides an overview of the extra training the participating 
pharmacists had to undergo in order to provide their respective services. This is described 
in table 4.4 below.  
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Author Date 
Delivery Content 
Quality Self-directed 
learning 
Face to face 
training 
Role play 
Diabetes 
knowledge 
Measurement 
techniques 
Guidelines Study design 
Regular 
monitoring 
Correr 2011          
Fornos 2006          
Krass 2007          
Krass 2011          
Mehuys 2011          
Oyetayo 2011          
Taylor 2005          
Wermeille 2004 No information provided  
Table ‎4.4 Training provision for pharmacists 
 = no input;  = all knowledge acquired face to face but no role play;  = training included role play 
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In four out of the eight studies the training for the pharmacists followed a similar pattern of 
self-directed learning e.g. a diabetes manual, followed by a training session held usually 
at the university that lasted anywhere from eight hours to two days. Two of the studies 
(Mehuys et al., 2011, Wermeille et al., 2004) provided little or no information about the 
training they required the pharmacists to attend and in the final two studies one held a 
university training session (Correr et al., 2011) and one conducted a live four-hour face to 
face training session with an endocrinologist and specialist pharmacist (Oyetayo et al., 
2011).  
 
All of these training sessions covered the basics of diabetes, the complications and 
prognosis of the disease, medication used to treat diabetes, an overview and practical 
demonstration of diagnostic equipment (if required for the study) and information about 
the study protocol e.g. details on the pharmacotherapy follow-up programme. Fornos et al. 
included as part of the on-going training, regular sessions where pharmacists could 
present and discuss drug related problems that they had identified during the course of 
the study. For Taylor et al. consistence was important across all the pharmacies and 
therefore the participating pharmacists were visited by the research team after their 
attendance at the training session to ensure consistency within the programme.  
 
All of the studies recruited participants based on different aspects of their diabetes care 
and therefore it is useful to understand the inclusion criteria and how this may affect the 
outcome of the study. Inclusion criteria are detailed in table 4.5. 
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Author Date 
Recruitment based on: 
Quality Prescription of oral 
diabetes medicines 
Age HbA1C 
Medical practice confirmation 
of results before recruitment 
Comments 
Correr 2011     >30 years old  
Fornos 2006     OHAs >12 months  
Krass 2007     
>7.5% + 1 OHA or insulin OR >7.0% + 1 OHA and 
other medicine for hypertension, angina or lipids 
 
Krass 2011     >7.0%  
Mehuys 2011     
45-75 years old, OHAs >12 months 
BMI >25, approached consecutively 
 
Oyetayo 2011     Hispanic  
Taylor 2005     
<85 years old 
>3 medicines 
 
Wermeille 2004     >40 years old  
Table ‎4.5 Inclusion criteria 
 = some recruitment criteria;  =based on HbA1C;  = recruitment based on HbA1C and number of medicines  
99 
 
With reference to the inclusion criteria, all of the studies apart from two (Krass et al., 2011, 
Oyetayo et al., 2011)  used whether a patient was receiving oral medicines to treat type 2 
diabetes to screen eligible participants. Two studies (Krass et al., 2007, Krass et al., 2011) 
included HbA1C as a criterion for inclusion; the patient had to be poorly controlled before 
participating. Both studies utilised a control group for comparison and produced a 
significantly greater decrease in HbA1C in the intervention group when compared to the 
other studies. Oyetayo et al. did not recruit using HbA1C results; however, they did perform 
a sub-analysis on their data to account for those patients that were poorly controlled at the 
start. These patients achieved a significant decrease in the HbA1C result compared the 
non-significant result seen in all participants.  
 
Finally, intervention design is detailed in table 4.6. 
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Author Date Number of consultations  Length of intervention 
Content Action 
Quality 
Adherence D&L DRP Monitoring Referral 
Correr 2011 12 12 months       
Fornos 2006 13 13 months       
Krass 2007 5 6 months       
Krass 2011 4 or 6 6 or 12 months respectively       
Mehuys 2011 Each visit 6 months       
Oyetayo 2011 4 12 months       
Taylor 2005 7 9 months       
Wermeille 2004 2 24 – 28 weeks       
Table ‎4.6 Description of intervention 
D&L: diet and lifestyle; DRP: drug related problems;  = short duration, small number of interventions;  =large number of interventions, covered small number of 
topics;  = large number of interventions, covered all aspects of diabetes care 
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There is no common theme threading through the design of these interventions that 
clearly produces improvements to HbA1C. However, most of them cover the same topics in 
the consultation and most follow roughly the same pattern; a service that has multiple 
consultations with the participant over an extended period of time. The content of the 
consultation was approximately the same for all of the included studies and covered 
aspects such as diabetes and its complications, medicines and their correct use, lifestyle 
and diet advice and adherence advice.  
 
Nearly all of the studies sought to see the patient as part of the intervention anywhere 
between once every month to once every three months for up to 1 year with some studies 
having an intensive intervention at the start which then tapered off as the year progressed. 
Only one study did not follow this model instead interviewing the patient at the start of the 
study and providing them with the necessary information they wanted and then re-
interviewing at the end (24-28 weeks later) to collect the follow-up data (Wermeille et al., 
2004).  
 
In terms of the length of follow-up and the number of clinics provided as part of the 
intervention, Krass’s 2011 study sought to determine the ideal length of time for an 
intervention such as this. One group received four visits over six months and the other 
group received six visits over 12 months. Both arms were followed up at 18 months and 
both demonstrated a 0.9% decrease in HbA1C over this period. The first group did 
demonstrate a slight worsening of control over the follow-up period, however this was still 
significantly lower than the baseline figure.  
 
These studies all produced varying drop-out rates from 2-65%. Those with the best drop-
out rates engaged with their participants on a regular (usually monthly) basis to encourage 
them to continue attending the service. The total length of the intervention (from baseline 
to final follow-up) appeared to have no effect on the rate of attrition in this group of 
patients.  
 
A final aspect that appears useful in these studies is the apparent integration of the 
community pharmacist into the primary care team. All apart from one of these studies had 
some level of referral system in place to liaise with the patient’s physician However, the 
extent of the pharmacist-doctor communication differed with some only providing advice to 
the prescriber, some simply referring patients and others actively working with the 
prescriber to identify and solve drug-related problems. 
 
The overall rating for each study is provided in table 4.7 where they are ranked in order of 
quality.   
102 
 
Author Date 
Star rating (see individual table): 
Outcome P-value Comments Design 
(4.3) 
Training 
(4.4) 
Inclusion 
criteria (4.5) 
Intervention 
(4.6) 
Krass 2007     -1.0% (-0.8 to -1.3)  <0.01 (int vs cont diff) 
Krass 2011     No difference  0.98  
Comparison of 6- month and 12-month 
groups; -0.9% (-0.7 to -1.1 in both groups) 
Mehuys 2011     -0.5% (0.1 to 0.9)  0.009  
(difference between groups); p<0.001 (within 
intervention group); -0.6% (-0.3 - -0.9) 
(intervention) 
Fornos 2006     -0.5%  <0.001 
8.4% (1.8) to 7.9% (1.7); 
control group increased 
Taylor 2005     -0.46%  0.02  
7.86% (1.37) to 7.40% (1.34) (intervention);  
Control: 7.41 (1.14) to 7.38 (1.08); p=0.81 
Oyetayo 2011 -    -0.2%  0.516 
(patients not at goal values: -0.6% 
(p=0.006)) 
Correr 2011     -2.2% vs -0.3%  <0.001  (-2.8 to -1.6) vs (-0.8 to 0.2) 
Wermeille 2004 -    -0.8% (-1.1 to -0.5);  <0.001  
Table ‎4.7 Ranked studies based on overall quality assessment and outcomes 
 
All the studies included produced encouraging results to support the inclusion of the 
community pharmacist in the care of patients with type 2 diabetes. The eight studies in 
this review recruited a combined 1849 patients with type 2 diabetes and 1366 of those 
were included in final analyses. Seven of the eight studies produced a significant result in 
terms of HbA1C reduction either in the form of a significant decrease in the intervention 
group or a significant difference between the control group and intervention group at the 
end of the study. One of these studies (Mehuys et al., 2011) achieved a significant 
difference between groups at the end of the intervention period but this was not sustained 
in the extended 18-month follow-up period. One study (Oyetayo et al., 2011) found no 
significant fall in HbA1C as a result of participating in the study. However, when a second 
analysis was conducted on those patients entering the study with an above target HbA1C 
reading, the reduction over the course of the study became significant.  
 
Falls in other clinical outcome measures such as blood pressure, total cholesterol and 
triglycerides were recorded in six out of the nine studies with two studies not reporting any 
other clinical outcomes (Mehuys et al., 2011, Taylor et al., 2005). Five studies reported 
humanistic outcomes; with the diabetes pharmacy interventions having positive effects on 
diabetes knowledge, health-related quality of life and self-management activities. One 
study reported no significant improvement in quality of life (Krass et al., 2011) and one 
study reported no significant improvement in adherence despite a significant fall in HbA1C 
(Wermeille et al., 2004).  
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4.6 Discussion 
This review has identified a number of successful community pharmacy interventions 
aimed at improving the care of patients with type 2 diabetes. However, there is a lack of 
data to suggest whether a targeted diabetes intervention could work within the current UK 
community pharmacy contractual and operational framework. The only UK study included 
was conducted in a manner that would not be possible to implement on a larger scale and 
therefore does not provide an accurate assessment of the role of the pharmacist in the 
care of these patients. There are several problems that arise from this study. This study 
provides no information on the training the pharmacists were given and did not include a 
power calculation on which they based their sample size. The study demonstrated a 
significant fall in HbA1C levels in 59 participants but was delivered in the medical practice 
for ‘space’ reasons. Whilst this does not meet the inclusion criteria for this review, the 
study was conducted at a time when it was not commonplace for pharmacies to have their 
own private space for counselling patients. If conducted today, this study would almost 
certainly have been conducted within the community pharmacy. This, along with the 
review of the pharmaceutical care plan by three other pharmacists, does not align with the 
current operational framework which is in place for UK community pharmacy. If this 
service was extended to other pharmacies then it would potentially become impractical 
very quickly due to the other professionals needed to verify to the PCP from the 
originating pharmacist. 
 
The extent to which the pharmacist accessed the medical records of the participant is also 
unclear which poses an important challenge from a community pharmacist’s perspective. 
If the pharmacist needed access to medical records then a mechanism would have to 
exist to ensure better communication between the medical team and the community 
pharmacy in order for the pharmacist to view this information.  
 
The interviews (as described in the article) also provide cause for concern as they 
appeared to be knowledge testing rather than where the participant was allowed to 
express concerns or problems with their treatment. Most of the pharmaceutical care 
issues could potentially have been identified by examining their personal record held at 
the medical practice rather than interviewing the participant.  
 
Inclusion in this review has been useful as it demonstrates that, to date, there has not 
been a large scale community pharmacy diabetes study performed in the UK. It would 
therefore be appropriate to design such a novel intervention based on the processes 
examined in the international research but with the UK community pharmacy setting in 
mind. This is an important point as the UK primary care sector is distinctly different from 
models of care internationally. In the UK, the work of managing patients with diabetes 
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primarily lies with the practice nurse in the medical practice, with the GP being called in to 
deal with “difficult” patients. Primary care nurses are generally less expensive to employ 
than a community pharmacist and GP and therefore based on cost alone it may appear 
more sensible to leave the management to this group of patients to other healthcare 
professionals rather than a more expensive community pharmacist. The practice nurse is 
a role that has been developed heavily over the past ten years in the UK primary care 
setting and as such is one of the reasons why they have become more involved in the 
care of this group of patients. This is not the case in other countries, including some of 
those explored in this section and therefore may limit the generalisability of the results to 
the UK setting.  
 
Despite the lack of UK evidence, this review has provided a large amount of international 
evidence regarding the type of intervention that is likely to benefit patients, the training 
associated with that intervention and the types of patients that should be targeted to 
achieve the optimal results. It is clear from this evidence that the most successful studies 
are those that recruit a large number of pharmacies and ask them to approach a small 
number of patients to participate in the intervention.  
 
Three studies randomised participants to control or intervention at the level of the 
pharmacy and not the patient. This cluster approach to randomisation is one that can 
reduce contamination between the participants in each arm of the study as well as 
providing practical benefits for the pharmacists involved, in that they only have to train for 
one set of processes. However, although practical in this particular setting, cluster 
randomised trials may not always be the best design as they may introduce selection bias 
and often greater sample sizes are required (Torgerson, 2001) and this can result in lower 
statistical precision during analysis (Donner and Klar, 2004). Both the Belgian study and 
two of those from Australia recruited a large number of pharmacies and asked them to 
recruit a small number of participants. This appears to have worked at achieving, even 
surpassing, their recruitment targets and may provide an assessment of whether a 
programme such as this would be feasible in community pharmacies on a national scale. 
As described in chapter two, in the PLEEZ study, some pharmacists found it 
uncomfortable providing the intervention and control as they felt it was depriving their 
patients of a service. If randomisation is performed at the pharmacy level then this may 
contribute to relieving these concerns. 
 
One aspect that is central to the success of these studies is the training programme 
provided by the research team. For many pharmacists, services such as these may be 
new roles for them and therefore it is essential that they are provided with both the 
knowledge and the means to convey that knowledge to the participant e.g. role play or 
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consultation skills. This needs to be factored into study design and, importantly, if a cost-
effectiveness analysis is performed, the ongoing costs should be taken into account as 
the guidelines for treatment are constantly changing and pharmacists will need to be kept 
up-to-date.  
 
The level of training given to the pharmacist may impact on how well participants perform 
over the course of the study. From the studies identified, it appears that training of 
pharmacists may need to be two-fold. The first aspect is a self-directed learning package 
and the second is a face-to-face element with the study co-ordinators to explain the 
research. Self-directed learning may be less effective whereas face-to-face enables the 
pharmacists to become familiar with practical application of the knowledge. This final 
aspect also included input from other healthcare professionals to help explain local 
practice and clarify aspects of the self-directed learning.  
 
Most advanced and enhanced services in the UK require a degree of self-directed 
learning but the face-to-face element varies depending on the service. With medicine use 
reviews (MURs), pharmacists are able to provide the service if they have undertaken the 
short online training and assessment exercise lasting approximately three hours (CPPE, 
2012) whilst the new medicine service only requires pharmacists to self-assess their 
competency without any additional training before providing the service (PSNC, 2012b). 
For enhanced services, most primary care trusts require pharmacists to have undertaken 
a self-directed learning package, usually provided by the Centre for Pharmacy 
Postgraduate Education (CPPE), and then attend a short training session of 
approximately three hours. These services are generally one-off opportunistic 
interventions and as such may only require a small amount of training, however, the 
services identified as part of this review require much longer and more in-depth training 
and the extent to which pharmacists in the UK will engage with this, in terms of availability 
and practicality, needs to be determined.  
 
The inclusion criteria for these studies indicate that it may be better to target those 
patients most in need of a reduction in HbA1C levels. For the same cost of the intervention 
it would appear that targeting those patients who are poorly controlled provides a greater 
opportunity to not only reduce their HbA1C level but to reduce it further than those patients 
who are well controlled at baseline. In a public health system such as the NHS this would 
provide better use of restricted financial resources. Targeting patients via their medication 
seems appropriate as the patient can be identified through the pharmacy’s own 
medication records; however, it gives no indication as to the level of control the patient is 
currently experiencing. It may, therefore, be appropriate to use this method of identifying 
potential participants and then confirm their inclusion using HbA1C data from the medical 
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records.  This may indicate a better use of resources as they are focused on those with 
greatest need.  
 
In these studies all of this clinical information had to be obtained from the patient’s general 
practitioner before they commenced participation on the study which may have added 
time and costs to the programme that other studies did not have. Setting up a similar 
service in the UK would require increased collaboration between the patient’s medical 
practice and the community pharmacy, which may increase the patient’s perceived value 
of the service and provide a more focused intervention. This could be achieved with the 
use of Summary Care Records, due to be introduced in the UK, or a referral and feedback 
system between the medical practice and community pharmacy.  
 
The successful studies often involve the pharmacist meeting the patient on a regular basis 
over a period of months or years. These interventions appear to work well, however, they 
lack definition and the pharmacists in each study appear to cover every aspect of the 
condition of diabetes when conversing with their patients. This may be necessary; 
however, it would be prudent to determine if an intervention covering such a wide variety 
of topics could be reduced to fewer ‘core’ topics and still be effective. This also has 
implications for cost as a longer intervention will be more expensive to implement. None of 
these studies provided information on the length of each consultation and therefore if 
studies like these were to be conducted in the UK then a measurement of time spent with 
the pharmacist may be useful in defining cost more effectively.  
 
The published work by Krass et al. in 2007 and 2011 demonstrates a good approach to 
this type of research. The service itself aligns with current treatment pathways in Australia 
and aims to add to the service provided by the patient’s physician rather than duplicating 
it. However, Krass and Taylor in their three interventions provided their participants with 
blood glucose testing devices and at each consultation downloaded the results from the 
meters onto the pharmacy computers. These results then formed the core content of the 
consultations and the pharmacists used them to develop goals that were agreed with the 
participant. The use of blood glucose monitors, whilst helpful for pharmacists to aid goal 
setting for patients, does not seem essential for the significant reduction in blood glucose 
levels. Other studies that are included in this review have not used this particular tool and 
have still demonstrated a significant effect. It is not current UK guidance to recommend 
the use of self-monitoring devices in patients that are non-insulin controlled and this will 
have an impact on the design of any future pharmacy services (NICE, 2009b). 
 
The study by Mehuys, as part of the intervention, also included point of care testing for 
clinical parameters, which may not be something that pharmacists are used to performing 
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and therefore may not be representative of the community pharmacy environment around 
the world. In the UK, it may be more appropriate to obtain this information from the 
medical practice. 
 
Only two of the included studies test the intervention provision once they have trained the 
pharmacists. The study conducted by Fornos includes regular meetings to discuss 
progress and outcomes and focuses on case-based discussions between the participating 
pharmacists to ensure they are all providing similar information. Krass’s 2007 study 
focusses on the research team making visits to the pharmacies to ensure that they are 
adhering to the study protocol. They also maintain regular contact with them to keep them 
informed and motivated about the study (Krass et al., 2007). This aspect of intervention 
fidelity checking is important as it ensures not only that the pharmacists are all following 
the study protocol correctly but that they are providing consistent advice to their 
participants. Some form of this should be factored into the design of our novel 
intervention.  
 
The only cost-effectiveness analysis conducted was performed from the health system 
perspective and therefore did not include the societal costs of type 2 diabetes, which may 
be important in this group of patients (Taylor et al., 2005). The analysis was only 
performed over the course of the nine months of the study and the authors acknowledge 
that given the long-term nature of the condition this may need to be revisited in the future. 
The authors also identify that they did not include the cost of training and although this is 
just an initial factor in the analysis, if the service was to be implemented these costs may 
become significant and ongoing.  
 
In summary the studies identified here have provided positive evidence for the inclusion of 
the community pharmacist in the care of patients with type 2 diabetes. The HbA1C 
reductions ranged from 0.2% to over 2% with the three highest quality studies suggesting 
that a reduction of between 0.5% and 1.0% could be realistically achieved in this setting. 
The quality of the evidence presented varies but most provide a good basis on which to 
design a novel intervention that could be developed for the UK community pharmacy 
setting.  
 
4.6.1 Strengths and limitations 
This review identified a number of significant published articles relating to the 
effectiveness of community pharmacy diabetes services in a systematic manner. It has 
identified the current evidence base for this type of community pharmacy service and, 
importantly, the salient aspects of each project to determine which would need to be 
considered when developing my own community pharmacy diabetes clinic.  
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However, although these studies were examined and compared to each other, steps 
could have been taken to increase the reliability of the results produced. Following the 
PRISMA guidelines for systematic review and meta-analysis reporting (Moher et al., 2009) 
there are a number of steps that could have been taken to improve the quality of this 
review.  
 
In any robust systematic review, study identification and data extraction should be 
undertaken independently by two researchers. This was not the case in this review due to 
funding and time constraints. In terms of data extraction, a standardised document should 
be developed to ensure the same information from each study is reviewed. Again, this 
was not the case in this review as all data extraction and review were performed by one 
researcher. Finally, bias e.g. publication or selective reporting in these studies has not 
been assessed.  
 
If this review was to be conducted again, then a full systematic review with meta-analysis 
would need to be conducted according to the principles stated in the PRISMA guidelines.  
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4.7 Conclusion 
From the evidence presented, appropriately trained community pharmacists have 
demonstrated the ability to improve clinical outcomes associated with diabetes, however, 
there still remains a lack of evidence as to whether this is the case in the UK. In 
developing a novel community pharmacy service a comprehensive training programme, 
clear inclusion criteria and an intervention that has multiple interactions with the 
pharmacist over an extended period of time may be the most effective way of improving 
the control of these patients. However, the extent to which these factors align with the 
current community pharmacy contractual and operational framework is unknown and 
requires further research.  
 
To undertake a randomised controlled trial in the UK, the following factors would need to 
be considered: 
 
Randomisation at the level of the pharmacy 
This review has demonstrated that those studies that have randomised at the level of the 
pharmacy produced the most positive results and have had no problems with recruitment. 
This may have also been due to the small recruitment target set for each pharmacy, which 
should also be considered for future studies. 
 
Training provision  
All of the included had some aspect of face-to-face learning usually with the two studies 
that demonstrated the most positive result having aspects of self-directed learning and 
role play to re-enforce the information provided.  
 
Targeting of poorly controlled patients 
The need to target poorly controlled patients was emphasised by the two highest quality 
studies and the sub-analysis conducted in one article and their associated decrease in 
HbA1C. As stated in the discussion, targeting these patients may provide a better 
allocation of resources in a publicly funded healthcare system. 
 
Multiple consultations  
All of the studies had a significant number of consultations with patients over sustained 
period of time to achieve the results that were reported. This is a clear theme emerging 
from the review and may or may not be possible to implement in the UK community 
pharmacy setting.  
 
Improved communication  
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Improved communication between the medical practice and community pharmacy was a 
central component to each of the interventions whether for identifying patients, discussing 
pharmaceutical care or for the referral of patients whom the community pharmacist could 
not manage.  
 
However, more work still needs to be conducted to determine what a pharmacist 
consultation with these patients would consist of as the studies explored here have failed 
to narrow down the focus of the intervention. 
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 Chapter Five   
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5. An evaluation of prescribing for type 2 diabetes in primary 
care: optimizing the role of the community pharmacist in the 
primary healthcare team. 
 
5.1 Introduction 
The care of patients with long term conditions centres around prescribing, monitoring, 
adherence and the provision of general information relating to the prevention of related 
conditions and lifestyle and diet advice. This chapter will focus on the prescribing and 
monitoring aspects of the management of patients with type 2 diabetes to determine if the 
community pharmacist may have a role in these areas of their care.  
 
In the UK, the National Diabetes Audit (NDA) is conducted annually to determine national 
and local figures for the number of patients that are achieving goals for treatment with 
reference to blood glucose, blood pressure and lipids (The NHS Information Centre, 
2011b). It also characterises the spending on medicines and devices both nationally and 
by PCT area, however, it does not provide detail as to whether a patient is being 
prescribed their medicines in line with national guidance. Nationally, the NDA shows a 
large population for whom control is not being achieved (The NHS Information Centre, 
2011b). As described in the chapter three, it is important that these patients achieve 
control as this can decrease their cardiovascular (CV) risk as well as renal, ocular and 
neuropathic complications. A summary of the target levels and the percentage of patients 
achieving those targets is provided in table 1. 
 
Measure Target value % of patient achieving target value 
HbA1C <59 mmol/mol 66.5 
Blood pressure <140/80 mmHg 60.7 
Total cholesterol 
(more stringent target) 
<5.0 mmol/L 
<4.0 mmol/L 
78.3 
40.9 
Table ‎5.1 Summary of targets for diabetes and the % of patients achieving the desired values 
From this data there is clear evidence that these patients, particularly with reference to 
blood pressure control and total cholesterol reduction may need further support to help 
them achieve these targets. Some areas that have emerged from the review conducted in 
chapter four is that of medication management and identification of drug-related problems 
by the pharmacist and liaising with the patient’s physician about possible changes to their 
treatment plan. However, in the UK there have been little data to suggest whether there is 
a problem with the prescribing in primary care associated with type 2 diabetes and certain 
co-morbid conditions and whether this may be impacting on the level of control of some 
patients. Therefore, it is unclear, from a UK perspective, whether the pharmacist should 
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be involved in this aspect of a patient’s treatment. With reference to prescribing in type 2 
diabetes, the areas that a pharmacist could target are: drug selection, dose optimisation, 
monitoring and adherence to treatment.  
 
The National Institute of Health and Clinical Excellence (NICE) has issued guidance on 
drug selection and management of type 2 diabetes including complications and co-morbid 
conditions such as hypertension and hyperlipidaemia (NICE, 2009b). These guidance 
documents provide specific, evidence based and cost-effective treatment options for 
patients at various stages of their disease. It is important that these documents are 
adhered to by prescribers so that patients receive the best possible care and the NHS 
obtains the best possible value from the medicines that are prescribed. Currently in the 
UK, there is evidence examining the adherence to NICE guidance for other conditions 
such as type 1 diabetes in children (Edge et al., 2005), epilepsy in children (Chinthapalli et 
al., 2008), head injuries (Shravat et al., 2006), the use of COX-2 NSAIDs (Price-Forbes et 
al., 2005) and various other conditions (Sheldon et al., 2004). However, there appears to 
be no published audits of adherence to type 2 diabetes guidance in primary care.  
 
Within primary care, the management of patients with diabetes is the principal 
responsibility of the specialist practice nurse with support from the patient’s doctor. Other 
professions within the primary care team have defined roles in the care of such patients 
e.g. the dietician and the podiatrist. The community pharmacist, part of the wider primary 
care team, will see the patient on a regular, monthly basis when they collect their 
medicines but does not have a defined role other than that of medicines supply.  
 
As a result of monthly prescription collections, community pharmacists have the 
opportunity to develop a long-term relationship with these patients including those that 
may not be attending the medical practice. There is therefore an opportunity to improve 
the use of the medicines, the condition and resulting co-morbidities. Pharmacists are 
already providing adherence based interventions such as medicine use reviews (MURs) 
and the new medicine service (NMS), however, these focus on a patient’s ability to take 
their medicines and are not clinically focused. This audit will help determine the necessity 
for clinical medication review in a community pharmacist consultation. 
 
Clinical audit is a useful tool aimed at identifying where there may be problems with an 
established care process and where treatments do or do not follow relevant current 
guidelines. It is distinct from research and service evaluations in that these focus on 
producing knowledge to develop guidelines or policy, or aim to describe the state of a 
service at one particular time in one particular location respectively (National Clinical Audit 
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Advisory Group, 2009). In this scenario, NICE guidance will be used as the benchmark for 
the audit standards.  
 
The purpose of the audit was to determine whether prescribing is in accordance with 
NICE guidance, patients are adequately controlled and identify any areas where role of 
the community pharmacist in the primary healthcare team could be refined. 
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5.2  Audit method 
5.2.1 Practice selection 
The protocol for this audit is included in appendix nine. Approval for the audit was sought 
from NHS Norfolk’s Research and Development department (appendix 10). NHS Norfolk’s 
prescribing advisors identified ten practices as potential participants in the audit based on 
their likelihood of participation. Each practice was approached by the relevant prescribing 
advisor to seek consent to participate. Once agreed, an alphabetical list of all patients at 
each practice that met the following inclusion criteria was obtained from the practice 
manager for the researcher. 
 
5.2.2 Inclusion criteria 
This audit focused on the adherence of prescribers to NICE guidance for type 2 diabetes. 
The guidance was originally issued in 2008 and then partially updated in 2009. Before this 
point there were five separate guidelines that covered the different aspects of care for 
patients with the condition and certain co-morbidities. The audit focused on the most 
recent guidance and as such patients who were only recently diagnosed were included as 
their treatment would be based on the current algorithms. Selecting only those patients 
who had been diagnosed since 2008 would have potentially reduced the patient 
population to select from, however, as prescribing practices change it was decided to only 
go back five years to account for this.    
 
It was also decided to exclude those patients under the age of 18 and those prescribed 
with insulin as these patients are generally managed by the secondary care team.  
 
5.2.2.1 Summary inclusion and exclusion criteria 
 Confirmed diagnosis of type 2 diabetes within the previous five years 
 Aged over 18 
 Not prescribed insulin 
 
5.2.3 Sample size justification 
With a sample size of 250 the confidence interval around a proportion of 10% non-
adherence to NICE guidance would be ±3.72 and around a 50% proportion would be 
±6.20. 
 
5.2.4 Selection of participants 
A random number generator was used to select 25 patients from the alphabetical list 
provided in each participating practice. If there were fewer than 25 patients eligible then all 
patients were used. Once a patient was selected, the date of diagnosis, age and 
medication prescribed was checked to ensure that the patient met the inclusion criteria.  
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5.2.5 Audit standards 
100% adherence to NICE guidance for the management of type 2 diabetes in terms of 
clinical monitoring intervals and achievement of target levels where provided by NICE for 
HbA1C, blood pressure, weight, cardiovascular risk, renal function, lipids, retinal and 
neurological examinations. 
 
The clinical monitoring criteria state that HbA1C and blood pressure measurements should 
be conducted at least every six months. This frequency rises if the patient is not well 
controlled for either one of these parameters. The other clinical measurements should 
occur at least once every 12 months. The target levels for HbA1C, blood pressure and 
lipids are defined in chapter three, however they are summarised in box 4.2. 
 
Box 4.1 NICE target levels  
HbA1C:   <59 mmol/mol or 7.5% 
Blood pressure:  <140/80 mmHg or  
   <130/80 mmHg if renal, eye or cerebrovascular damage is present. 
Total cholesterol: <4.0 mmol/L 
LDL-cholesterol: <2.0 mmol/L 
 
100% adherence to NICE guidance for prescribed therapy in accordance with a stepwise 
management approach for diabetes and co-morbid conditions covered by Clinical 
Guideline 87 (NICE, 2009b) will also be assessed. The stepwise approach to the 
management of type 2 diabetes and the supporting evidence has also discussed in more 
detail in chapter three.  
 
5.2.6 Data collection 
Records were reviewed to determine whether the patient had received the appropriate 
number of clinical tests in the previous 12 months. A two week allowance for non-
attendance at the practice was incorporated. This means that if the patient was due for a 
blood test two weeks either side of the audit date then data were considered as present.  
Data were not collected to allow the calculation of renal function. 
 
Medication prescribed for the treatment of diabetes was recorded together with the 
sequence in which it was initiated and whether there was a clinical need for that medicine 
i.e. was a patient’s HbA1C level high enough to justify initiation of a new medicine. 
Information obtained on blood pressure medication was used to determine whether a 
patient with hypertension and diabetes was prescribed an angiotensin converting enzyme 
(ACE) inhibitor or angiotensin II receptor antagonist .  
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The audit tool (appendix 11) was tested prior to data collection by one of the practice 
managers to determine if it was possible to collect all the data I set out to collect. This 
information was fed back to me in order that alterations to the tool could be made. The 
audit tool consisted of three pages of tables designed for efficient completion. The first 
page was provided for recording information regarding clinical measures and outcomes, 
the second; information on diabetes prescribing and the third, information on prescribing 
in co-morbidities. A code system was used for medicines and class of medicines that 
made it easier when entering onto the database for analysis. Data were collected and 
entered by one researcher (MT) for all patients and practices.   
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5.3  Audit results 
5.3.1 Clinical outcomes 
Nine practices agreed to participate in the audit from which data for 194 patients were 
collected. These practices represented a spread in total antidiabetic spending per head 
and a variation of scores on the Quality and Outcomes Framework (QOF) indicator DM5 
(number of patients that had received an HbA1C blood test within the previous 15 months). 
The team achieved a good distribution of practices in terms of dispensing/non-dispensing 
practices and a mixture of rural, town and city practices, as shown in table 5.2. The mean 
(SD) age in years for patients was 65.13 (12.1) and the mean (SD) length of time since 
diagnosis was 29 (17.4) months.  
 
Table 5.3 summarises adherence to the audit standards for the clinical tests and the 
number of patients achieving targets for those parameters. Practices performed well for 
the number of patients with a recorded weight, lipid profile and renal function, however, for 
HbA1C, blood pressure and cardiovascular (CV) risk practices were lower than the target 
100 % adherence standard set by this audit.  
 
The breakdown of clinical results, cardiovascular risk and BMI is shown in table 5.4 and 
demonstrates the large number of patients that remain uncontrolled with their diabetes 
especially with respect to blood pressure and total cholesterol. This table also 
demonstrates that 86% of those patients audited were classed as overweight or obese 
and 69% had a cardiovascular risk greater than 20%.   
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Practice N No. of patients on the diabetes register 
(% of practice population) 
QOF indicator DM5 result (centile) Dispensing / non-dispensing Location 
1 25 269 (4.9%) 68 Dispensing Rural 
2 22 336 (4.2%) 73 Dispensing Rural 
3 25 261 (3.7%) 85 Dispensing Rural 
4 24 133 (4.3%) 76 Non-dispensing City 
5 13 171 (3.0%) 42 Non-dispensing City 
6 25 178 (4.2%) 68 Dispensing Rural 
7 10 300 (4.1%) 42 Dispensing Town 
8 25 261 (4.0%) 75 Non-dispensing City 
9 25 403 (4.1%) 29 Non-dispensing City 
Total 194 2312 (4.0%)    
Table ‎5.2 Practice demographics (QOF 2009-2010 data) 
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NICE Criterion Recommended frequency 
of test (months) 
% Adherence to monitoring 
frequency (95% CI) 
HbA1C measurement  6 79.4 (73.7 – 85.1) 
BP measurement  6 71.6 (65.3 – 77.9) 
Weight & BMI measurement  12 92.3 (88.5 – 96.1) 
Cardiovascular risk 
assessment  
12 31.4 (24.9 – 37.9) 
Lipid measurements  12 95.4 (92.5 – 98.3) 
Renal function  12 93.3 (89.8 – 96.8) 
Table ‎5.3 Adherence to testing criteria (N=194 for all tests) 
 
Clinical Test Number of patients (%) 
with recorded value 
Adherence to NICE 
standard % (95% CI) 
HbA1C <58 mmol/mol (7.5%) 194 (100) 82.4 (77.0 – 87.8) 
Blood pressure < 140/80 mmHg 194 (100) 61.3 (54.3 – 68.3) 
Lipids <4.0 mmol/L 194 (100) 47.4 (40.3 – 54.5) 
  
Number of patients (%) 
with recorded value 
 
% (95% CI) of patients 
with recorded value 
BMI 
 Underweight/ideal weight  
 Overweight  
 Obese 
 Morbidly obese 
186 (95.9)  
14.0 (9.0 – 19.0) 
28.0 (21.5 – 34.5) 
31.2 (24.5 – 37.9) 
26.9 (20.5 – 33.3) 
Cardiovascular risk assessment  
 <10% 
 10-20% 
 >20% 
29 (14.9)  
6.9 (-2.3 – 16.1) 
24.1 (8.5 – 39.7) 
69.0 (52.2 – 85.8) 
Table ‎5.4 Patient outcomes 
 
5.3.2 Medication 
One hundred and thirty nine (71.6%) patients were prescribed at least one medicine to 
manage their diabetes, 38 (19.6%) patients were prescribed two medicines and four 
(2.1%) patients were treated with three oral antihyperglycaemics. Fifty five (28.4%) 
patients were not prescribed any medicines for their diabetes and were presumed to be 
controlled by diet alone of which only three patients were classed as uncontrolled. All first, 
second and third line therapies matched NICE recommendations. In 36 out of the 38 
patients who were prescribed second line therapy, their HbA1C level was sufficiently high 
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at the time of initiation (>6.5%) to warrant that addition. For third line therapy, three out of 
four patients met the NICE recommendations for additional therapy (HbA1C >7.5%).  
 
For those prescribed a Thiazolidinedione or DPP-4 inhibitor, NICE states there must have 
been a 0.5% drop in their HbA1C level after six months of treatment for it to be continued. 
This was the case in four out of the twelve prescribing incidences. Two did not see a 
decrease, of which one was stopped and one was not. Data were unavailable for the 
remaining patients as they had only been recently prescribed.  
 
A total of 135 patients were prescribed at least one medicine for hypertension of which 
118 (87.4%) were prescribed an ACE inhibitor or angiotensin II receptor antagonist. There 
were 37 (27.4%) patients prescribed a β-blocker, currently 4th line in NICE guidance and 
not recommended due to their effect on carbohydrate metabolism. 
 
Finally, 74.7% of patients were prescribed a lipid-lowering medication and 39.7% of 
patients were prescribed an anti-thrombotic medication e.g. aspirin. In patients who had 
un-controlled lipid levels (total cholesterol level >4.0 mmol/L; n=101) 38.6% were not 
prescribed any lipid-lowering medication.  
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5.4  Audit discussion 
From the results it can be seen that there is generally good adherence to the audit 
standards with reference to NICE guidance. The majority of patients were undergoing the 
appropriate clinical tests at the recommended intervals and the medicines for diabetes 
and blood pressure were being prescribed in accordance with recommendations made by 
NICE. The discussion of this audit, and where the pharmacist may have a role, centres on 
managing cardiovascular risk, medication dosage and adherence as these have been 
identified as potential gaps in current care.  
 
The reporting of CV risk assessments varied according to practice and therefore further 
research would be warranted to determine the exact figure. The majority of data required 
to perform a CV risk assessment was found in patient records. This deficit in reporting 
could therefore be rectified by the appropriate use of software within the medical practice. 
Currently, many community pharmacies are providing a CV risk assessment service or 
health-check enhanced service aimed at primary prevention of cardiovascular events 
(PSNC, 2012a) and are aimed at a population that would not ordinarily interact with the 
medical practice. The patients audited here already have all of the details needed to 
perform a CV-risk assessment recorded at the medical practice therefore it may not be 
appropriate for pharmacists to unnecessarily measure these patients for a second time 
when all of the information required has already been obtained.  
 
However, of the patients that did have a documented CV risk, 70% were in the high 
category. CV risk is composed of several factors such as blood pressure and total 
cholesterol and once identified and appropriately communicated to the pharmacist, 
evidence has shown that they may have a role in reducing this risk by modification of 
blood pressure and lipid-lowering therapy (Lowey et al., 2007). This study was conducted 
in a hospital setting and therefore further work would need to be conducted to determine if 
the results are generalisable to the community pharmacy setting.   
 
In this audit over four-fifths of participants were classed as either overweight or obese. 
With the link between increased weight and increased blood pressure firmly established 
(Stamler et al., 1978), it may also be appropriate to target weight management as a proxy 
to reducing blood pressure and therefore CV risk. There is some promising evidence that 
weight management clinics in community pharmacy can produce significant results, 
however these need to be investigated further (Blenkinsopp et al., 2008).  
 
All medicines to treat diabetes were prescribed in line with the most recent NICE guidance 
and if a patient required an additional medicine to control their HbA1C level, this was 
initiated at the appropriate time interval. Medication to treat hypertension was simply listed 
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on the audit tool and not sequenced as with diabetes medication, due to the complex 
nature of a patient’s condition and that some of the medicines had been prescribed pre-
diabetes diagnosis therefore making it difficult to compare to the NICE guidance. This 
finding has been confirmed in previous research (Simoens et al., 2009). However, at the 
point at which the audit was conducted the majority of patients were prescribed ACE 
inhibitors or ARBs which is ideally first line therapy for patients with type 2 diabetes due to 
its reno-protective effects.  
 
The low prescribing rate of aspirin may be a reflection of the recent evidence that it has 
limited benefit for primary prevention of cardiovascular events in diabetes (Chunyu et al., 
2010, De Berardis et al., 2009). However, it may be appropriate for pharmacists to 
approach patients to ascertain if they are aware of this new evidence and if they have 
discussed it with the GP or practice nurse.  
 
In terms of control of lipid levels, there were 25.3% of patients not prescribed a statin and 
of those classed as uncontrolled (n=101) almost 40% had no prescription for a lipid 
lowering medication. This is a routine medication for patients with type 2 diabetes apart 
from those that are under the age of 40 and who have a low cardiovascular risk profile.  
 
With reference to monitoring, approximately one fifth of patients did not receive a blood 
glucose measurement and almost a third of patients did not receive a blood pressure 
measurement at least every six months. Blood pressure monitoring is a service widely 
available within community pharmacies and therefore, with appropriate communication 
systems between medical practices and pharmacies, may be a means for pharmacy to 
contribute to adherence to NICE guidance.  
 
The monitoring results indicate that there are still a number of patients who are not 
controlled on their current medications with reference to HbA1C (approximately one fifth), 
blood pressure (approximately two fifths) and cholesterol (over half). This may be due to 
inadequate dose titration by the prescriber (data that was not collected), the need for 
additional medicines to be prescribed, current medicines are not working or the patient is 
non-adherent. 
 
This audit set out to determine if any gaps in care could be identified in terms of 
prescribing for type 2 diabetes. It demonstrated that the prescribing of medicines is in line 
with NICE guidance, although information was not obtained regarding doses. Therefore, 
this implies that there may be little role for the community pharmacist in changing the 
medicines prescribed for diabetes. The audit does not, however, provide information 
regarding dose optimisation or adherence in this group of patients. If it is found that there 
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is a problem with either of these, in future work, then dose optimisation may require the 
use of the patient’s medical record and therefore it may be appropriate for this aspect of 
care to be conducted by a healthcare professional at the medical practice e.g. GP, 
practice nurse or primary care pharmacist. However, adherence is an aspect of care that 
may not require the use of the medical record and could potentially be conducted by 
community pharmacist as well as those professionals in the medical practice.  
 
Through regular attendance at the pharmacy to collect their medicines, it may be 
appropriate for the community pharmacist to become more involved with these patients. In 
response to a significant lack of therapy effectiveness, through patients not taking their 
medicines, the Government has introduced brief pharmacist-led, adherence-focused 
interventions e.g. medicine use reviews and the new medicine service to increase the 
responsibility placed on the pharmacist in patients with long-term conditions. However, 
these new services do not have a robust evidence base supporting their implementation.  
 
In conjunction with this, it may also be appropriate for community pharmacists to become 
involved in blood pressure management with its associated effect on the development of 
diabetic complications and cardiovascular risk. Pharmacists have already demonstrated 
that they can perform this type of management service in the hospital setting; however, 
the extent to which community pharmacists, in the current contractual and operational 
framework, could achieve the same results may be limited. 
 
These aspects of care that have been identified as appropriate for the community 
pharmacist to conduct could also be beneficial to the medical practice as well as the 
patient. The pharmacist could contribute to the medical practice’s targets on the Quality 
and Outcomes Framework (QOF) by measuring blood pressure, managing weight and 
managing cardiovascular risk. This information could then be fed back to the practice 
which may lead to increased collaboration between the two groups of professionals.    
 
5.4.1 Limitations 
This audit was only conducted in nine practices in Norfolk and therefore the results have 
limited generalisability. The audit covered the medicines prescribed for diabetes and co-
morbid conditions. It did not include other aspects of care covered by the NICE guidance 
such as smoking status or lifestyle advice given to the patient. Half the practices audited 
were dispensing practices and as such patients will not have access to a community 
pharmacist and ways of building a model for these patients need to be considered.  
 
All of the audit results were communicated to the medical practices involved. However, 
due to time and funding constraints there is no plan to re-audit.   
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5.5  Audit conclusion 
Prescribing for type 2 diabetes is generally in line with national guidance. There are, 
however, still uncontrolled patients and this may be due to lack of dose titration, the need 
for further medicines to control their condition or adherence problems on the part of the 
patient. The community pharmacist, who has the opportunity to interact with the patient on 
a monthly basis when they collect their prescription, may have a role in improving 
adherence in uncontrolled patients due to their access to the patient medication record 
and experience at providing similar services. In future they may be able to identify these 
patients by the use of summary care records that are being phased in across the country. 
However, for this to be effective, good lines of communication between themselves and 
the medical practices would be required.  
 
The audit has demonstrated that it may not be appropriate for community pharmacists to 
be conducting CV-risk assessments on this group of patients as most of the data already 
exist in medical practice records. However, it may be appropriate for pharmacists to target 
those patients that have already been identified as having a high CV risk and provide 
weight management, blood pressure and lipid-lowering management services to them, if 
the medical practice referred such patients to the community pharmacy.  
 
In terms of developing an intervention for patients with type 2 diabetes to be delivered in 
the community pharmacy, the pharmacist should be targeting poorly controlled patients as 
these are the patients who are most likely to gain long term benefits from a reduction in 
HbA1C, blood pressure or lipids. At present, these patients would need to be identified 
from medical practice records as community pharmacists do not have the ability to identify 
their level of control. The intervention should be focused on either adherence which is 
already conducted as part of the MUR service. Any new type of service may be a more 
advanced version of the MUR, something which community pharmacists are already 
familiar with and may require little additional training to perform.  
 
In this chapter, the aspects of an intervention that would be appropriate for a community 
pharmacist to conduct have been discussed. The next chapter will discuss the patients’ 
perspectives on the role of the community pharmacist in their care. It is important that this 
is characterised so that a service is designed with patients in mind and is something that 
they are likely to engage with.  
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 Chapter Six 
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6 Focus group discussions with type 2 diabetes patients 
6.1 Introduction 
The next stage in the development of this complex intervention involves approaching 
patients to ascertain their views and experiences of their community pharmacist and the 
role they play in their care. This will be central to understanding where a particular 
intervention would be best targeted and whether patients with this condition would engage 
with such a service to help them control their diabetes. It will also prove useful as there is 
a lack of UK literature available to ascertain the conditions under which such a service 
would be viable with patients in the context of the NHS.  
 
As previously discussed, the main government vision for community pharmacy in the UK 
is for pharmacists to assume greater responsibility for the management of medicines for 
patients with long-term conditions including diabetes (Department of Health, 2008).  To 
achieve this transformation, public perception of the role of the community pharmacist 
may also need to be changed as many people still view the main role of the pharmacist as 
one of medicines supply (Gidman et al., 2012).  
 
The limited research available on patient perceptions of community pharmacists suggests 
that they are currently not considered the primary source of information about health 
matters, but do have a role in relation to the provision of advice related to medicines 
supply (Anderson et al., 2004). Whilst some patients report an educational benefit from 
the services a pharmacist provides (Johansson et al., 2009), others prefer to see their 
own doctor about matters relating to their health and treatment (Hibbert et al., 2002, Salter 
et al., 2007).  
 
Much of the available UK evidence for patient satisfaction with the pharmacist derives 
from questionnaires completed by patient research participants (Bissell et al., 2008, Tinelli 
et al., 2007), which is informative but does not provide us with perception held by the 
general public or even regular pharmacy visitors. A survey of patients participating in a 
randomised controlled trial of a medication management service reported both positive 
and negative comments regarding the involvement of the pharmacist in their care (Bissell 
et al., 2008). They liked how the pharmacists appeared to listen to them for longer than 
they expected the GP would do and found it a good source of reassurance that another 
healthcare professional was interested in their care. Some were surprised at how much 
the pharmacist knew about the medicines they were taking. However, when considering 
whether the pharmacist should make recommendations to the GP for their treatment they 
expressed more anxiety, citing concerns regarding drug companies’ influence on 
pharmacists, and their need to make profit and so preferred that the GP should make the 
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final judgements on any treatment recommendations. As discussed in chapter one, 
findings from Tinelli et al. also confirm this preference, shared by over three quarters of 
participants (n=1355) in their study who still prefer to discuss their medicines with their 
physician, even after a pharmacist intervention (Tinelli et al., 2007).  
 
In a recent US study by McAuley et al. patients with epilepsy were asked to complete a 
questionnaire about their perception of the current and future role of the pharmacist in 
their care. Patients used their pharmacist for information about drug interactions and side 
effects, with fewer patients wanting to discuss their condition, adherence and impact on 
their lifestyle (McAuley et al., 2009). Many patients (n=75) in the survey identified that the 
pharmacist had the knowledge and time to discuss with them their epilepsy medicines and 
the condition but was impeded from doing so by the space that is available to them in the 
pharmacy.   
 
Most recently, research was conducted in the US to ascertain the patient’s perspectives 
on information they wanted about their medicines and the barriers to asking pharmacists 
questions. In brief face-to-face interviews (n=600) in the pharmacy setting, participants 
were asked to comment on the role of the pharmacist and what information they desired 
from them at the initial dispensing of a medicine and the repeat dispensing of a medicine. 
Participants generally sought information such as basic instructions for use, adverse 
effects and drug interactions. However, participants collecting repeat medicines; mainly 
sought information about repeats remaining on their prescription with relatively few 
wanting a reiteration of the initial information. The barriers to asking pharmacists 
questions fell into two categories: patient and pharmacist-related. The patient barriers 
included fear or embarrassment, lacking initiative, having no need for any information and 
time constraints. The barriers perceived as relating to the pharmacist were being 
unapproachable and not being seen as a credible information source. Participants again 
highlighted their trust in the physician to provide most of their information but also that by 
speaking to the pharmacist they were in some way going against their doctor (Krueger 
and Hermansen-Kobulnicky, 2011).  
 
Specific patient groups have highlighted where they view the role of the pharmacist and 
this largely depends on their personal experience. Patients also have an idea about how 
far this role extends to the greater management of their condition with most indicating that 
they still need the physician to be involved in their care if they are to trust what the 
pharmacist is doing for them. This is important information if the government’s vision for 
pharmacy, as described in previous chapters, is to be realised in patients with long-term 
conditions.  
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Patients with diabetes, particularly those who are newly diagnosed, often do not 
understand the seriousness of their condition. They assume they can control it themselves 
until they reach a point at which they start developing symptoms or complications and this 
can have an impact on the extent to which they seek advice from healthcare professionals 
(Thoolen et al., 2008). It has been suggested that clear plans for treatment and 
information provision to patients with diabetes is both helpful and has an impact on 
behaviour (Peel et al., 2004, Polonsky et al., 2010). In patients who are prescribed insulin 
(for type 1 and type 2 diabetes) this is particularly important as adherence barriers include 
time available to inject, emotional problems or embarrassment and that less restrictive 
regimens that take account of a patient’s lifestyle may improve blood glucose results 
(Peyrot et al., 2012). There is also evidence to suggest that patients who experience 
episodes of hypoglycaemia have greater levels of fear and worry about their condition 
(Williams et al., 2012).  
 
The perceptions of patients with diabetes regarding the current and future role of the 
community pharmacist in the UK in addressing some of these problems have not been 
ascertained. If community pharmacists are to assume a greater role in the management of 
long-term conditions, understanding the patient perspective will help to facilitate this role 
change. This chapter will examine patient perspectives on the current and future roles of 
the community pharmacist in the management of type 2 diabetes. 
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6.2 Aims and objectives 
6.2.1 Aims 
To describe the relationship between a community pharmacist and patients with type 2 
diabetes and where patients see the pharmacist having the greatest role in their 
healthcare in the future.  
 
6.2.2 Objectives 
The objectives of the focus groups were to understand: 
 how diabetes affects patients’ lives 
 when and in what situation patients would deem it appropriate to see the pharmacist 
and what bearing their condition has on this decision 
 the extent to which patients interact with different healthcare professionals when 
discussing their diabetes 
 the personal experiences of patients with the community pharmacist 
 the view of patients regarding the community pharmacy environment 
 how patients see the role of the pharmacist developing 
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6.3 Focus group method 
The protocol and supporting documentation for this study are included in appendix 12. 
This study received UK ethical approval from the Cambridgeshire National Health Service 
(NHS) Research Ethics Committee (appendix 13) and governance approval from NHS 
Norfolk’s Research and Development Committee in 2011 (appendix 14).  
 
6.3.1 Focus group rationale 
The data that I was aiming to collect revolved around patients’ current experiences and 
thoughts on the future role of the community pharmacist. I had anecdotal knowledge from 
my practice, that many patients would have experiences of the community pharmacy that 
were limited to the collection of their prescription. Therefore, focus groups with patients 
were chosen as a method in order to collect data on their experiences but also to explore 
how they viewed other patients’ experiences of interacting with the pharmacist. The aim of 
the project was not to gain an in-depth knowledge of the patient’s own experiences but 
rather to understand the norms of this group of patients when visiting and interacting with 
the pharmacy support staff and pharmacist. Focus groups can encourage group 
discussion and debate about the topics raised and highlight a wider range of experiences 
and understanding (Kitzinger, 1995). They can also be more useful at exploring criticism 
than in-depth interviews as participants may be more likely to express diverse and 
contrasting views in a group setting than one-to-one (Kitzinger, 1995). This debate can 
lead to explication of personal processes and norms that otherwise may have gone 
unchallenged in an individual interview. I was not looking for a one-size-fits-all approach to 
be generated at the end of each focus group discussion or, overall, for this study.  Rather, 
the focus groups were seen as providing contextualising information to understand how a 
variety of patients’ recent experiences may have affected their diverse perceptions of the 
community pharmacist and pharmacy. 
 
6.3.2 Participant recruitment 
I gained the agreement of 20 community pharmacies in Norfolk to assist in the recruitment 
of patients. These included small independent pharmacies, large multiples (chains) and 
supermarkets in a variety of locations across the county. Patients that presented at one of 
the pharmacies with a prescription for a medicine to treat type 2 diabetes were informed 
about the study and given an information sheet by the pharmacist. If they were interested 
in participating, they were given a consent form to complete in their own time. This was 
returned directly to me. Pharmacists distributed most of the information sheets they had 
been given (n=32 for each pharmacy). Potential participants were asked to complete a 
series of demographic questions on the reverse of the consent form. These asked about 
age, gender, length of time since diagnosis and number of medicines on their repeat 
prescription form.  
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Once the consent form had been received, participants were entered into a pool from 
which participants were selected for each focus group based on their answers to the 
demographic questions. The reasons for selecting the four demographic characteristics on 
which to base sampling are detailed below: 
 
Gender: There is evidence to suggest that men and women cope differently with type 2 
diabetes and that it can impact on their ability to handle the condition (Svenningsson et 
al., 2011). 
Age: As age increases, a patient is more likely to be prescribed more medicines (Skegg 
et al., 1977) and therefore may have a more in-depth experience of visiting the pharmacy 
and interacting with pharmacists. 
Number of medicines prescribed: If patients are prescribed more medicines they may 
be visiting the pharmacy more often and interacting with the pharmacist.  
Length of time since diagnosis: Those patients who have been diagnosed with a long-
term condition for more years may have had the opportunity for more involvement with the 
pharmacist as they will have visited the pharmacy on more occasions since diagnosis.  
 
Ethnicity was not chosen as demographic data for Norfolk suggested that it may be 
difficult to recruit on the basis of ethnic background (Norfolk County Council, 2004). Each 
of the participants was given a £10 voucher as a thank you for attending. 
 
6.3.3 Participant selection 
Data were collected over three months between May and July 2011. For the initial focus 
group, maximum variation sampling (Patton, 2002) was used to gain an overview of the 
widest variety of participants’ views and experiences. While eight was the maximum target 
number of participants in each focus group, inability to attend and non-attendance 
resulted in eight participants in the first focus group, seven in the second, six in the third 
and four in the fourth.  The sampling strategy was informed by a process of constant 
comparative analysis. After initial analysis of the second focus group, which highlighted 
the potential relevance of repeated visits to the pharmacy to patients’ views, the decision 
was taken to invite only those participants who had either been diagnosed for a long 
period of time or those that were prescribed a high number of medicines. The aim was to 
determine whether specific views and experiences were more likely to be shared to 
patients with an extensive experience of visiting the pharmacy. The subsequent fourth 
group returned to a general sample to verify the findings from the previous groups. No 
new themes emerged from analysis of the fourth focus group’s data, indicating that data 
saturation was likely to have been achieved. 
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6.3.4 Topic guide 
During the focus groups, participants were asked open questions about their current 
experiences of the pharmacist and what they thought the future role of the pharmacist 
should be. Their views were elicited by using a set of small scenarios of common 
pharmacy experiences (set out in Box 1.) derived from my personal experiences of 
working in community pharmacy and the current literature on novel pharmacy services 
directed at this group of patients. Scenario 3 was based on research conducted by Krass 
et al. in Australia which indicated that a person-centred, flexible intervention had a positive 
effect on a patient’s sense of control of their condition (Krass et al., 2007). These 
scenarios were used to stimulate discussion around the research question as many 
participants will have had diverse experiences likely to reflect those indicated in one or 
more of these scenarios. 
 
Box 1: Scenarios used to stimulate discussion 
Scenario 1: You pick up your prescription from the pharmacy once a month, a counter 
assistant hands it to you and you never speak to the pharmacist. 
Scenario 2: As number 1 except once a year you have a chat with the pharmacist 
about your medicines in the pharmacy consultation room. 
Scenario 3: As number 2 except patients with poorly controlled diabetes have more 
consultations with the pharmacist to try and improve their condition. The number of 
consultations would be based on patient need over a period of about 4-6 months.  
 
6.3.5 Data analysis 
All focus groups were audio-recorded and transcribed by me. The transcripts were 
analysed independently using the principles of thematic analysis (Braun and Clarke, 2006) 
without reference to the original material by two researchers (myself and my supervisor). 
Thematic analysis is a widely used framework for analysis of meanings derived from 
qualitative data as it can summarise key features of a large body of data whilst offering 
‘thick description’ of the data set (Braun and Clarke, 2006). The thematic analysis process 
is described previously in chapter two. No software was used to analyse the data.  
 
We met several times during the study to discuss and agree the emergent themes, this 
was completed in the final meeting. If there was a discrepancy between the views of the 
researchers, discussion was held and a compromise achieved based on reference to the 
original data. The final report was independently checked for consistency with the 
transcripts and themes by two researchers (myself and my supervisor). Disagreements 
were resolved by discussion amongst ourselves and the wider research team. 
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6.4 Focus group results 
Forty-four patients were consented from whom 25 participants were recruited and 
attended one of the four focus groups. The remaining participants were not selected either 
as the demographic information made them less suitable, or they were unable to attend 
one of the focus groups. Participant characteristics are detailed in Table 6.1. 
 
Focus 
group 
Participant 
number 
Demographics 
Age (years) Gender Length of time since 
diagnosis (years) 
Number of 
medicines on repeat 
list 
1 1 61-70 M 5+ 2 
 2 61-70 M 5+ 6 
 3 51-60 M 5+ 10 
 4 51-60 F 5+ 8 
 5 51-60 F 5+ 4 
 6 71-80 M 5+ 10 
 7 61-70 F 1-2 5 
 8 71-80 F 2-5 3 
2 1 41-50 M 1-2 2 
 2 61-70 M 2-5 4 
 3 61-70 F 2-5 4 
 4 71-80 M 5+ 11 
 5 61-70 M 5+ 7 
 6 61-70 F 5+ 5 
 7 61-70 F 5+ 8 
3 1 61-70 F 5+ 10 
 2 61-70 M 2-5 9 
 3 61-70 F 5+ 10 
 4 71-80 M 5+ 18 
 5 71-80 M 5+ 9 
 6 71-80 F 5+ 11 
4 1 51-60 M 1-2 6 
 2 51-60 F 0-1 5 
 3 61-70 F 5+ 3 
 4 51-60 M 5+ 13 
Table ‎6.1 Participant demographics 
Participant data from the four focus groups, provided accounts of varied experiences of 
the community pharmacy and views about the role of the community pharmacist in their 
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care. These views fell into two broad themes: the place of pharmacy in the wider primary 
care team and the pharmacy as a healthcare destination.  
 
6.4.1 The place of pharmacy in the wider primary care team 
The need for information 
Many participants in our focus groups expressed their needs for information about their 
disease, medicines and lifestyle. Some were quite knowledgeable about their condition, 
but still described occasions where they would have liked more information or advice and 
the opportunity to seek this from an appropriate healthcare professional. This information 
included advice on diet, side effects of medicines, interactions between medicines 
(including over-the-counter preparations) and alternatives to their currently prescribed 
therapy. They also wanted to know why they were prescribed so many medicines, and 
why they were prescribed them, particularly when first diagnosed. 
 
“I felt as if I had gone from being healthy and no tablets to all of a sudden, I must 
be, well I have got all these tablets and I don’t really want them erm coz my blood 
pressure is ok, it’s a little bit on the high side, but needed to come down but 
probably if I wasn’t diabetic I wouldn’t have been put on anything erm and the 
same with statins and I felt quite vulnerable really.” (F3, FG4 (female number 3, 
focus group 4) 
 
Here, this participant is pointing up the suddenness and quite intimidating prescription of 
medicines for not only their diabetes but also other conditions. This participant’s lack of 
understanding as to why these medicines have been prescribed might reflect a collective 
failure to provide information by any of the various healthcare professionals involved in 
this participant’s care.  
 
One theme that emerged emphatically from all focus groups concerned taking 
responsibility for their own condition especially with regards to managing their blood 
glucose levels and that they had occasional needs for advice from an appropriate 
healthcare professional to be able to achieve this.  
 
“I feel that part of type 2 diabetes is managing a lot of it yourself to some extent 
with guidance from the GP and the pharmacist” (F7, FG2) 
 
All participants identified the need for some formal regular review of the control of their 
diabetes to provide them with the information they needed to prevent developing 
complications. In one case, during the first focus group, participants themselves 
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expressed anxieties when one of them revealed that they had not received a review in 
some time: 
 
“I think you had better go to the doctors and stamp your feet, it doesn’t seem like 
they’re doing it properly at all” (F3, FG1) and “that’s the only way you know you’re 
looking after yourself, if not how do you know that you’re... I’m quite concerned for 
you actually” (M1, FG1).   
 
Such comments emphasised the intense feeling in relation to this topic. Some participants 
specifically identified the need for an alternative source of information to the GP because 
they were not always available when the need arose. 
 
“if you want to talk to somebody about the problem, coz sometimes with diabetes 
you do have problems, you can’t not always get to the doctor coz as good as he is 
and you really want someone to be able to speak to.” (M1, FG1) 
 
All of these types of information requests and topics contained within them could be 
addressed within the professional competence of the community pharmacist, however, 
whether these participants would be likely to approach the pharmacist for advice on these 
topics depended on a variety of factors including: perceived expertise of the pharmacist, 
their perception of the healthcare hierarchy, their experiences of the medical practice and 
the healthcare environment the pharmacy setting provides. 
 
Perceived expertise of the pharmacist 
All participants identified that the primary expertise of the community pharmacist was 
medicines supply and advice regarding over-the-counter preparations and the interactions 
with their prescribed medicines.  
 
“if you want to query anything you want to take, like I’m not a very good traveller 
on the sea so I wanted some tablets to take for sea sickness so I asked him [the 
pharmacist] and you could say what would go with the tablets I was taking” (F3, 
FG3) 
 
There were differing views about how much further the pharmacist’s role extended to 
advising on prescription medicines and disease advice. Their perceptions of pharmacist 
expertise appeared to vary with their length of time since diagnosis and the number of 
medicines prescribed. Participants who had lived with the condition for a long time or were 
prescribed a large number of medicines acknowledged the pharmacist as someone with 
greater expertise than the doctor or nurse when discussing medication. These ‘more 
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experienced’ participants viewed the pharmacy as somewhere they could obtain much of 
the advice they wanted, that was easy and convenient to access and felt that if the 
pharmacist could not deal with the problem they could rely on them to refer patients to the 
doctor or nurse. 
 
“you can’t always get in to see your doctor, that quickly but I mean er you know 
you can just whip in there and they will at least give you a good bit of advice if you 
know nothing else” (F6, FG2) 
 
However, there was still general unease, even in this group as well as those with less 
experience, of wanting to talk to the pharmacist about, or acknowledge their ability to 
provide advice on, the condition of diabetes.  
 
“the thing to do with pharmacists is that I wouldn’t necessarily go to my pharmacist 
and ask about my erm health around my diabetes I would go and ask “I have got a 
raging cold can I take  this?”, and that’s where I find my pharmacist really helpful” 
(F5, FG1) 
 
“you know if I’ve got a bad cold or something, that would be the pharmacy but like 
discussing anything else that certainly wouldn’t be the pharmacist” (F3, FG2) 
 
This highlights the perceived expertise of the pharmacist as someone who can help and 
advise patients with regards to over-the-counter medicines and minor ailments but whom 
they would not approach for advice regarding their diabetes. A potential reason for this is 
explored in the next section.  
 
Experiences of the medical practice 
In all focus groups it was apparent that those participants who had a good relationship 
with, and received  all their information from, the medical practice had little desire to seek 
further information from the pharmacist beyond that of prescription supply and over-the-
counter requests. Even after hearing positive experiences of other participants’ 
information they had doubts about whether the pharmacist was the right person to 
approach for advice about prescription medicines or their condition.  
 
“she [the nurse] explains in great detail what that’s for and if there’s any side 
effects then ring me, which when I first started taking it I did, took a couple of 
weeks, just made a phone call, obviously she was busy, she phoned me back and 
hour or two later and made another suggestion so there’s no need to go to the 
pharmacist, just make a phone call” (F3, FG2) 
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Conversely, those who described either a poor relationship with their medical practice or 
having received little information from them identified the pharmacy as their first port of 
call as they continued see them regularly to pick up their prescriptions and they found it 
easy to ask them questions.  
 
“well I find our pharmacist very very good I mean he’s far better than my doctor , 
we could talk to him can’t we and he’ll help you, he know most things and erm he’s 
just brilliant you know. We can talk to him about things we couldn’t with the doctor 
or the practice nurse and he just... help quite a bit with the different things, if he 
can help you he will, he is brilliant” (F6, FG3) 
 
However, even those participants who identified the pharmacist as their first port of call, 
would not necessarily act on advice without first confirming it with their doctor. This is 
something that can be explained by examining their perception of the healthcare 
hierarchy.  
 
The healthcare hierarchy  
Participants saw it as extremely important to take note of whether advice given by 
someone needed to take into account a health professional’s position in what they saw as 
a healthcare hierarchy when deciding whether to act on advice that a professional gave 
them. Participants tended to view their GP as the ‘controller’ of their medical care and that 
he/she was the person who took overall responsibility for treatment and care for their 
condition. This appeared to impact on whether they felt comfortable approaching other 
professionals and most therefore suggested that they would need the doctor to validate 
the role of the pharmacist in their care before they could commit to any advice the 
pharmacist had given them. Participants stated they would be unwilling to let the 
pharmacist change their prescription medicines unless the doctor had agreed that this 
was the correct thing to do and had assessed the situation themselves. 
 
“if the pharmacist suggests it to you then you go to the doctor with it and that 
suggestion but I would be reluctant to rely entirely on the pharmacists decision that 
this is different, that this is better or… I wouldn’t take advice from a pharmacist 
without, especially over the change of medication, without seeing the doctor but 
then I have got a very good doctor as well” (M4, FG2)  
 
This participant appears happy to have received advice from the pharmacist but the extent 
to which he acts on it depends on the relationship with the doctor, in his case a good one, 
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and therefore that means he will have to pass this through them before he can proceed 
with implementation.  
 
“If I’ve got a problem with managing my diabetes I go to my diabetic nurse or the 
doctor because for me I would want to know what it is that’s causing the problem... 
I’d be asking about do I need to increase the tablets erm or do I need to go onto 
insulin or something like that, whatever the situation might be I can’t imagine I 
could go to the pharmacist to do it because that’s not what I’ve really thought that 
pharmacists do, pharmacists manage the medication and hand it out and they are 
kind of behind the scenes boys if you like” (M4, FG4) 
 
These participants are commenting on what seems to them the anomalous positioning of 
pharmacist’s authority in the primary care team especially with regards to medicines 
management. They may have the knowledge to be able to advise patients with regards to 
medicines, side effects, interactions and supply, however they do not have the ability to 
make these usually small, distinct changes to their treatment. This does not necessarily 
extend to advice regarding their condition; they view this as the primary responsibility of 
the GP and not the pharmacist. As the previous participant highlighted, the types of 
queries a patient may have are often longer and more complex than the issues they may 
have surrounding medication. Therefore the GP, with more information, such as blood test 
results, is acknowledged as being in a better position to advise them.   
 
In relation to pharmacy service provision, whilst some participants had already 
experienced being offered and had participated willingly in the medicine use review 
(MUR), an adherence-focused pharmacy service, some said they would want a doctor to 
refer them to the pharmacist if, as a patient, they were to perceive any benefit to it and if 
they were to engage with it fully. Repeatedly in the focus groups, participants refer to 
‘joined up care’ and at present their perception of the pharmacist is of them offering 
isolated, and sometimes duplicating, interventions.  
 
“I’ve been offered it [MUR] but very nicely declined it, I didn’t feel I needed it, 
having been seen down at the surgery and stuff, I have been offered it” (F3, FG4) 
 
Again, participants wanted the doctor to initiate and validate pharmacist-led interventions. 
 
“if the doctor referred me I’d be happy but if the pharmacist just took it on himself I 
wouldn’t be happy… but I would think if the doctor said go and see the pharmacist 
to discuss it that would be good.” (F1, FG3) 
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For these participants to engage fully with the pharmacist and to understand what their 
role may be in the primary care team, pharmacists would need to be seen as more 
integrated within the team whilst still maintaining the position of the doctor as overall 
‘controller’ of their medical care. For most participants, pharmacy is seen to occupy a 
unique place in the primary care team in relation to medicines supply and over-the-
counter advice, which is recognised as their primary role. Participants with more 
experience of interacting with pharmacists are more willing for them to become involved in 
wider aspects of their care, with the proviso that it could be seen to be ‘joined up’ with the 
work of the rest of the primary care team and that they understood why the pharmacist 
was becoming involved and what they could add. However, it is important to note all 
participants had reservations as to how this could be achieved in the current community 
pharmacy environment. 
 
6.4.2 The pharmacy as a healthcare destination 
Since 2005, community pharmacy has had to become more patient-focused, however, it is 
clear seven years after the commencement of the new pharmacy contract, that our 
participants still had concerns about the pharmacy being somewhere they would be willing 
to discuss private medical problems. These concerns relate to space, time, privacy and 
relationships with the pharmacist.  However, this was also a topic on which there was 
marked diversity between different participants’ perspectives regarding what they 
perceived as acceptable or as their priorities. 
 
The starkest contrasts were in their diverse views on supermarket pharmacies and ‘local’ 
pharmacies. Many participants thought that supermarkets lacked the privacy to enable 
them to fully discuss their medical problems with the pharmacist. Others thought that the 
supermarket pharmacy was ideal for their convenience. However, all pharmacies 
(supermarket and ‘local’) came under critical scrutiny as being less likely to allow 
discussions to be conducted with sufficient privacy. So the supermarket pharmacy 
environment might be equated with the supermarket counter. 
 
“Occasionally I have gone to the supermarket pharmacy... they’ll start talking 
openly in a supermarket, over the counter to you about your condition. Now, I don’t 
want to do that, I don’t want other people listening to what my problems are... It’s 
that lack of privacy that I don’t like, discussing over the counter that I don’t like that 
I think that’s awful” (M4, FG4) 
 
However, other participants saw any crowded place, including the medical practice 
pharmacy as being at least as restrictive in terms of privacy. 
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“I mean if I went to the one at the medical practice it’s not a big pharmacy, and 
quite often it’s packed with people so you’re still going to be standing there at the 
counter and it’s all people listening so I can’t see there’s any difference, not for 
me.” (F2, FG4) 
 
For others, any loud conversation conducted in earshot of anyone else would be public. 
 
“erm its erm quite a public place. If the pharmacist speaks to you, you’re in earshot 
of everybody else.” (M1, FG1) 
 
These quotes illustrate the public nature of the pharmacy environment and the discomfort 
caused with discussing medical problems in this setting. Compared to the medical 
practice, with private consultation rooms as standard, it is not surprising that participants 
identified their absence in the pharmacy environment as a flaw for conducting confidential 
conversations. This lack of a suitable, formal and uninterruptable consultation space also 
appeared to impact on whether participants were likely to request a conversation with the 
pharmacist.  
 
Participants also highlighted the visibly multiple calls on the pharmacist’s time and how 
this might affect their availability to answer any questions they may have. This lack of a 
formal individual appointment time also impacted on whether they were likely to approach 
the pharmacist for advice.  
 
“it seems very intrusive to take him away from his job to do something that I feel is 
not part of what his job is, it, I always view the pharmacist as someone who gives 
you your medicine, mixes it up for you if necessary and dispense it to you as the 
doctor has prescribed it and you take it as prescribed and I would view the doctors 
surgery is the place to go for advice and not the pharmacist” (M1, FG1) 
 
Giving dedicated time to individual patients is not seen as part of the pharmacist’s 
professional public role, so much so that talking to the pharmacist can be seen as “taking 
them away from their job”. 
 
“in my experience I not seen the pharmacist at all, I mean they’re just so busy, you 
know, and er you feel you are imposing if you say to him can I have a word about 
this?” (M2, FG2) 
 
The pharmacy environment itself is seen as too busy a place to be individual-focused. 
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“5: ...everybody that go in the chemist is always asking questions  
6: oh he’s always talking to somebody  
5: always so busy, always! And that’s only a small little chemist but that always 
busy and run off their feet sometimes” (M5 & F6, FG3) 
 
Whether community pharmacists were actually and equally busy over the course of the 
working day was not discussed during the focus groups however, it was an important and 
commonly-shared perception. In primary care, pharmacists are the sole profession where 
patients can observe them conducting almost every part of their job, from dispensing to 
advising patients on the counter. No other profession experiences this in primary care and 
it appears to undermine the possibility that patients feel they can approach the pharmacist 
to obtain the advice they may need to control their condition more effectively. This 
perception appeared to be moderated slightly if the participants knew their pharmacist and 
therefore knew more about the terms under which they could be approached for advice.  
 
Despite the qualifications and limitations in their perceptions of circumstances in which 
they might seek advice from pharmacists, all participants saw the pharmacist-patient 
relationship as extremely important. To enable this relationship to exist, participants 
pointed to the need for the pharmacist either to be there all the time, or to be able see a 
regular face, and for both the patient and the pharmacist to know each other’s names. 
This was viewed as central for patients to be able to trust the advice that was being given 
to them or to seek advice from the pharmacy in the first instance.  
 
“the relationship part of it is very important, it’s the trust got to build, you can’t just 
have the locum pharmacist coming in and you know he knows nothing about you... 
you build that relationship before you put your trust in them.” (F7, FG1) 
 
This quote highlights a distinction made between locum and regular pharmacists. While 
there is no assertion of any difference in their clinical abilities, it is the regular pharmacist’s 
knowledge of patient specifics that the participant views as important, something that they 
see the locum as lacking.  
 
“I find it much easier to go in if you know the pharmacist... if I go in with any 
queries or anything and you know I’ll say to the assistant you know can I just 
speak to [the pharmacist] and he’ll come through and we’ll discuss things” (M4, 
FG3) 
 
This participant focuses on the impetus to go and ask the pharmacist questions. He 
implies that there is an initial barrier to asking questions, which is one of knowing each 
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other which would make it difficult to approach a pharmacist if they did not know them 
already. 
 
“it is a convenience and because you know him like, you know your pharmacist, he 
is more like a friend” (F3, FG3) 
 
This highlights a potential difference in the relationship dynamics between the patient and 
pharmacist and the patient and GP in viewing the pharmacist as more of a friend than a 
formal healthcare professional and potentially more approachable.  
 
Those participants that had experienced a consultation with the pharmacist made some 
interesting points about the space and environment in which it was conducted and their 
thoughts about being initially invited for a consultation with the pharmacist which they did 
not necessarily know how to interpret at first. 
 
“a bit strange, yeah a bit strange but yeah fine yeah that’s that’s not a problem or 
an issue at the end of the day. I rather know, I’d rather make sure I know what I’m 
taking, rather than not know what I’m taking” (M3, FG1) 
 
They might view the pharmacy consulting space as not recognisable as an official part of 
the activity 
 
“so we’ll go back into the little back room there”  (F6, FG2) 
 
The occasion and the space could be so unfamiliar that it might even convey an air of the 
patient themselves having “broken the rules” 
 
“she called me into the consultation room and I thought why, why am I being called 
in here? You know I go to the diabetic nurse every six months they’re quite happy 
and I was a bit why is this happening and you sort of sit in this private room as if 
you have done something really naughty” (F1, FG3) 
 
These quotes explain a little about the perception of the consultation room as also being 
seen as an ambiguous environment to conduct private conversations about health 
management. They indicate how these participants were unaware of the existence of a 
private area in the pharmacy. They also pointed to the need for pharmacists to explain 
more about why they might be asking patients to enter into the ‘little’ room so that they 
don’t feel like it is ‘strange’ or that they have been ‘naughty’.  
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Finally, this next participant had no previous experience of interacting with the pharmacist 
and had described his work as “all I see him as dispensing” and viewed the consultation 
room itself as somewhere very much out-of-bounds since it was a place “to give drug 
addicts the privacy to take their methadone”.  However, after listening to the comments 
from other focus group participants she altered her view to observe that it could be 
worthwhile under certain conditions:  
 
“…if you are going to use the pharmacist, it would be very useful and would help 
you understand more about your condition and about your tablets, and the doctors 
don’t have time for that, but I would want to do that in a consultation room. I would 
want a pre-arranged appointment and I would want to build a relationship with the 
particular pharmacist because otherwise I don’t think the benefit would be there” 
(F7, FG1) 
 
This participant encapsulates views held by other participants in a similar situation, once 
they knew more about the pharmacy and had formed an idea where the pharmacist’s 
expertise could be beneficial to them from other participants, they were prepared to 
moderate their views and consider the pharmacist as a professional that may be valuable 
in their care providing certain criteria were met.  
  
146 
 
6.5 Focus group discussion 
The findings from this series of focus groups involving patients with type 2 diabetes 
indicates that they do perceive pharmacists as an essential part of the wider healthcare 
team, particularly with reference to allaying patients’ anxiety regarding over-the-counter 
medicines and matters associated with the ordering of prescriptions. These are roles that 
have long been associated with community pharmacists and it could be expected that 
patients would be more familiar with these rather than recent changes in service provision 
that might have impacted less on their own healthcare experiences of the pharmacy.  
 
This group of patients clearly articulated their need to control their diabetes themselves 
and the importance they attached to self-monitoring was evident. This was reflected by all 
participants and not just those that had experienced complications or symptoms as 
identified elsewhere in the literature (Thoolen et al., 2008). However, when seeking 
information about their condition, they did not necessarily see the pharmacist as their first 
port-of-call for healthcare advice. This has been confirmed in other research that 
demonstrates pharmacists do not serve as the primary healthcare resource for patients 
(Anderson et al., 2004). Our participants seeking information and advice would normally 
first approach their doctor or nurse as these professionals could make any necessary 
changes to medication or treatment plans. If, for some reason this were not possible either 
due to a problematic relationship between them or being unable to obtain an appointment, 
then the pharmacist became the next port of call.  
 
Our participants viewed the doctor as the ‘controller’ of their medication in a strictly-
observed health hierarchy so that they did not want to go against any treatment 
recommendations made by their doctor by obtaining advice from the pharmacist. They 
saw approaching the pharmacist as violating the natural line of treatment. Urban et al. 
have previously identified that pharmacists believe it is difficult to recruit patients for an 
MUR as they may be concerned about advice provided that conflicts with their GP’s 
(Urban et al., 2008). Bissell et al. identified it in relation to accepting a pharmacist’s 
treatment recommendation as part of a community pharmacy medicines management 
service, again viewing the GP as the ‘health professional in charge’ of their medicines but 
also citing worries about the commercial interest of pharmacies and their need to make 
money (Bissell et al., 2008). Participants also referred to what they saw as the isolated 
position of the pharmacist within primary care, as they did not see them as fully integrated 
with the rest of the primary care team. In characterising what the pharmacist could provide 
they highlighted it as lacking in joined up care and as duplicating services they received 
from the medical practice. This aligns with other research that has highlighted the isolated 
working practices and environment of the community pharmacy (Cooper et al., 2009) and 
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is something that, professionally, community pharmacists may be limited as to what they 
can alter.  
 
However, their discussions also made clear that participants were not simply ‘anti-
pharmacist’; it was more that they did not have a clear understanding of where pharmacist 
expertise could be useful to them in managing their condition. Participants identified that, 
for their view to change, pharmacists needed to become more integrated into the primary 
care team with better communication between the different professionals. Such 
communication would include being referred by the doctor to the pharmacist, so validating 
the pharmacist’s input whilst not deviating from what they saw as the natural line of 
treatment as well as developing procedures so that the pharmacist can communicate 
information back to the doctor if necessary without the patient having to visit the medical 
practice. 
 
However, even if this improved method of communication was to be developed, 
participants still have many reservations about the pharmacy as a suitable place for 
obtaining comprehensive, confidential healthcare advice that they could act on with 
confidence. It is perhaps surprising that seven years after the new pharmacy contract in 
England was implemented, pharmacies have not adapted sufficiently to create an 
appropriate environment in which patients feel comfortable asking personal medical 
questions.  
 
Our participants highlighted that pharmacies are busy places, often full of patients 
collecting prescriptions or asking the pharmacist questions and this may have an impact 
on whether and when they feel it is appropriate to ask for advice. Cowley and Gidman’s 
similar research on what the general public think about community pharmacist 
consultations suggests the perception that pharmacists are too busy to engage with 
patients (Cowley and Gidman, 2011). Our research seems to support at least part of this 
idea in that our participants saw pharmacists as lacking individually-available time but 
while they did not see pharmacists as unable to engage with patients, this view did 
influence whether they were likely to approach the pharmacist for detailed, personal 
health management-related information.   
 
Pharmacists’ public role and professional knowledge were not clearly understood by 
patients in identifying which of their questions pharmacists can appropriately answer.  
Participants identified the existence of a relationship between the pharmacist and patient 
as another criterion for their being willing to engage with the pharmacist; or with any 
services in the community pharmacy. They prioritise the need for a ‘regular face’ before 
they would begin to trust the pharmacist. They saw it as vital that pharmacists should 
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know their patients and their histories before entering into discussions about their 
condition or for them to accept any advice or recommendations that the pharmacist might 
make during a consultation.  
 
In terms of the pharmacy environment, most pharmacies cannot offer the privacy that this 
group of patients was seen to prefer to enable them to adequately discuss their medical 
condition.  Even the consultation room, with which most pharmacies are now equipped, 
did not escape criticism. The ‘little room’ as it was described is often used as stock 
storage space and was often small and cramped (Rapport et al., 2009). Some patients 
reported wondering why they had been taken into the room, fearing they had done 
something wrong or identifying it as somewhere stigmatised groups such as drug addicts 
might be treated. This gives the impression that community pharmacy services and the 
consultation room are still not used routinely by patients and as a result they are still wary 
of them and what to expect once in there. Pharmacists may assume that patients are 
aware of the consultation room and what it entails, and that the patient is automatically 
comfortable and happy with these consultations as they will view them as similar to those 
they will have encountered in their medical practice. However, in previous research 
patients have identified the opposite citing a small room and a lack of knowledge about 
why they were asked into the room in the first instance, suggesting that pharmacists are 
not explaining to patients the purpose of the encounter and setting (Iqbal and Wood, 
2010). These findings underline the further work the profession may be need to do to 
demonstrate to patients what the community pharmacy consultation room is like and how 
it can be used. 
 
Viewing all of these features of both the pharmacy and pharmacist together, highlights 
many changes the community pharmacist and the wider healthcare team will need to 
make if patients with diabetes, or others with chronic conditions, are going to confidently 
and effectively engage with new pharmacy services and see the pharmacist as a credible 
healthcare professional. This may involve changing the perception of the pharmacist by 
patients but also, and possibly more importantly, changing the way pharmacists work and 
are paid by the NHS. Changes to the national pharmacy contract may be appropriate to 
ensure pharmacists have the time and space to not only engage effectively with patients 
but also members of the wider primary healthcare team.  
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6.5.1 Strengths and limitations 
This study focused on the experiences and perceptions of patients with type 2 diabetes 
relating to the community pharmacy. These outcomes demonstrate that a focus group 
method could enable participants to articulate, debate and share common and different 
perspectives and experiences with each other to allow the researcher to examine how 
these develop in this group of participants (Kitzinger, 1995). The study only recruited 25 
purposively-selected participants, which would not reflect the whole range of patients with 
diabetes visiting the community pharmacy, however, the nature of the study required 
participants to be aware of their experiences in this setting in order to be able to discuss 
them knowledgably and therefore this ‘self-selection’ may not be a significant bias. The 
purposive sampling strategy enabled me to capture diversity in a range of conceptually-
relevant characteristics such as length of diagnosis and number of medicines prescribed. 
 
A key limitation with this study was that it could not include the views and experiences of 
patients with type 2 diabetes who do not interact with the pharmacy or the pharmacist. 
Gaining these views would have helped provide insights into what factors would make 
them engage with the pharmacist about their condition and why they do not currently 
engage with even basic pharmacy services. Accessing and studying the views of this 
group would call for a different study using different methods. The perspectives found 
here are also limited to the UK which may differ from perspectives in other countries which 
may have different organisational structures in which community pharmacy operates 
(Farris et al., 2005).  
 
Another limitation of this study was the necessity to allow the pharmacists to select 
potential participants from those presenting in the pharmacy which may have lead to 
‘cherry-picking’ of patients. This could have been avoided by placing a researcher in the 
pharmacy to recruit directly or posting out an information sheet and consent form to all 
those patients with type 2 diabetes registered with the pharmacy or medical practice. This, 
however, still would not have removed the self-selection bias of this study as the 
pharmacy staff would still have had to ask patients for permission to allow the researcher 
to approach them. 
 
The focus group was conducted by a pharmacist and the participants were aware of this 
from the outset. This may have impacted on their ability to speak freely, however, all were 
informed at the beginning that they were free to say anything they wished and that nothing 
would leave the room or affect their care. To help address this problem, the first focus 
group was also moderated by an experienced, non-pharmacist, qualitative researcher to 
ensure that the main researcher did not lead the participants into providing certain 
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answers. The secondary moderator was comfortable with the first focus group and for 
subsequent groups a second non-pharmacist researcher assisted with the sessions.   
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6.6 Focus group conclusion 
When designing a novel community pharmacy intervention, researchers need to be aware 
of patients’ currently held beliefs and practices which will inform the relevance and 
acceptability of the design to them. In the series of focus groups examined here, 
participants drawing on their experience of living with diabetes indicated that the 
pharmacy is not yet acceptable to them as an environment where wider healthcare 
conversations can be seen as readily or appropriately conducted. While these patients 
acknowledge that the pharmacist will have a wealth of expertise relevant to administration, 
supply, side effects and interactions of medicines, because they see pharmacists as 
isolated from the rest of the primary care team they are less comfortable with taking up 
community pharmacist interventions which they see as possibly disrupting treatment by 
the participant’s established care team. Pharmacists have long-established roles as 
suppliers of prescription and over-the-counter medicines. However, if this is to change to 
include more condition-led management of complex long term conditions such as type 2 
diabetes it seems that changes in the national pharmacy contract and working practices 
will be needed which can ensure that the community pharmacist becomes more fully 
integrated within the wider care team and, importantly, in the pharmacy environment in 
which these interactions take place. Any assumption by pharmacists that patients view the 
consultation room as simply a small medical practice rather than a completely different 
environment may need to be challenged.  
 
These focus groups have proved useful in establishing not only the sort of topics patients 
are willing to speak to the pharmacist about but also who and how patients are identified 
for the research project. It has highlighted the need to involve the medical practice from 
the outset of targeting patients and for some kind of referral system from them to the 
community pharmacy. Without this, participants in our focus groups have told us they 
would be unlikely to engage with the project. 
 
Issues surrounding the pharmacy environment may be impractical to address in a study 
being designed here, however, the perception of the pharmacist as ‘busy’ can be 
addressed. Participants identified  that there may be a need for additional pharmacist 
support so that they did not feel they were taking them away from their ‘core’ dispensing 
role.  
 
The final aspect highlighted by participants involved access to the pharmacist. They liked 
the ease and convenience of speaking to the pharmacist and the lack of need for 
appointment bookings. In the intervention developed as a result of this work, access and 
convenience need to be maintained in order to retain the incentive for the patient to visit 
the pharmacy.  
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The subsequent study, detailed in the following chapter, will include all of these features in 
an attempt to create a successful intervention in the community pharmacy setting.  
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 Chapter Seven 
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7  Diabetes Drop-in Clinic: A feasibility study 
7.1 Introduction 
The preceding chapters have focused on preliminary work aimed at developing a complex 
intervention designed to complement that advocated by the 2008 MRC framework 
(Medical Research Council, 2008). This process has involved a systematic literature 
review, an audit of prescribing in primary care and a series of focus group discussions and 
has assisted in the definition and structure of the intervention and the target population 
described in this chapter.  
 
The literature review described how patients are often prescribed a significant number of 
medicines for type 2 diabetes and its co-morbid conditions and that they may have 
concerns and questions about their treatment that may affect whether they take those 
medicines as prescribed. Non-adherence in this group of patients has been shown to be 
influenced by a number of factors including the number of medicines prescribed, the 
number of daily doses, the patient’s understanding of the regime and the perception of 
side effects and the likelihood of experiencing them. 
 
The community pharmacist is ideally positioned to be able to address these problems both 
in terms of their specialist knowledge and the frequency with which they will see these 
patients, demonstrated by the evidence provided in chapter four. These studies 
highlighted several factors that should be considered before any novel intervention is 
trialled, namely the training provision for pharmacists, the inclusion criteria and the 
intervention design. Any service developed in the UK also needs to assimilate itself with 
the current care team and the wider NHS. Evidence from the literature review implies that 
training for pharmacists should involve an element of self-directed learning together with a 
face-to-face training session provided by the university covering aspects such as 
consultation techniques, local treatment guidelines and information on the study 
processes.  
 
The content of the consultations analysed in chapter four’s review of the literature 
provided little information in relation to which ‘core’ areas the pharmacist should be 
focussing on e.g. diet and lifestyle, adherence or drug-related problems. As such, most of 
these consultations were wide ranging in the topics covered with patients. In the future it 
may be appropriate to narrow down the focus of the pharmacist’s consultation; however, 
at this point there is a lack of common data to suggest what this should be.  
 
In terms of attempting to address this issue of consultation focus, an audit of prescribing in 
type 2 diabetes was conducted to determine if it were appropriate for the pharmacist to 
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become involved in this aspect of a patient’s treatment. Chapter five demonstrated that 
prescribing for type 2 diabetes is generally in line with the most recent NICE guidance. 
However, this audit and the annual National Diabetes Audit provide evidence to suggest 
that there are still a large number of patients for whom control cannot be achieved and 
this may be due to lack of dose titration, the need for further medicines to control their 
condition or sub-optimal adherence. If problematic, dose optimisation may need to take 
place in the medical practice but it may be appropriate to address sub-optimal adherence 
in the community pharmacy as they are already equipped to provide this type of service.  
 
Again if problematic, the audit identified that the community pharmacist may not only have 
a role in adherence but also in managing cardiovascular risk, blood pressure 
measurement and weight. For a community pharmacist to be able to target these patients, 
effective lines of communication between the medical practice and community pharmacy 
would be required. At present, with the delay of the introduction of summary care records 
in community pharmacies, pharmacists would need to rely on the direct referral of poorly 
controlled patients from the medical practice to the pharmacy in order to target these 
patients.  
 
In the series of focus groups described in chapter six, participants drawing on their 
experience of living with diabetes indicated that they would be willing to engage with a 
service aimed at improving their condition providing that it met certain criteria. The first of 
which was the inclusion of the medical practice and their doctor in any treatment or 
service offered by the community pharmacy. Participants saw it as necessary in terms of 
validating the knowledge of the pharmacist but also not violating the natural line of 
treatment between them and the doctor. 
 
As discussed in chapter six, issues surrounding the pharmacy environment may be 
impractical to address in a study being designed here, however, the perception of the 
pharmacist as ‘busy’ can be addressed. Participants identified  that there may be a need 
for additional pharmacist support so that they did not feel they were taking them away 
from their ‘core’ dispensing role. The final criterion highlighted by participants involved 
access to the pharmacist. They liked the ease and convenience of speaking to the 
pharmacist and the lack of need for appointment bookings. In the intervention developed 
as a result of this work, access and convenience need to be maintained in order to retain 
the incentive for the patient to visit the pharmacy. 
 
All of this information from the literature review, audit and patient focus groups has been 
brought together to develop the idea of a diabetes drop-in clinic in the community 
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pharmacy setting. This service will pull together the core findings from the work conducted 
as demonstrated in table 7.1 below.  
 
 
Core finding Rationale for inclusion 
Targeting poorly controlled patients Studies in the literature review that worked 
best targeted poorly controlled patients. 
The audit identified along with the literature 
identified that there were a significant 
number of patients who were uncontrolled 
with respect to blood glucose, blood 
pressure and total cholesterol.  
A system of referral from the medical 
practice to the community pharmacy 
Focus group participants identified this 
aspect as essential if they were to engage 
with the community pharmacist in relation to 
their diabetes. The PLEEZ study identified 
that relying solely on pharmacists to recruit 
participants opportunistically may not be an 
appropriate approach for this kind of 
service. 
A training programme that has a self-
directed learning aspect as well as face-to-
face sessions. 
The pharmacists in PLEEZ highlighted that 
they liked the training provided to them as 
part of the service and in the studies 
detailed in the literature review most utilised 
this approach.  
No appointment system Focus group participants have identified 
this as a benefit to community pharmacy 
and it should try to be incorporated into any 
service developed. 
An additional pharmacist to provide support 
to the service pharmacist 
The introduction demonstrated that a 
significant concern for pharmacists is time 
available to conduct a service. The PLEEZ 
study failed to recruit participants, 
potentially due to the lack of support 
provided to the pharmacist whilst they were 
providing the service. Focus group 
participants also identified that pharmacists 
“appear busy” all the time and they feel as 
157 
 
though they are imposing on them if they 
were to ask a question. This finding may 
help to limit that feeling. 
A focus on adherence as well as diet and 
lifestyle advice 
The literature review identified that 
pharmacists could provide a service that 
encompassed all of these items and 
produce positive results. The audit ruled out 
the inclusion of changing medication and 
providing screening for cardiovascular risk.  
Table  7.1 Core findings from previous chapters detailing to rationale for inclusion in the drop-in 
clinic 
As a result of the work conducted in chapter two and working within the MRC framework 
for developing complex interventions, this chapter will focus on testing the feasibility of the 
diabetes drop-in clinic that comprises all of the elements listed above together with 
assessing whether this service is acceptable to both patients and pharmacists.   
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7.2 Aims and Objectives 
7.2.1 Aims  
The overall aim for my research in this area is to determine whether a community 
pharmacy diabetes drop-in clinic improves the care of patients with type 2 diabetes. The 
aim for this initial study is:  
 
 To determine whether a pharmacy diabetes drop-in clinic is feasible and acceptable to 
patients with poorly controlled diabetes. 
 
7.2.2 Objectives 
To determine: 
 the feasibility of a community pharmacy drop-in clinic for poorly controlled diabetes 
patients 
 recruitment methods and rate of participation in the drop-in clinic 
 the characteristics of patients accessing the service and identify their needs 
 the ability of service recipients to complete the follow-up questionnaires 
 the potential effect on the following potential outcome measures: 
o BMQ 
o SIMS 
o Morisky 
o Community pharmacy utilisation 
 the most suitable outcome measures  
 the suitability of the questionnaires for informing the consultation 
 the content of the intervention 
 the acceptability of the service to patients and pharmacists 
 the acceptability of the research design in terms of 
o recruitment methods 
o training provision 
o questionnaire design 
o locum support 
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7.3 Drop-in clinic method 
7.3.1 Ethical Review 
The protocol and supporting documentation are included in appendix 15. This study was 
given approval to commence from Essex NHS Research Ethics Committee (appendix 16) 
and NHS Norfolk Research and Development committee (appendix 17). The substantial 
amendment paperwork is also included (appendix 16) as a result of requested changes 
from NHS Norfolk.  
 
7.3.2 Study Design 
The diabetes pharmacy drop in clinic specifically targeted patients who were poorly 
controlled with respect to HbA1C, blood pressure or lipids. The clinic was conducted in five 
pharmacies with the regular pharmacist in the private consultation room.  
 
7.3.3 Practice and pharmacy recruitment 
In conjunction with the local primary care trust, the researchers identified potential 
independent community pharmacies where the study could be conducted. This study was 
partly funded by an organisation that represents independent community pharmacies and 
therefore this was the reason for selecting only these pharmacies initially. The pharmacies 
were selected based on convenience and their proximity to a medical practice (all were 
co-located together). Once these sites were identified, the researchers approached both 
the pharmacy and the medical practice and arranged meetings to discuss the project and 
seek consent to participate in the study. After discussion with the Local Pharmaceutical 
Committee, and to ensure fairness to all community pharmacies in the area, those in the 
vicinity of the previously identified independent pharmacy were invited to participate as 
well, this resulted in two additional pharmacies being recruited that were part of a multiple 
pharmacy chain.   
 
7.3.4 Pharmacist training 
Pharmacists were required to complete the CPPE Diabetes Management training 
package and have read the NICE guidance for the management of type 2 diabetes before 
undergoing a training session conducted by me. The pharmacists were paid to complete 
this training and took approximately 10 hours to complete. The learning outcomes of the 
training package were as follows (CPPE, 2010): 
 
 identify risk factors associated with developing diabetes 
 distinguish between type 1 and type 2 diabetes 
 describe best practice in managing patients with type 1 and type 2 diabetes 
 understand and monitor various parameters which are used to judge metabolic control 
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 make recommendations to prevent the complications of diabetes or manage them 
should they occur 
 enhance the contribution made to the care of people with diabetes.  
 
Once this was completed, the researcher visited each pharmacist and undertook a short 
(one-hour) training session aimed at contextualising the study by presenting the results 
from the patient focus group discussions along with information about the study design. 
Excerpts from the focus groups were used to highlight real concerns that patients may 
have and how they felt they should be dealt with. Consultation skills were not addressed 
as part of the training as there were limited funds available and part of the aim of the 
project was to determine if this was necessary. 
 
7.3.5 Participant identification 
The medical practice was asked to identify poorly controlled patients subject to the 
following criteria: 
 
 Confirmed diagnosis of type 2 diabetes 
 Aged > 18 years 
 Poorly controlled with respect to the following QOF outcomes: 
o Patients not achieving QOF indicator DM26 (HbA1C < 59 mmol/mol) AND/OR 
o Patients not achieving QOF indicator DM31 (BP < 140/80 mmHg) AND/OR 
o Patients not achieving QOF indicator DM17 (TC < 5 mmol/L) 
 
From the generated list of patients, the medical practice was asked to remove the 
following patients: 
 Those patients on the QOF dementia register 
 Those patients on the QOF palliative care register 
 Those patients who have been exception reported for QOF 
 
The medical practice was also permitted to remove any patient that, in their experience, 
would not be suitable for the service e.g. those that they knew were housebound or 
resident in a care home.  
 
For all identified patients the researcher provided the medical practice with pre-filled 
envelopes enclosing a letter from the practice partners and a leaflet advertising the 
service and they were asked to mail these to patients identified. The leaflet contained 
information including clinic times and what was involved when patients attended the 
pharmacy. The researcher had no access to medical records for this process. In order to 
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test the need for a repeat mailing, one medical practice was asked to send a second letter 
out to all potential participants identified. Another medical practice was asked to send out 
a repeat mailing to a select number of participants based on the experience of the practice 
as to whether they thought they would attend the clinic and the third medical practice did 
not send out a repeat copy of the invitation letter.  
 
7.3.6 Participant recruitment and consent 
The leaflet advertising the service contained a consent section on the back that the patient 
were asked to bring along to the clinic. In the case of forgetting, they were asked to 
complete a consent form before the consultation could commence. The pharmacist, 
researcher or pharmacy staff were available to assist the patient in completing the 
consent form and subsequent questionnaires should they need any help. Once the patient 
had consented, the consent/data collection form was detached from the information leaflet 
so that the patient could keep that section and the pharmacist could keep the consent 
form. The participant, researcher and medical practice were also be given copies of the 
consent form if they requested it.   
 
7.3.7 The drop-in clinic 
The clinic was conducted for a four-hour period once a week for four weeks (six weeks in 
one pharmacy). The patient also had the opportunity to visit the pharmacy outside of the 
clinic times but was informed that they may have to wait a short while to see the 
pharmacist.  
 
The patient was then asked to complete a short questionnaire containing three validated 
questionnaires: the Beliefs about Medicines Questionnaire (BMQ) (Horne et al., 1999), the 
Satisfaction with Information about Medicines questionnaire (SIMS) (Horne et al., 2001) 
and Morisky measure of adherence (Morisky et al., 1986) all of which have been 
described previously. Data was also collected regarding how many times and why they 
have used the community pharmacy over the preceding three months.  
 
Once the participant had completed these, the pharmacist started the consultation. The 
content of all the consultations was negotiated between the pharmacist and the patient 
based on the needs of the patient and the responses to the questionnaire. This could 
have included questions relating to their disease, lifestyle and diet or medicines. The 
breadth and depth of the discussion was not dictated to the pharmacists. They were 
asked to let the patient lead the consultation and use the baseline questionnaire to inform 
any discussions as necessary. The questionnaire had been shown to the pharmacist 
during the training session to allow themselves to become familiar with it. The different 
elements were explained and how these might be useful in guiding the consultation.  
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The information sheet provided to the participants suggested that this was a one-off clinic 
and gave no impression that they had to attend the clinic on multiple occasions. However, 
there were no restrictions on how many times they were allowed to attend over the course 
of the study if they found it beneficial. No time limit in terms of length of consultation was 
suggested to the pharmacists.  
 
If necessary, the pharmacist was able to liaise with the prescriber and discuss any 
potential changes that the pharmacist thought would be beneficial to the patient. 
Prescription changes were agreed by the participant, pharmacist and prescriber and were 
arranged by the pharmacist in conjunction with the medical practice staff.   
 
The patient then completed a feedback questionnaire post consultation which contained 
questions regarding the conduct of the pharmacist, the surroundings in which the 
consultation occurred and their opinions on the consultation. The patient was asked to 
post the completed questionnaire directly to me at the university to manage social 
desirability bias which could result from posting to the community pharmacy. At the end of 
the questionnaire, there was an option for patients to include their telephone number so 
that should any aspects of their answers need clarification, I was able to contact them. It 
was made clear on the questionnaire that by giving their telephone number they were 
consenting to me calling them for clarification. 
 
7.3.8 Pharmacist data collection 
The pharmacist collected information from the participant including age, gender and 
postcode and called the medical practice after the consultation to obtain the following 
information required to complete the data collection form: 
 
 Most recent HbA1C, blood pressure and total cholesterol results 
 Number of medicines prescribed 
 Length of time since diagnosis 
 
The pharmacists were asked to describe the contents of the consultation with the 
participant using a tick box form which included space to write any additional comments if 
needed. Information such as length of the consultation, the topics of discussion, 
alterations to the care received from the pharmacy and any changes requested from the 
medical practice were sought in this form.  
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7.3.9 Patient follow-up questionnaire 
Three months after the consultation, the patient was asked to complete a repeat of the 
baseline questionnaire. This was posted to their address by the researcher, contained 
only the patient number and was returned in a pre-paid envelope to the University.  The 
researcher kept track of which patients were due to receive a questionnaire and if they 
had returned it. If they did not return the questionnaire within two weeks, they were sent a 
follow-up.  
 
7.3.10 Funding  
The medical practice was paid a set fee for participating in the evaluation. The pharmacy 
received free locum support from myself on the day of the clinic and were paid per patient 
that attended the drop-in clinic to a maximum of 40 between the five pharmacies. 
 
7.3.11 Pharmacist interviews 
As part of the follow-up to the study, pharmacists were interviewed to determine their 
views on the drop-in clinic, patient interaction and the study design. These ‘de-brief’ 
interviews asked pharmacists to comment on the following areas to inform the design for a 
subsequent pilot study: 
 
The service: 
 What was your general impression of the service? 
 Did you have enough time to prepare for the service? 
 What did you think of the delivery and content of the consultations? 
 How do you think the service benefitted: 
o Patients? 
o Relationship with the medical practice? 
o You personally? 
 What impact do you think the pharmacy environment has on this kind of service? 
 How has your practice changed as a result of providing the service? 
 
The research: 
 What are your thoughts about the research design? 
 What was your impression of the targeting of patients for this study? 
 What did you think of the conduct of the research and the research team? 
 What did you think of the paperwork for the study? 
 What did you think about liaising with the medical practice? 
 Do you think the data collected for the study was appropriate? 
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Other questions were asked where necessary to clarify remarks made to me. These 
interviews were held at a convenient location and time for the pharmacists and were 
audio-recorded and transcribed verbatim by me. They were analysed using content 
analysis with reference to the original questions initially by me in conjunction with my 
supervisor.  
 
7.3.12 Sample size calculation 
As this was a feasibility study a formal sample size calculation was not performed. 
However, based on the previous research described in chapter four it was deemed 
sensible to only ask each pharmacy to recruit a small number of participants. Therefore an 
initial target of 40 was set to allow each pharmacy to recruit eight participants.  
 
7.3.13 Data analysis 
The data were analysed using the Statistical Package for Social Sciences (SPSS) version 
18. All demographic and clinical data from the participants were analysed using 
descriptive statistics. Each section of the questionnaires was assigned a score according 
to the respective validated tool and was then analysed using descriptive statistics to 
identify any differences between baseline and follow-up. Appropriate parametric and non-
parametric tests were used to determine the statistical significance of any differences. The 
BMQ questionnaire was analysed in terms of the necessity and concerns scale as well as 
the differential score with the SIMS questionnaire analysed in terms of the action and 
usage section and potential problems section as well as the total score. Adherence was 
dichotomised into adherent and partially adherent. A ‘yes’ response to any of the Morisky 
questions implied the participant was partially adherent. McNemar’s test was used to 
determine any significant difference in adherence between baseline and follow-up. This 
was used as it tests the difference between two related groups, when nominal data have 
been used (Field, 2009). It needs to be used when you have two dichotomous variables 
(adherent/partially adherent) and they are related to each other (before and after). This 
test was also used to determine any differences in the community pharmacy use section 
of the questionnaire.  
 
The free-type sections of the questionnaires were summarised and a selection are 
presented as an overview of the data. All views will be represented. The pharmacist 
interviews were transcribed and coded by the researcher and themes were developed 
using content analysis. A second researcher also read the transcripts and familiarised 
themselves with the participants responses. The two researchers then had discussions 
surrounding the themes to arrive at a consensus and resolve any conflicting views.   
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7.3.13.1 Null hypothesis 
No difference will exist between baseline and follow-up for the following measures: 
 
 BMQ necessity, concerns and differential scores 
 SIMS action and usage, potential problems and total scores 
 Morisky, change in adherent behaviour 
 Frequency of visits to the community pharmacy and interacting with the pharmacist 
 Topics of conversation with the pharmacist 
 
7.3.13.2 Content analysis 
Content analysis involves breaking individual interviews down into units of analysis usually 
determined by the questions asked of the participants (Graneheim and Lundman, 2004). 
In our interviews the units of analysis are: training provision, conduct of the service, the 
study paperwork and the benefits arising out of the study. These units of analysis contain 
all the references made in all the interviews and are formed together in one text for 
analysis. This text is then progressively coded until categories, subthemes and themes 
are established. These interviews will be analysed using a deductive approach as 
described in the literature (Elo and Kyngäs, 2008). This is due to the researchers 
knowledge of where problems may have occurred from work conducted in previous 
chapters. The themes were discussed between two researchers who had reviewed the 
text independently and consensus was sought.  
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7.4 Drop-in clinic results 
7.4.1 Participant demographics 
Five pharmacies and three medical practices were recruited in three locations across 
Norfolk. The pharmacies dispensed the majority of the prescriptions issued by their 
associated medical practices. The medical practices identified and posted the invitation 
letter and information sheet to 342 potential participants. Thirty-three participants (9.6% 
response rate) were recruited in four of the five pharmacies as detailed in table 7.1. The 
demographics of the recruited participants are detailed in table 7.2. The participants 
postcode was used to determine distance travelled to the clinic. Of those that attended, 
44.5% were uncontrolled with respect to blood glucose, 74.1% for systolic blood pressure, 
81.5% for diastolic blood pressure and 48.1% for total cholesterol with some patients 
being uncontrolled for multiple measures. 
 
Pharmacy Number of participants recruited Repeat mailing? 
1 12 Yes 
2 7 Yes 
3 8 No 
4 6 No 
5 0 Yes 
Total 33  
Table ‎7.2 Number of participants recruited in each pharmacy. 
 
 N Mean (SD) % of patients controlled 
Distance travelled to clinic (miles) 33 3.1 (2.7) n/a 
Most recent HbA1C result (mmol/mol) 27* 63.5 (13.2) 55.5 
Most recent SBP result (mmHg) 27* 133.6 (21.7) 25.9 
Most recent DBP result (mmHg) 27* 78.8 (16.1) 18.5 
Most recent total cholesterol result (mmol/L) 27* 4.4 (1.4) 51.9 
Number of medicines prescribed 29* 8.8 (4.2) n/a 
Years since diagnosis 29* 8.1 (5.0) n/a 
Table ‎7.3 Participant Demographics 
*Data unobtainable for some participants presenting at pharmacy 4. SBP: systolic blood pressure; 
DBP: diastolic blood pressure; data normally distributed 
 
7.4.2 Baseline and follow-up questionnaire  
All participants completed the baseline questionnaire and I received 26 follow-up 
questionnaires, data from which are presented in tables 7.3 and 7.4 with figures 7.1 and 
7.2 illustrating the responses to the SIMS and Morisky questionnaires respectively before 
and after the intervention. The final part of the questionnaire asked for information 
167 
 
regarding pharmacy use before and after the study, the results of which are detailed in 
table 7.5. 
 
Measure 
Before N=33  
(median (quartiles))* 
After N=26 
(median (quartiles))* 
p-value# 
BMQ – necessity scale /25 20 (17 – 23) 20 (17 – 22) 0.674 
BMQ – concerns scale /25 14 (11 – 18) 16 (12.75 – 18) 0.445 
BMQ – differential score 6 (2 – 9) 4.5 (-0.25 – 8.25) 0.500 
SIMS – actions and usage 
score /9 
7 (4 – 8) 7 (5 – 9) 0.117 
SIMS – potential problems 
score /8 
4 (2.5 – 7) 5.5 (2.25 – 7.25) 0.940 
SIMS – total score /17 11 (8 – 13) 11 (7.75 – 16) 0.558 
Table ‎7.4 Baseline and follow-up questionnaire data 
#
Wilcoxan signed-ranks test for all variables; BMQ: beliefs about medicines; SIMS: satisfaction with 
information about medicines scale 
 
 Baseline (n=33) Follow-up (n=26) 
Adherent 61.5% 76.9% 
Partially adherent 38.5% 23.1% 
Table ‎7.5 Morisky adherence scale change from baseline to follow-up 
P=0.219; McNemar’s test 
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Not counting today, how many 
times in the last three months 
have you: 
Before n=33 
Mean (SD) 
After n=26 
Mean (SD) 
p-value 
   
 Visited the pharmacy 3.37 (2.82) 3.37 (2.65) 0.454* 
 Spoken to the pharmacist 0.96 (1.54) 1.91 (2.51) 0.134* 
What have you spoken to the 
pharmacist about? 
% responding ‘yes’ % responding ‘yes’ 
 
 Your condition 0 38.5 0.002# 
 Your medication 15.2 34.6 0.070# 
 Over-the-counter advice 18.2 23.1 0.500# 
 Lifestyle 6.1 19.2 0.219# 
 Dietary advice 9.1 26.9 0.063# 
 Other medical conditions 12.1 26.9 0.125# 
 Minor ailments 9.1 19.2 0.250# 
 Medicine supply 21.2 53.8 0.004# 
Table ‎7.6 Community pharmacy use before and after the study 
#
McNemar’s test; *Paired samples t-test
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Figure ‎7.1 Responses to the SIMS questionnaire, before: n=33; after: n=26 
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Figure ‎7.2 Responses to Morisky questionnaire, before: n=33; after: n=26 
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Figure ‎7.3 The content of the 33 consultations and whether the topic was raised by the patient or the pharmacist. 
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7.4.3 Pharmacist data collection  
The mean (SD) time for the consultation was 32.5 (12.0) minutes but ranged from 15 
minutes to 65 minutes. Out of the 33 consultations, the topics covered are illustrated in 
figure 7.3 with the free type sections summarised below. 
 
Other information requested by the patient 
Most of this additional information requested by the patient involved the use of devices 
and monitoring of blood glucose. Participants wanted more information on the use of their 
test strips and needles (if they were prescribed insulin) together with information about 
what to do in the case of a hypoglycaemic episode. Other information that was requested 
related to correct portion size, alternatives to the medicines they were currently prescribed 
and why they were still taking oral medicines when they have recently been prescribed 
insulin. 
 
Other information raised by the pharmacist 
The pharmacists felt it necessary to discuss additional points such as the recently 
changed Driver and Vehicle Licensing Agency’s (DVLA) requirements for patients with 
diabetes as well as adherence to treatment recommendations. In a number of participants 
this revealed a lack of adherence to therapy of which two examples are provided below: 
 
 Participant had been prescribed gliclazide 80mg three times a day and was only taking 
half a tablet in the morning. 
 Participant only taking one metformin twice a day when they should have been taking 
two twice a day.  
 
Alterations requested of the pharmacy 
The changes that the pharmacists thought they could enact themselves in the pharmacy 
were limited to adherence aids, providing information leaflets on appropriate diet and 
lifestyle changes, offering a delivery service and removing a participant from the managed 
repeat service. 
 
Alterations requested of the medical practice 
The pharmacists identified a number of clinical problems that needed to be addressed by 
the medical practice in addition to informing them if a patient was not taking their 
medication as prescribed. These issues are listed below: 
 
 Participant needs a review of their current medication 
 Participant has reported not receiving a blood test and diabetes review in some time. 
 Request for an alternative cholesterol medication 
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 Participant may require calcium and vitamin D prescribed as they are currently taking 
Bonviva and long term steroids 
 Participant is uncontrolled, is overweight and has not been prescribed metformin. 
Recommendation to add metformin to current therapy 
 Alter metformin dose from two twice a day to two modified-release tablets in the 
morning to aid compliance 
 Increase quantity prescribed as dose has increased and participant keeps running out 
of tablets. 
 
7.4.4 Feedback questionnaire 
Participants were asked to complete a feedback questionnaire after the consultation and 
post it back to me at the university. In total, 27 completed questionnaires were returned 
and the results are summarised in table 7.6 and figure 7.4.  
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Table ‎7.7 Responses to the feedback questionnaire 
Questions 
Questionnaire responses (%) 
Very good Good Average Poor 
Very 
poor 
What was your general impression of the service you received today? 74.1 25.9 0 0 0 
What did you think of the invitation and leaflet telling you about the 
diabetes clinic?  
42.3 57.7 0 0 0 
 
A lot Some help 
A small 
amount 
No help 
How much do you think attending the drop in clinic will help you 
manage your diabetes? 
55.6 40.7 3.7 0 
 
More likely 
About the 
same 
Less likely Not sure 
Would this service make you more or less likely to consult a pharmacist 
in future about other conditions? 
59.3 37.0 3.7 0 
 Too long About right Too short 
What did you think about the length of time for the consultation? 11.1 88.9 0 
In terms of length, what did you think of the first questionnaire? 15.4 86.4 0 
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Figure ‎7.4 Responses that required a yes/no/not sure answer from the feedback questionnaire 
0 10 20 30 40 50 60 70 80 90 100
Did you find it useful to speak to the pharmacist about your condition?
Were you satisfied with the information you received during the consultation?
Did you feel the information given was at a level that you could understand?
Do you think this service, or a service like it, could be useful for other patients
with diabetes or other conditions?
Would you use this service again?
Would you recommend this service to other patients with type 2 diabetes?
Did you think that a direct leaflet was the best way to inform you of the clinic?
N=25
In terms of content, do you think the first questionnaire asked the right
questions for you?
Do you think the pharmacy was the right place for this type of clinic?
Do you think the pharmacist is the right person to conduct this type of clinic?
% of patients responding 
Q
u
e
st
io
n
 
yes
no
not sure
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At the end of the questionnaire there were five boxes for participants to free-type 
comments. Participants were impressed that the pharmacist appeared to know what they 
were talking about and that they were able to talk to them without any time pressure and 
in a manner that they found approachable and professional. They identified that the 
pharmacist had the time to sit and discuss their problems in a way that helped to reassure 
them about their condition and provide advice to them in a way they could understand. 
However, one quote demonstrated that the participant was aware of the limitations of the 
service as the pharmacist still had to refer to other healthcare professionals to alter 
treatment regimens:  
 
“Good but needed to refer to the 'diabetes' nurse for direction of prescription”.                                                                                                                                                                                                        
 
Two of the pharmacies held their consultations in the medical practice due to space 
restrictions and they received positive feedback. Participants in the pharmacy consultation 
rooms highlighted that there may still need to be some work done to convince them that it 
is a place where they would feel totally comfortable.  
 
Apart from two negative comments about the clinic being a waste of time, most 
participants were extremely positive about their experiences in the clinic and thought that 
it should be available to all patients with diabetes.  
 
“The pharmacy diabetic clinic is a brilliant idea and I sincerely hope it takes off big 
time, I for one would use it.” 
 
“Pharmacists seem to be more approachable than doctors and speak to patients 
on their level so that they do not feel intimidated. More information can be gleaned 
this way. Feel that this service would be invaluable. A consulting room would need 
to be earmarked due to lack of space in this pharmacy.” 
 
Overall, from all the responses, participants identified this as a valuable service, helping to 
reassure them and provide them with advice and information on alternatives in an 
environment where they could take their time and get the most out of the opportunity to sit 
down with a well-trained, knowledgeable healthcare professional. 
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7.4.5 Pharmacist de-brief interviews                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
The pharmacist debrief interviews centred on four areas of discussion: training provision, 
conduct of the service, the study paperwork and the benefits arising from the service.  
 
Training provision 
The participating pharmacists identified that the training provision for the service which 
consisted of a self-directed learning package and a short face-to-face training session was 
adequate to cover their needs for the study.  
 
“the training that you did here was brilliant I mean, convenient was the thing so no 
travel for me which is absolutely brilliant so but yeah very straight forward, you got 
it clearly set out, what you had done, why you had got to this stage, I thought it 
very clear, very good and I could see why you had set the study up as it was so 
thought that was really good.”  Pharmacist 1 
 
Pharmacists refer to the training as informative and some stated that it gave them the 
confidence to provide the service and that it was good to re-cap knowledge that they had 
not revisited for some time. As part of the face-to-face element, pharmacists were 
informed of the previous work from the focus groups with patients. This helped them to 
contextualise the clinic within their practice and tailor their consultations with this 
information in mind. There was, however, one aspect of training that two of the 
pharmacists thought could have improved: interaction with other participating pharmacists 
and healthcare professionals. One pharmacist identified that, in her opinion, interaction 
with her peers would have been useful to determine how each of them was going to 
implement the service and what they had learnt as a result of the training in diabetes and 
study documentation thus far whereas another pharmacist wanted interaction with other 
healthcare professionals.  
 
“I personally would’ve liked... time with either the diabetes nurse or one of the 
doctors at the practice er just to clarify er sort of their guidelines and what they 
were trying to achieve with their patients.” Pharmacist 3 
 
There was a need for this pharmacist to integrate further with the medical practice and 
determine their patterns and guidelines for treatment as he did not want to go against the 
wishes of the practice nurse or GP when making suggestions to them for treatment 
alterations.  
 
Conduct of the service 
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In terms of providing the service, pharmacists identified that due to the nature of the 
clinics, they had very little time to prepare for the consultation. None of the pharmacists 
viewed this as a problem with some even highlighting that it helped them to not lead the 
conversation, instead allowing the patient to dictate the direction of topics as they had no 
prior information. Once in the consultation, pharmacists identified a number of topics that 
patients wanted to cover and these varied for each pharmacist. 
 
“Quite a few people wanted to know about like the prognosis of diabetes, I thought 
that was quite interesting that they didn’t quite realise that they would be on 
medication for like a long time” Pharmacist 2 
 
This pharmacist appeared surprised at the content of the consultation, expecting 
participants to focus on medicines but instead wanting to discuss other matters 
surrounding their condition. With the pharmacist below, their perception was that 
participants just wanted reassurance that they were doing the right things to control their 
diabetes.  
 
“I think most people came with some ideas, some had things they just wanted 
reassurances about other people just came to say their diabetes is fine and 
explain their medications and... some had directed questions they wanted, some 
just came along because it was a clinic and it was something they are interested 
in...” Pharmacist 5 
 
“it was good to just sort of talk through the diet and each person I guess had some 
myths that they were following that weren’t particularly true so I think you know 
that was good” Pharmacist 3 
 
The pharmacists felt that because of this wide variation in topics covered during the 
consultation, this meant they were sat with the patient for an extended period of time, 
which they felt had its benefits but could only be achieved because another pharmacist 
was covering their dispensary workload. 
 
“They don’t normally get to spend a long time talking to the doctor or nurse, they 
are often rushed, so they liked the idea of coming whenever it suited them and 
having a open length of time just to discuss any problems with their diabetes, I 
think it’s quite well received by patients...I think it would be very difficult to run that 
kind of service if I didn’t have any locum cover or second pharmacist cover... they 
[patients] feel less intimidated disturbing what you are doing.” Pharmacist 5 
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This statement confirmed that the pharmacists would not have been able to conduct this 
service had a second pharmacist not been available to them, it allowed them to focus on 
the needs of the patient as well as completing all of the relevant paperwork required for 
the study.  
 
Study paperwork 
Despite most of the questionnaires being completed in full and the follow-up 
questionnaires returned to me, some of the pharmacists identified a number of problems 
with their design and wording. 
 
“they [the patient] didn’t always understand the questions erm you know if they 
were asked how they feel about this or what they think about this” Pharmacist 2 
 
“I think some people found the questionnaires difficult to fill in... Maybe I would 
have posted the questionnaire with the original invite to the clinic and people could 
have had that would have prompted people to go away and have a think about 
things that they didn’t know before the clinic and they might have come with more 
ideas of things they wanted to discuss” Pharmacist 5 
 
Here the pharmacists were concerned that although the questionnaire was composed of 
smaller, validated questionnaires that have been used many times by other researchers, 
these patients at times seemed to struggle with some of the concepts. They acknowledge 
that this may have been as a result of the questionnaire wording but also the fact that they 
had to complete it in the pharmacy before seeing the pharmacist. In their opinion this 
reduced the time they had to think about the questions and therefore it may have been 
more appropriate to send the questionnaire to them with the original letter and information 
sheet.  
 
Pharmacists also liked the nature of the data collection form as they were able to tick 
boxes for most elements and this reduced the amount of time they had to devote to 
completing this form which meant that unlike the PLEEZ study described in chapter two all 
of the paperwork that the pharmacist was required to complete was done so in full.  
 
Benefits arising out of the study 
Pharmacists identified that participating in this study had benefits to patients, themselves 
as healthcare professionals and their interaction with the medical practice. Pharmacists 
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highlighted that a positive aspect of the study was that they had had participants return to 
them after the consultation to update them on their progress, which is something that, as 
pharmacists, they are not used to. They also identified that it increased the awareness of 
the pharmacy as the first port of call with reference to their medical condition and that 
could only be a good thing for all healthcare professionals involved in their care.  
 
“I mean we’ve already had somebody come in this morning to say how his levels, 
his readings have improved as a result of just having a chat. I think it is fantastic if 
we can do it in future and if there is the ability for pharmacists to get away from 
checking prescriptions and providing a service like this its great” Pharmacist 4 
 
Most pharmacists highlighted that participating in the study was beneficial to their wider 
practice as well as the drop-in clinic and that it had given them more confidence to speak 
to this group of patients. One final benefit that was highlighted was the increased 
collaboration with the medical practice. 
 
“I think it has strengthened the link with the diabetes nurses coz a lot of the time 
we have had further questions about a patient whose medication I couldn’t change 
and I’ve referred to the diabetes nurse… there has been 3 or 4 different 
interventions which have all been beneficial to the patient… it’s a been a good link” 
Pharmacist 5 
 
“I can only imagine that this the surgery seeing us carrying out these services 
would be good, it would be good for them, and it does help them, hopefully if the 
results are good and there is an improvement in people’s controls then it will only 
be of benefit to them coz they have got their targets as well we can help them do 
that” Pharmacist 4 
 
All of the pharmacists saw this kind of service as benefitting the relationship with the 
medical practice and demonstrating where the community pharmacist could help when 
trying to control patients with type 2 diabetes. They also stated that this would help to 
raise the profile of pharmacy more generally within the medical practice, which could only 
be good for pharmacy.  
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7.5 Drop-in clinic discussion 
The primary aim of this study was to determine if a drop in clinic aimed at patients with 
poorly controlled type 2 diabetes and conducted in the community pharmacy was feasible 
and acceptable to patients and pharmacists.  
 
This was successfully achieved with the drop-in clinic recruiting 33 poorly controlled 
participants via the medical practice. The study achieved a response rate of 9.6% from the 
postal invitation, something that has implications for generalisability of the results. A low 
response rate such as this may imply that only motivated patients were encouraged to 
participate in the study and therefore these patients may not be representative of the 
wider population with diabetes. This response rate for also has implications for calculating 
the required number of participants for a larger study. A low rate will mean any larger 
study will have to identify a significant number of patients to invite to the study without 
necessarily increasing the generalisability of the results.  
 
All recruitment methods (comprising the different levels of follow-up mailings between the 
medical practices) produced approximately the same number of participants and therefore 
one particular method cannot be preferred from these results. The rate of recruitment 
using these methods of identifying and alerting potential participants to the study is in line 
with other published work using a similar approach (Gardner et al., 2011) however it is still 
low and further work may need to be undertaken to determine how this can be increased. 
Further work will also need to be undertaken to determine the most appropriate 
recruitment criteria and methods of identification of potential participants. In this group of 
patients the QOF cut-off that was used in this study is set at a level of 59 mmol/mol. This 
may not be appropriate for all patients and clinicians may have identified certain patients 
for whom targeting below this level would be inappropriate. This may be resolved by 
greater involvement of clinicians at the outset of a study to determine the most appropriate 
recruitment criteria in this group of patients.    
 
The questionnaire was completed by all 33 participants at baseline and was returned by 
26 (78.8%) three months later as a response to follow-up mailing. This rate of drop-out 
from the study is within the range taken from the studies detailed in chapter three (2-65%). 
The questionnaire results from baseline to follow-up demonstrated no differences except a 
slight increase in the BMQ concerns scale, an increase in the SIMS potential problems 
score and that five participants that were classed as partially adherent before the clinic 
became adherent at follow-up. This study was not powered and it can be seen that only 
differences of greater than 30% were found to be significant. The aim of this chapter was 
to estimate the effect size in the selected outcome measures.  
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Closer inspection of the baseline data from the Morisky and SIMS questionnaires 
demonstrates that in this group of participants almost a quarter reported sometimes 
forgetting to take their medicines and an eighth stopped taking their medicines if it made 
them feel worse. It also highlighted that many participants were not satisfied with the level 
of information received in relation to side effects, the nature and risk of experiencing them, 
how long the medicine will take to act, how you can tell it is working and whether their 
medicines will interfere with each other. This provides an indication that this was an 
appropriate group of patients to target as they were either not using their medicines 
appropriately or they may have had further information needs.  
 
Results suggested that although there was no increase in the frequency of visits to the 
community pharmacy there was an increase in the number of times participants spoke to 
the pharmacist. At baseline, participants wanted to speak about their medicines, over-the-
counter remedies and prescription supply whilst at follow-up this changed to include a full 
range of enquires not just related to these three areas with significant changes to the 
number of participants wanting to speak about their condition and medicines supply. In 
terms of the number of consultations this intervention provided it suggests that 
pharmacists are comfortable with providing a single intervention to patients. However, if 
this study is to align with the outcomes from the previous chapters then it appears that an 
approach that factors in multiple consultations may be needed. In this study a single 
consultation was used to determine whether pharmacists were capable of providing a 
diabetes-focused service to patients and whether the training and support put in place 
was adequate. It was also due to the resource and time restrictions that were in place. 
Now that we have this information it may be possible to further define the intervention and 
feasibility test some of the components that have not been tested here.  
 
In terms of the appropriateness of the validated questionnaires forming part of the larger 
questionnaire, participants found some of these questions slightly ambiguous and were 
not sure what they were ‘supposed’ to answer. The questionnaire responses produced 
little change in all of the measures from baseline to follow-up and it may be prudent to 
alter the design and composition for future use. It may be more accurate and less time 
consuming for the participant to use prescription refill rates to calculate adherence rather 
than a questionnaire. If conducted on a larger scale and to enable a cost-utility analysis to 
be performed a health-related quality of life questionnaire e.g. EQ-5D or the SF-36 
questionnaire (Brazier et al., 1992, The EuroQol Group, 1990) would also need to be 
included. The outcomes used may, in this study, be appropriate as intermediate 
measures, helpful in informing training requirements and the content of the intervention. 
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However, for a larger study they could be changed to HbA1C, health-related quality of life 
and prescription refill rates as this would provide a better indication of the effect on the 
patient at the same time as removing some of the questionnaire burden.   
 
Most pharmacists identified that they let the participant lead the consultation and only 
used the questionnaire when the participant appeared to think they had been called in and 
didn’t have any particular topics they wished to discuss. Most pharmacists stated they 
quickly reviewed the questionnaire towards the end of the consultation to ensure nothing 
had been overlooked. 
 
The consultations themselves lasted significantly longer than GP consultations (Carr-Hill 
et al., 1998) with the mean time at approximately 32 minutes. This allowed the pharmacist 
to spend a longer time with the participants discussing all aspects of their care but may 
prove an expensive intervention if conducted more widely. The cost, per 32 minutes, for 
the pharmacist intervention is £71.13 which compares to £28.27 for a nurse in a general 
practice, £26.13 for a nurse specialist, £53.33 for a nurse practitioner and £117.87 for a 
general practitioner (Curtis, 2012). This therefore means that although the intervention 
was less expensive than a GP consultation, it was significantly more expensive than a 
nurse consultation. This could have implications for this type of community pharmacy 
service in primary care and means that there will need to be a further defining of the 
intervention in order to make it distinct from current nurse provision, which is less 
expensive.   
 
Over 90% of participants felt it was useful to speak to the pharmacist about their diabetes 
and that the length of the consultation was about right. Participants identified that they 
were satisfied with the information they received and that it was given to them in a way 
they could understand. There is evidence to suggest, from GP consultations, that the 
longer the time spent with a patient the more satisfied they will be and more likely they will 
follow any recommendations made (Ogden et al., 2004), however, this may refer to quality 
time (in the patient’s view) rather than actual time (Cape, 2002).  
 
All aspects of diabetes were covered from the condition itself to prognosis, diet and 
lifestyle to medicines with pharmacists identifying the most popular topics raised by the 
participant as: 
 
 Diabetes – the disease 
 Diabetes – the effect on lifestyle 
 Lifestyle – diet and nutrition 
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 Medicines – side effects 
 
As a result of the consultations, pharmacists made a number of recommendations (n = 20) 
for either the pharmacy to implement or to the prescribing team at the medical practices. 
Some of these involved formulation and dose changes to facilitate improved adherence to 
treatment, changes to prescribed quantity and on one occasion the pharmacist identified 
that the participant should have been prescribed a statin and discussed this with them. 
Most of the changes were focused on the patient’s diabetes, however, on a number of 
occasions this expanded to include some of their other conditions, highlighting the 
pharmacist’s confidence in providing the intervention and making recommendations to the 
GP. However, it may be necessary to provide the pharmacists with detailed consultation 
skills in an attempt to keep them on the topic of diabetes and to reduce the overall length 
of the interaction. 
 
In terms of participant feedback, the majority had a good impression of the service, with 
over 90% saying that they thought it would help them to manage their diabetes. The 
impression of the pharmacist also improved with nearly 60% saying it would make them 
more likely to consult a pharmacist in the future, 100% stating that this kind of service 
should be available to patients with diabetes and other conditions and that they would 
recommend the service to others.  
 
Consultation time was noticed and commented upon by participants with many of them 
identifying on their satisfaction questionnaires that the pharmacist did not appear to rush 
them and was not distracted by other work in the dispensary. Participants also identified 
that the pharmacists appeared knowledgeable, professional and approachable with some 
participants highlighting that the doctor and nurse don’t have the time to sit with them and 
answer all their questions so it was beneficial to have time with the pharmacist.  
 
In terms of the space in which the consultation was conducted, two pharmacists used 
rooms in the medical practice next door to the pharmacy for practical reasons. The other 
two pharmacies used their own consultation rooms and a couple of participants referred to 
these as small and cluttered and wondered if it could have been a bit more private.  
 
Finally, from the de-brief interviews, pharmacists stated that they enjoyed providing the 
drop-in clinic as it allowed them to use the knowledge that they had learnt from their 
training, it allowed them to interact with patients more formally and for longer and they 
especially enjoyed the feedback and hearing from patients about their progress once the 
study had finished.  
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Some of the pharmacists highlighted that although they liked the method of recruiting the 
participants, it meant that they had no idea who was going to present for the clinic and 
what their circumstances were. One pharmacist, who had access to the patient’s medical 
record, suggested that it may be useful to target patients in an ad-hoc way as well as 
posting an invitation to them. This pharmacist is unusual in that most community 
pharmacies do not have access to this data and therefore cannot tell whether a patient is 
poorly controlled or not. Another aspect one pharmacist identified was the potential need 
to stagger the posting of the invitations to prevent a sudden influx of patients on the day of 
the first clinic. Although this did not happen, it is a valuable consideration to retain for 
future, larger studies.  
 
Pharmacists identified that the training was sufficient to prepare them for consultations 
with patients with the CPPE package being well received and covering all the topics 
necessary. Some pharmacists found it extremely beneficial for their day-to-day practice as 
well as the drop-in clinic. Pharmacists also highlighted that the face-to-face training was 
useful as it provided a context to the study that allowed pharmacists to tailor their 
conversations with patients. As a result of this training, they had a good understanding of 
the study procedures and paperwork and with the researcher being present at every clinic 
it gave the pharmacists the opportunity to focus on completing that documentation in full 
with support available if necessary.  
 
One aspect to the training that the pharmacists would have liked more of was interaction 
with other pharmacists and healthcare professionals involved in the study. This was to 
provide two benefits: to interact with other pharmacists involved in the study in order to 
understand their perspective and how they were going to implement it in their practice, 
and other healthcare professionals, notably the GP and practice nurse, to understand 
local guidelines and targets for treatment. This last point would have been useful to 
ensure an integrated strategy for treating these patients between the community 
pharmacy and medical practice.  
 
In terms of feedback on the questionnaire from the pharmacists, they believed that some 
of the questions particularly in the BMQ section were ambiguous and that it could have 
been easier to complete with one pharmacist saying it was also too long. However, this 
was not identified by the participants’ feedback with the majority saying that the 
questionnaire was the right length and asked the right questions for them.  
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The other issue identified with the questionnaire was the method of administering it at 
baseline; pharmacists thought that it may have put participants under pressure to 
complete it in a short period of time and that it may have been better to send it out with the 
postal invitation instead. This would have allowed the participants to think about the 
answers more carefully and then come to the consultation with a more informed idea 
about what they wanted to discuss. They also felt that the answers from the first and 
second questionnaires may have differed because of the different setting in which it was 
completed. However, this method of administering the questionnaire may have reduced 
the response rate even further.  
 
In terms of the feedback on the consultation, the pharmacists identified that one of the 
most important aspects to the service was the locum support provided as part of the 
research. This enabled them to focus on the patient and not feel distracted by events in 
the dispensary.  
 
This study has demonstrated that pharmacists are able to provide a diabetes drop-in clinic 
in the community pharmacy setting and that it will attract poorly controlled patients 
referred from their medical practice. It has provided information for a larger study such as 
the appropriate method of recruitment, response rate, topics covered during the 
consultation and has alluded to the kind of interactions the pharmacist may have with the 
medical practice when requesting changes to medication. It has also demonstrated the 
need to re-design the questionnaire and potentially shorten it to one validated health-
related quality of life measure coupled with clinical measures and prescription re-fill rates 
as outcome measures.  
 
7.5.1 Limitations of the study 
In terms of a feasibility testing, this study has been successful. The medical practices 
were willing to refer patients to the service, pharmacists could conduct the consultations 
and patients find them acceptable and are willing to engage with the process. However, 
this study could only be conducted with the researcher support that allowed the 
pharmacist to spend the length of time they did with the participants and is unclear how 
manageable this would be on a larger scale.  
 
In a larger study, the primary outcome measure would be HbA1C and this would need to 
be collected for sometime after the end of the study and any changes made requested by 
the pharmacist as a result of the clinic would need to be followed-up to determine their 
implementation rate. The extent to which both of these can be achieved was not tested 
during this study. To inform a larger study a pilot study would be required with HbA1C as 
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an outcome measure or good evidence from the published literature. Adherence was 
characterised using a self-report method which may be less reliable than other forms of 
adherence measurement e.g. prescription refill data. Again, the extent to which this data 
could be collected would need to be tested in any subsequent pilot study.  
 
From the literature review in chapter four, it was identified that a successful intervention in 
this group of patients may require multiple consultations over an extended period of time. 
This study did not examine that scenario in a UK context and therefore further feasibility 
testing may be required to ascertain if this would be possible.  
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7.6 Drop-in clinic conclusion 
This study of a community pharmacist diabetes drop-in clinic has demonstrated that the 
concept is feasible within the setting and is acceptable to both participants and 
pharmacists. This service identified patients that were poorly controlled of which some 
were non-adherent to their treatment and some may have had concerns about taking their 
medicines. The pharmacists in our study aimed to address these problems and in view of 
the participant’s feedback succeeded in appearing knowledgeable and engaged with their 
needs as a patient. The clinic helped to improve the number of participants classed as 
adherent as well as providing clinical recommendations to the medical practice.  
 
The pharmacists spent longer with the participants during the consultation than their GP 
or practice nurse would do normally and covered almost every aspect of their diabetes 
care. This helped to establish a relationship between the pharmacist and participant that, 
from the feedback, they both found valuable. The pharmacists also made a number of 
clinical recommendations as a result of the study that they had discussed and agreed with 
the participant before approaching the prescriber. These recommendations were made in 
line with national guidance that the pharmacists had been provided with as part of the 
training for the study.  
 
Pharmacists suggested the questionnaire provided little help in guiding the conversation 
and they let the patient lead the discussion. However, it may be appropriate in future to 
include an element of consultation skills training in order that the pharmacists can balance 
this aspect of time and content in a sustainable way for a larger number of participants. 
The consultations lasted for an extended period of time and covered topics that are 
potentially already covered by a nurse-led service that is significantly cheaper.  
 
In future, the use of the questionnaire may need to be adjusted in terms of content and 
time of completion. In order to obtain a more considered answer it may be more 
appropriate to provide the participant with the questionnaire before they arrive at the 
pharmacy. This may mean that the patient has more time to think about the answers and 
the information needs they may have before consulting with the pharmacist. However, it 
may also be appropriate to determine appropriate measures for inclusion such as health-
related quality of life rather than adherence, which can be measured in other ways. 
 
One of the main aspects of this study that assisted its successful completion was the 
presence of a researcher in the community pharmacy at the time of the clinics. This locum 
support allowed the pharmacist to concentrate solely on providing the clinics and focusing 
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their attention on the participant. Without this support, the study may have replicated the 
RCT conducted in chapter two.  
 
After visiting the clinic, there was a small positive change in the perception of the 
pharmacist as someone with the knowledge to be able to assist these patients manage 
their condition. This was referenced by the increase in the number of variety of 
discussions between the two. Pharmacists also felt that it had helped them to interact with 
the medical practice and patients in a way that was not usual for their practice. As part of 
future training it may be appropriate to include the medical practice in the training aspect 
of the study in order that pharmacists can understand their priorities for care in this group 
of patients.  
 
This study has demonstrated that this type of clinic is feasible in the UK community 
pharmacy setting. However, further changes would need to be made to ensure that this 
service does not duplicate those that are already being provided in the primary care 
setting and an increased cost to the NHS.     
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 Chapter Eight  
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8 Overall discussion 
The original aim for my PhD was to determine whether there was a role for the community 
pharmacist in the management of long term conditions. On reflection, this has not been 
achieved as part of this process. However, the work contained within this thesis has 
contributed to the definitions of both ‘role’ and ‘management’ within this aim even though it 
does not provide an answer to the original question. It has helped to identify that the 
pharmacist’s ‘role’ needs to take into account other healthcare professionals in the UK 
primary care setting. It has highlighted that although the pharmacist may have a role in the 
management of these conditions this role cannot be simply put in place without due 
consideration of other healthcare professionals. The term ‘management’ has been further 
defined in terms of what the pharmacist could and should be focusing on as part of their 
consultations with patients. The audit ruled out certain aspects to a pharmacist 
intervention, including that of changing medication. Pharmacists in the intervention, 
without direction, focused on adherence as well as diet and lifestyle advice and 
information about their condition. This implies that any pharmacist intervention relates to 
more information provision than altering current therapy.   
 
One research question that has been answered relates to defining aspects of community 
pharmacy that form a conducive environment in which to conduct research to provide 
evidence for the role of the pharmacist. This is in reference to the need to have 
appropriate support mechanisms in place for a community pharmacist to perform 
research. This means researcher or locum support to free the pharmacist from their 
routine tasks and allow them to spend time with the patient. It also relates to the 
identification of participants, as pharmacists, if left to recruit by themselves, may not be 
able to successfully perform the required processes as part of the research. This will 
result in disengagement and poor recruitment of participants.  
 
The evidence contained within this thesis provides a backbone on which to conduct 
further research in the community pharmacy setting. It has detailed that before conducting 
research into a particular intervention, researchers need to conduct preliminary work to 
consider where and to whom the intervention should be targeted. This thesis has 
identified that it would be more appropriate to target poorly controlled patients, it has 
provided some definition to a pharmacist intervention and has tested that intervention for 
acceptability. However, there is still more to add to this ‘backbone’ particularly with 
reference to the context of primary care and the pharmacist’s role within that team and the 
content of the intervention. These aspects need to be researched more thoroughly before 
progressing with a definitive study.  
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It has attempted to define the concept of ‘management’ in patients with long term 
conditions as potentially one of information provision, as well as interacting with them to 
determine where they foresee the role of the community pharmacist in their care. Neither 
of these concepts have been explored in the UK before. The novel intervention has 
provided evidence, not of the effectiveness of the pharmacy service but of the feasibility of 
conducting such research in this setting and the considerations that need to be made in 
doing so. In conducting research in this setting, researchers need to be aware of the time 
and working constraints of community pharmacists when asking them to participate in a 
study. This will have implications for recruitment and provision of any intervention if it is 
not factored into the design of such work. We also need to be aware of the place of not 
just community pharmacy in the wider primary care team but also the place and role of the 
other healthcare professionals. In this case, the position of the practice nurse has 
particular importance for the provision of a community pharmacy service.  
 
The Government vision for community pharmacy is to move from a medicines-supply role 
to a more patient-focused approach by providing services aimed at managing long-term 
conditions. This vision has been re-enforced in several White Papers and it is now the 
responsibility of higher education institutions and community pharmacy itself to provide 
the evidence required to aid service implementation on a larger scale.  
 
The work in this thesis has discussed the current evidence base for community pharmacy 
services as well as published research examining new roles for the pharmacist. Published 
evidence of research in this area has either been lacking or when it has been conducted 
appropriately has often produced a negative result for the role of the pharmacist. This lack 
of a significant evidence base for community pharmacy services may be as a result of 
several factors that influence the ability to be able to conduct research which include the 
perception of research by pharmacists and patients, the extent to which pharmacists 
understand the processes behind research, the level of knowledge they currently have 
and the approach that researchers take to conducting studies in this setting.  
 
Leading on from this, the work in this thesis has been heavily influenced by the MRC 
framework for developing complex interventions in order that we could design a novel and 
robust community pharmacy intervention, that pharmacists could provide and patients 
would engage with. This started with the PLEEZ study which was a feasibility study that 
aimed to test whether an RCT could be used in community pharmacy to examine the 
effects of a pharmacist-led eczema support service. This seemed, at the time, to be the 
most appropriate approach to take as a first step before conducting a full scale RCT. 
However, the study failed due to a number of factors that could have been easily identified 
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with appropriate preliminary work and predicted with a more robust analysis of the MRC 
framework before conducting feasibility testing. This work may have identified that this 
approach to community pharmacy research was always going to lead to poor results and 
that problems such as pharmacist support and study paperwork were central to a 
successful recruitment process.  
 
At this point, I revisited the MRC framework and planned a series of preliminary projects 
prior to the design and implementation of a feasibility study. These projects included a 
literature review, an audit and a set of focus groups, the aim of which was to inform the 
design and content of the final project. The first change to be made was to the target 
disease state. We needed to focus on a disease state that will guarantee any future 
service a large number of potential participants as well as being targeted by the medical 
practice. Type 2 diabetes was chosen as it aligned with both of these requirements: a 
large number of diagnosed and poorly controlled patients and it is subject to the QOF 
targeting system.  
 
The literature review, audit and focus groups all occurred at the same time as described in 
the figure at the end of chapter two. The literature review examined the current treatment 
options and evidence surrounding type 2 diabetes and went on to detail the current 
evidence base from the UK and internationally regarding community pharmacist 
interventions in this area. The aim of this was to identify those trial designs from other 
studies that worked well and those that did not to determine what could be used in our 
study. This review indicated that the most successful studies could conduct an RCT in 
community pharmacy but if it were to be successful randomisation had to occur at the 
pharmacy and not the patient level. This will increase the size of any trial but may produce 
a more manageable and successful study. In terms of training provision, again the most 
successful studies provided the pharmacists with an extensive training programme aimed 
at increasing their clinical knowledge along with their communication and consultation 
skills. The inclusion criteria for these studies indicated that recruitment based on HbA1C 
levels is useful in targeting those patients that are poorly controlled with respect to their 
diabetes. It also demonstrated that this kind of targeting of patients is possible but that 
close working with the medical practice would be necessary to achieve it. Finally, the 
interventions provided to the patients were all conducted over a period of months with 
repeated visits to the community pharmacist and covered all aspects of their condition. 
 
The review was successful in identifying the design elements of a study that we wanted to 
conduct in the UK community pharmacy setting. However, the consultation content was 
wide ranging and the aim of the audit was to determine if such a consultation was 
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necessary in the context of the UK NHS. This was important as the role of the diabetic 
nurse specialist is clearly defined in the UK and it may have implications on whether the 
international studies identified can simply be transferred to the UK community pharmacy 
setting. The audit aimed to determine if prescribing for type 2 diabetes in primary care was 
in line with national guidance. The results demonstrate that this is largely the case in 
terms of the medicines prescribed for diabetes. However, there are still a large number of 
patients that remain uncontrolled with respect to blood glucose, blood pressure and lipids. 
The audit demonstrated that the pharmacist may have a role in providing services to these 
patients centred on the modification of cardiovascular risk, managing blood pressure or 
adherence support.  
 
Finally, the diabetes patient focus groups identified that patients value the input and 
expertise of the community pharmacist in their care especially in relation to information 
about side effects and interactions with over-the-counter medicines. However, they 
highlighted that they would be uneasy with community pharmacists conducting 
interventions aimed at addressing the control of their condition unless their medical 
practice had sanctioned their involvement. This was important for a number of reasons 
including the need for patients not to violate their perceived natural line of treatment and 
the need for GPs, as controllers of their medical care, to validate the role of the 
pharmacist in the primary care team. They also identified that it was important for the 
pharmacist to be able to communicate any intervention outcomes directly to the prescriber 
rather than the patient having to return to the medical practice to relay information. 
 
Participants in the focus groups also highlighted some important information regarding the 
community pharmacy environment as a place where they receive healthcare advice. After 
seven years of the new pharmacy contract, it appears that our participants still have 
reservations about the privacy available in the community pharmacy and the ability of the 
pharmacist to engage with them as they perceived them as ‘always busy’ in the 
dispensary. 
 
All of this work helped to inform the design of the diabetes drop-in clinic which was 
conducted in five community pharmacies in Norfolk. The study factored the following 
elements into the design (as described more fully in chapter seven): 
 
 Targeting poorly controlled patients 
 A system of referral from the medical practice to the community pharmacy 
 A training programme for the participating pharmacists 
 An access system which did not require an appointment 
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 An additional pharmacist to provide support to the service pharmacist 
 A focus on adherence as well as diet and lifestyle advice. 
 
This drop-in clinic produced excellent results with 33 patients attending one of the 
sessions in four of the five pharmacies, encouraging results from the outcome measures 
tested, positive patient feedback and comments from the pharmacists during their de-brief 
interviews that can be used to inform future studies. 
 
Pharmacists were able to cover a wide variety of topics during the extended consultations 
with patients. Patients acknowledged that the pharmacist had the knowledge, 
communication skills and professionalism to give them confidence in the information they 
received from the consultation and they would like it to be more widely available to 
patients with diabetes. The study also demonstrated a slight increase in the number of 
times patients spoke to the pharmacist and the topics about which they were prepared to 
speak to them. However, the consultation lasted for a significant period of time and at 
times ventured on to topics not associated with diabetes. This may point to the need to 
provide the pharmacist with consultation skills training in order to conduct a more focused 
conversation with the patient.  
 
At the same time the drop-in clinic was being conducted, a similar study had been 
published which had also been conducted in the UK. This study was based in 
Hertfordshire and used an RCT methodology in two pharmacies (Ali et al., 2012). The 
pharmacists were provided with an eight hour training package at the University of 
Hertfordshire (UH) that included workshops with a consultant diabetologist and a 
specialist diabetes nurse. Participants were alerted to the service using posters, leaflets, 
referred from the GP/nurse or identified at prescription dispensing. Those approached and 
asked to participate were over 18 years old, had no significant co-morbidity, were not 
involved in other research, were able to attend regular visits and had an HbA1C > 
53mmol/mol (7.0%). This final measurement was conducted in the pharmacy and sent to 
an external testing company for analysis.  
 
The intervention involved regular monitoring and consultations with the community 
pharmacist for 12 months; a total of six consultations. It consisted of a targeted MUR if 
appropriate, lifestyle modification and referral to the GP if necessary. It also included 
education about diabetes and its complications and a review of the patient’s medicines. 
 
The UH study aimed to recruit 30 participants in total however the power calculation used 
to ascertain this figure does not align with other studies that have reported in this area and 
           
196 
 
have been discussed in chapter four. The study actually recruited 48 participants and 
included 46 in the final analysis which is encouraging as it demonstrates that patients 
were willing to attend all the sessions over an extended period of time. The results from 
the study indicated a significant difference in HbA1C between the intervention and control 
groups. There were also significant differences in other clinical outcome measures along 
with health-related quality of life, diabetes knowledge test, BMQ-necessity and concerns 
scores and SIMS.  
 
This study aligned well with the studies described in the literature review especially in 
relation to the number of consultations. This team demonstrated that it was possible to 
conduct multiple consultations with patients over an extended period of time. My study 
used a single consultation due to resource and time allocation. However, it may be 
prudent to determine which approach is better at improving the care of patients as one will 
be significantly less expensive than the other.  
 
All of this work has advanced the understanding of what the role of the pharmacists may 
entail, however, it has largely failed to factor in the primary care context. The degree to 
which any pharmacist intervention is implemented will rely on the gaps in care currently 
provided by other healthcare professionals. Further work needs to be undertaken to find 
this niche for the community pharmacist and design an intervention around this.   
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8.1 Conclusions 
The work in this thesis has demonstrated that there are still a significant number of 
patients for whom diabetic control cannot be achieved. These patients could potentially 
benefit from a community pharmacist-led service aimed at improving their care. In the past 
there have been problems with conducting research in the community pharmacy setting or 
have demonstrated negative results and this thesis has attempted to unpack these 
problems and factor them into the design of a new intervention. 
 
The results from this intervention, and the thesis as a whole, pose important questions in 
relation to the role of the community pharmacist in the management of patients with long-
term conditions. The work conducted internationally cannot simply be transferred to the 
UK setting in the hope that it will lead to the improvement of patient care. This is largely 
due to the increased role that nurses play in UK primary care. The intervention tested here 
is a case in point. All of the subjects that were discussed with the pharmacist during an 
extended consultation were those that could have been discussed easily with the practice 
nurse, with a dedicated consultation space and access to medical notes. This highlights 
two important issues in relation to community pharmacist services. The first issue relates 
to intervention definition. With many patients still uncontrolled in the current primary care 
environment, it may be appropriate for the community pharmacist to become involved in 
their care. However, this cannot simply be duplication of services but in a different setting 
as it has implications for cost to the NHS. Further work needs to be conducted to 
determine the exact gaps in patient care and where the pharmacist niche occurs for any 
intervention to be accepted by the wider primary care team and patients alike.  
 
The second relates to consultation skills and the need for pharmacists to be given the 
knowledge to be able to focus a consultation better. During my study pharmacists spent 
more time with patients than GPs or nurses. This may be necessary, but as it has 
significant cost implications, an investigation to determine the need for and potential for 
implementation of greater consultation skills training should be conducted.  
 
Although this work set out to answer a broad question about the role of the pharmacist in 
patients with long-term conditions, it has actually answered another question regarding 
the definition of both the role and management in relation to the pharmacist and the 
context of primary care in the UK. This raises further questions regarding the intervention 
definition, pharmacist niche and pharmacist consultation skills that all need to be 
addressed in order to provide a clear view of what the pharmacist can bring to the table 
that is distinct from what is currently available. 
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8.2 Recommendations for future work 
 
Further preliminary work to be performed before a definitive RCT: 
 
 Perform a full, systematic review and meta-analysis of the available literature 
examining the role of the community pharmacist in the care of patients with type 2 
diabetes. This would be to formalise the findings from chapter four. 
 
 Triangulation of focus group data by the use of a widely administered questionnaire to 
patients with type 2 diabetes, developed using that data.  
This will assist in determining whether the views detailed in the focus group chapter are 
more widely held in the population of patients with type 2 diabetes. This will assist in the 
validation of the focus group findings.   
 
 Qualitative interviews or focus groups with other healthcare professionals about their 
views and perceptions of the current treatment/management gaps in the care of 
patients with type 2 diabetes. 
This will help to determine where there are current gaps in the care of patients with type 2 
diabetes. This information can then be used to ensure that any pharmacist intervention 
does not duplicate a service conducted by other healthcare professionals or provides a 
service that could be conducted by a less expensive healthcare professional e.g. practice 
nurse.   
 
 A larger audit in a greater number of medical practices encompassing the findings 
from chapter five.  
This will attempt to capture information on medication doses as well as adherence as 
measured by prescription issue. This needs to be conducted to further define the 
intervention in terms of the consultation topics that should be addressed by the 
pharmacist. This audit will provide a better indication of the prescribing practices in this 
group of patients and whether there are any gaps in care. The reason for capturing 
adherence at the medical practice is that it will be more accurate than patient self-report 
and will determine if this is indeed a problem in this group of patients.  
 
 Appropriate quantitative and qualitative work to understand pharmacists’ current 
consultation skills and where they perceive any gaps in knowledge.   
This will help to understand the current practices surrounding pharmacist consultation 
skills. This mixed methods approach will involve conversations (preferably focus groups 
due to the nature of the data required) with pharmacists about their perception for the 
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need for good consultation skills when speaking to patients but also work to characterise 
the consultation process as it happens. This may take the form of observational research 
of pharmacists conducting consultations and assessing their performance against a 
standard grading scheme. This will assist in understanding how pharmacists conduct a 
consultation and if there are any needs for further training.  
 
Definitive study: 
 
 Perform a pilot study of a diabetes drop-in clinic in community pharmacy. 
The decision to perform this pilot study will rest on whether the above further work 
conducted refines the questions posed at the end of the thesis with regards to intervention 
definition and consultation skills. If no further intervention detail can be obtained then a 
follow-on study will not be necessary as it will be a repeat of the intervention described 
within this thesis. If, however, further definition to the intervention provided by the 
pharmacist can be obtained and it can align with the UK primary care setting, a pilot study 
will be performed. This pilot study will also have to factor in multiple consultations and 
collect HbA1C data as the primary outcome measure.  
 
The most important aspect of this work to be conducted first will be the further definition of 
the intervention and how this aligns with current primary care practices and healthcare 
professionals.   
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8.3 Publications and conference presentations arising from the thesis  
 
Peer-reviewed Journals 
Twigg MJ, Poland F, Bhattacharya D, Desborough JA, Wright D; The current and future 
roles of community pharmacists: the views and experiences of patients with type 2 
diabetes. Research in Social and Administrative Pharmacy. (In Press) 
 
Twigg MJ, Bhattacharya D, Poland F, Desborough JA, Wright D; (2012) The views of 
pharmacists who participated in a community pharmacy RCT; International Journal of 
Pharmacy Practice (In Press) 
 
Twigg MJ, Bhattacharya D, Desborough JA, Wright D; (2012) Is there a role for 
pharmacists in the management of patients with type 2 diabetes? An audit of prescribing 
in primary care. Primary Care Research and Development (In Press) 
 
Published Conference Abstracts 
Twigg MJ, Poland F, Bhattacharya D, Desborough JA, Wright DJ (2012) Patients’ 
perceptions of the current and future roles of the community pharmacist in type 2 diabetes 
care. International Journal of Pharmacy Practice 20 (Suppl. 1) 5-15 (Oral presentation at 
HSRPP 2012) 
 
Twigg M, Bhattacharya D, Desborough JA, Wright DJ (2011) Adherence to NICE 
guidance for prescribing in type 2 diabetes in primary care. International Journal of 
Pharmacy Practice, 19, 38-64. (Poster at RPS 2011) 
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